EurekaMag PDF full texts Chapter 54,965

Zed, P.J. 2009: Pharmacy practice residencies in Canada: opportunities and emerging challenges. Canadian Journal of Hospital Pharmacy 62(1): 7-11

Paciullo, C.A.; Moranville, M.P.; Suffoletta, T.J. 2009: Pharmacy practice residency programs in community hospitals. American Journal of Health-System Pharmacy: Ajhp: Official Journal of the American Society of Health-System Pharmacists 66(6): 536-539

Galato, D.; Alano, G.M.; Trauthman, S.C.; França, Tã.F. 2011: Pharmacy practice simulations: performance of senior pharmacy students at a University in southern Brazil. Pharmacy Practice 9(3): 136-140

Koshy, S. 2014: Pharmacy practice-based research networks: do pharmacists need them?. International Journal of Pharmacy Practice 22(6): 433-436

Lipowski, E.E. 2008: Pharmacy practice-based research networks: why, what, who, and how. Journal of the American Pharmacists Association: Japha 48(2): 142-152

Babar, Z.-U.-D.; Vaughan, C.; Scahill, S. 2012: Pharmacy practice: Is the gap between the North and South widening?. Southern Med Review 5(1): 1-2

Knowlton, C.H. 2009: Pharmacy practice: where's the value proposition?. Pharmacy in History 51(3): 94-97

Burgett, N.E.; Dennis, V.C.; Wideman, S.D.; Kirkpatrick, A.E.; Randall, D.L. 2012: Pharmacy preceptors' views on the value and optimal frequency of quality assurance visits to advanced pharmacy practice experience sites. American Journal of Pharmaceutical Education 76(3): 48

Bowden, D. 1949: Pharmacy problems of the smaller hospital. Canadian Hospital 26(8): 39

Barlas, S. 2009: Pharmacy product tracing likely to go national: costs to pharmacies worrisome. P and T: a Peer-Reviewed Journal for Formulary Management 34(1): 14

Anonymous 2008: Pharmacy program with DM component targets CKD. Disease Management Advisor 14(1): 8

Traynor, K. 2012: Pharmacy projects selected for Innovation Center awards. American Journal of Health-System Pharmacy: Ajhp: Official Journal of the American Society of Health-System Pharmacists 69(16): 1354-6 1358

Nguyen, B.T.; Zaller, N. 2010: Pharmacy provision of emergency contraception to men: a survey of pharmacist attitudes in Rhode Island. Journal of the American Pharmacists Association: Japha 50(1): 17-23

Murphy, P.A.; Frazee, S.G.; Cantlin, J.P.; Cohen, E.; Rosan, J.R.; Harshburger, D.E. 2012: Pharmacy provision of influenza vaccinations in medically underserved communities. Journal of the American Pharmacists Association: Japha 52(1): 67-70

Guénette, L.; Sirois, C. 2012: Pharmacy record registration of acetyl salicylic acid (ASA) prescriptions in Quebec. Journal of Pharmacy and Pharmaceutical Sciences: a Publication of the Canadian Society for Pharmaceutical Sciences Societe Canadienne des Sciences Pharmaceutiques 15(2): 252-255

Gomes, R.R.d.F.M.ãe.; Machado, C.J.; Acurcio, F.d.A.; Guimarães, M.D.C. 2009: Pharmacy records as an indicator of non-adherence to antiretroviral therapy by HIV-infected patients. Cadernos de Saude Publica 25(3): 495-506

Sangeda, R.Z.; Mosha, F.; Prosperi, M.; Aboud, S.; Vercauteren, J.; Camacho, R.J.; Lyamuya, E.F.; Van Wijngaerden, E.; Vandamme, A-Mieke. 2014: Pharmacy refill adherence outperforms self-reported methods in predicting HIV therapy outcome in resource-limited settings. Bmc Public Health 14: 1035

Varella, E.A. 2007: Pharmacy related professions in Byzance. Medicina Nei Secoli 19(3): 653-666

Walker, R. 2010: Pharmacy research and a fair society. International journal of pharmacy practice 18(2): 67-68

Deng, R. 2012: Pharmacy research at URI: bile acids and bile salt export pump: physiology and pathology. Medicine and Health Rhode Island 95(9): 290-291

Seeram, N.; Xu, J.; Li, L.; Slitt, A. 2012: Pharmacy research at URI: mining red maple (Acer rubrum) trees for novel therapeutics to manage diabetes. Medicine and Health Rhode Island 95(9): 283-284

De Lemos, M.ár.L. 2014: Pharmacy research by "nonresearch pharmacists". Canadian Journal of Hospital Pharmacy 67(4): 312-313

Baur, C.; Brach, C. 2013: Pharmacy research on health literacy can contribute to national goals and health care system improvements. Research in Social and Administrative Pharmacy: Rsap 9(5): 498-502

Shannon, S.Brandon.; Bradley-Baker, L.R.; Truong, H-An. 2012: Pharmacy residencies and dual degrees as complementary or competitive advanced training opportunities. American Journal of Pharmaceutical Education 76(8): 145

Johnson, T.J.; Teeters, J.L. 2011: Pharmacy residency and the medical training model: is pharmacy at a tipping point?. American Journal of Health-System Pharmacy: Ajhp: Official Journal of the American Society of Health-System Pharmacists 68(16): 1542-1549

Morton, J.; Koval, P.; Gal, P. 2013: Pharmacy residency match rates and predictors. American Journal of Pharmaceutical Education 77(10): 212

Ivey, M.F.; Farber, M.S. 2011: Pharmacy residency training and pharmacy leadership: an important relationship. American Journal of Health-System Pharmacy: Ajhp: Official Journal of the American Society of Health-System Pharmacists 68(1): 73-76

Toma, M.B.; Winstead, P.Shane.; Smith, K.M.; Lewis, D.A.; Clifford, T.M. 2007: Pharmacy resident participation in cardiopulmonary resuscitation events. American journal of health-system pharmacy: AJHP: official journal of the American Society of Health-System Pharmacists 64(7): 747-753

Pandya, K.A.; Ruf, K.M.; Winstead, P.Shane.; Cook, A.M.; Weant, K.A. 2010: Pharmacy resident participation with a 24-hour multidisciplinary stroke response team. American Journal of Health-System Pharmacy: Ajhp: Official Journal of the American Society of Health-System Pharmacists 67(22): 1901 1905-7

McKelvey, R.P.; Hatton, R.C.; Kimberlin, C.A. 2010: Pharmacy resident project publication rates and study designs from 1981, 1991, and 2001. American journal of health-system pharmacy: AJHP: official journal of the American Society of Health-System Pharmacists 67(10): 830-836

Ramsey, E.Zachary.; Miller, A.D.; Armitstead, J.A.; Smith, K.M. 2009: Pharmacy resident recruitment as a practical learning experience for current residents. American journal of health-system pharmacy: AJHP: official journal of the American Society of Health-System Pharmacists 66(4): 329-332

Traynor, K. 2013: Pharmacy resident takes care to new height. American journal of health-system pharmacy: AJHP: official journal of the American Society of Health-System Pharmacists 70(19): 1648

Franks, A.S.; Givens, C.B.; Barger-Stevens, A. 2012: Pharmacy residents and students as an adjunct to current smoking cessation education. Pharmacy practice 10(2): 92-96

Ashker, S.; Burkiewicz, J.S. 2007: Pharmacy residents' attitudes toward pharmaceutical industry promotion. American journal of health-system pharmacy: AJHP: official journal of the American Society of Health-System Pharmacists 64(16): 1724-1731

Miller, D.E.; Fox-Smith, K. 2012: Pharmacy revenue cycle audits can bring unexpected returns. Healthcare Financial Management: Journal of the Healthcare Financial Management Association 66(10): 78-82

Yoder, E.; Wysock, G. 2008: Pharmacy review of contrasted studies. Radiology Management 30(5): 66-68

Mobilian, M.A. 2009: Pharmacy school at "40 something". Journal of the American Pharmacists Association: Japha 49(4): 471-472

Knapp, D.A. 2012: Pharmacy school provenance and pharmacy practice. PharmacoTherapy 32(2): 99-102

Mészáros, K.ár.; Barnett, M.J.; Lenth, R.V.; Knapp, K.K. 2013: Pharmacy school survey standards revisited. American Journal of Pharmaceutical Education 77(1): 3

Lavine, G. 2008: Pharmacy schools help educate, treat Appalachian patients at Virginia health fair. American Journal of Health-System Pharmacy: Ajhp: Official Journal of the American Society of Health-System Pharmacists 65(14): 1311-1313

Briggs, W.P. 1946: Pharmacy service in the Veterans Administration. Bulletin. American Society of Hospital Pharmacists 3(6): 184-187

Briggs, W.P. 1946: Pharmacy service in the medical care of the veteran. Papers Presented at the . Annual Convention. American Hospital Association 48: 369-373

Grimes, T.; Duggan, C.; Delaney, T. 2010: Pharmacy services at admission and discharge in adult, acute, public hospitals in Ireland. International Journal of Pharmacy Practice 18(6): 346-352

Ried, L.D. 2009: Pharmacy services in ICU, antidepressant treatment, and Swedish pharmacists. Journal of the American Pharmacists Association: Japha 49(5): 710

Weiss, D. 2012: Pharmacy services prepares to launch online prior-authorization tool. South Dakota Medicine: the Journal of the South Dakota State Medical Association 65(3): 119

Collignon, U.; Oborne, C.Alice.; Kostrzewski, A. 2010: Pharmacy services to UK emergency departments: a descriptive study. Pharmacy World and Science: Pws 32(1): 90-96

Clews, G. 2009: Pharmacy services: powerful chemistry. Health Service Journal 119(6165): 22-24

Urbonas, G.; Jakušovaitė, I.; Savickas, A.ūn. 2010: Pharmacy specialists' attitudes toward pharmaceutical service quality at community pharmacies. Medicina 46(10): 686-692

Amesty, S.; Blaney, S.; Crawford, N.D.; Rivera, A.V.; Fuller, C. 2012: Pharmacy staff characteristics associated with support for pharmacy-based HIV testing. Journal of the American Pharmacists Association: Japha 52(4): 472-479; 1-9

Law, M.G.; Komura, S.; Murchison, A.P.; Pizzi, L.T. 2013: Pharmacy staff opinions regarding diabetic retinopathy screenings in the community setting: findings from a brief survey. American Health and Drug Benefits 6(9): 548-552

Glazier, H.S.; Malen, J. 2007: Pharmacy staffing and productivity. American Journal of Health-System Pharmacy: Ajhp: Official Journal of the American Society of Health-System Pharmacists 64(22): 2320 2322-3; Author Reply 2323-4

Westrick, S.C.; Mount, J.K.; Watcharadamrongkun, S.; Breland, M.L. 2008: Pharmacy stages of involvement in pharmacy-based immunization services: results from a 17-state survey. Journal of the American Pharmacists Association: Japha 48(6): 764-773

Terkola, R. 2008: Pharmacy standards for clinical trials. Onkologie 31(Suppl 2): 25-28

Hidayat, L.; Vansal, S.; Kim, E.; Sullivan, M.; Salbu, R. 2012: Pharmacy student absenteeism and academic performance. American Journal of Pharmaceutical Education 76(1): 8

Sonthisombat, P. 2008: Pharmacy student and preceptor perceptions of preceptor teaching behaviors. American Journal of Pharmaceutical Education 72(5): 110

Cain, J.; Campbell, T.; Congdon, H.B.; Hancock, K.; Kaun, M.; Lockman, P.R.; Evans, R.L. 2014: Pharmacy student debt and return on investment of a pharmacy education. American Journal of Pharmaceutical Education 78(1): 5

Christensen, S.ør.T.; Søndergaard, B.; Honoré, P.H.; Bjerrum, O.J. 2011: Pharmacy student driven detection of adverse drug reactions in the community pharmacy setting. Pharmacoepidemiology and Drug Safety 20(4): 399-404

McLaughlin, J.E.; Griffin, L.M.; Esserman, D.A.; Davidson, C.A.; Glatt, D.M.; Roth, M.T.; Gharkholonarehe, N.; Mumper, R.J. 2013: Pharmacy student engagement, performance, and perception in a flipped satellite classroom. American Journal of Pharmaceutical Education 77(9): 196

Bhavsar, V.M.; Bird, E.; Anderson, H.M. 2007: Pharmacy student focus groups for formative evaluation of the learning environment. American Journal of Pharmaceutical Education 71(2): 22

Carey, K.M.; Cross, J.E.; Silva, M.A.; Stefan, M.S.; Rothberg, M.B. 2011: Pharmacy student impact on inappropriate prescribing of acid suppressive therapy. American Journal of Pharmaceutical Education 75(9): 175

Rickles, N.M.; Noland, C.M.; Tramontozzi, A.; Vinci, M.A. 2010: Pharmacy student knowledge and communication of medication errors. American Journal of Pharmaceutical Education 74(4): 60

Ray, S.' M.; Wylie, D.R.; Shaun Rowe, A.; Heidel, E.; Franks, A.S. 2012: Pharmacy student knowledge retention after completing either a simulated or written patient case. American Journal of Pharmaceutical Education 76(5): 86

Kalari, S.; Dormarunno, M.; Zvenigorodsky, O.; Mohan, A. 2011: Pharmacy student perceptions of adverse event reporting. American Journal of Pharmaceutical Education 75(7): 131

Sheaffer, E.A.; Addo, R.T. 2013: Pharmacy student performance on constructed-response versus selected-response calculations questions. American Journal of Pharmaceutical Education 77(1): 6

Antworth, A.; Maffeo, C. 2014: Pharmacy student self-perception of weight and relationship to counseling patients on lifestyle modification. American Journal of Pharmaceutical Education 78(2): 35

Stewart, D.; Panus, P.; Hagemeier, N.; Thigpen, J.; Brooks, L. 2014: Pharmacy student self-testing as a predictor of examination performance. American Journal of Pharmaceutical Education 78(2): 32

Kato, H. 2011: Pharmacy student's approach on dope prevention education. Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan 131(12): 1757-1760

Kapp, K.; Talv, S.; Hinrikus, T.; Raal, A. 2012: Pharmacy students at the University of Tartu 1802-2010--a historical study. Die Pharmazie 67(7): 658-664

Jarrett, W.A. 1949: Pharmacy students learn in outpatient service. Hospital Progress 30(10): 294-296

Dalal, K.; McCall, K.L.; Fike, D.S.; Horton, N.; Allen, A. 2010: Pharmacy students provide care comparable to pharmacists in an outpatient anticoagulation setting. American Journal of Pharmaceutical Education 74(8): 139

Stebbins, M.R.; Frear, M.E.; Cutler, T.W.; Lightwood, J.M.; Fingado, A.R.; Lai, C.J.; Lipton, H.L. 2013: Pharmacy students teaching prescribers strategies to lower prescription drug costs for underserved patients. Journal of Managed Care Pharmacy: Jmcp 19(7): 534-541

Cain, J.; Scott, D.R.; Akers, P. 2009: Pharmacy students' Facebook activity and opinions regarding accountability and e-professionalism. American Journal of Pharmaceutical Education 73(6): 104

Degeeter, M.; Harris, K.; Kehr, H.; Ford, C.; Lane, D.C.; Nuzum, D.S.; Compton, C.; Gibson, W. 2014: Pharmacy students' ability to identify plagiarism after an educational intervention. American Journal of Pharmaceutical Education 78(2): 33

Saverno, K.R.; Malone, D.C.; Kurowsky, J. 2009: Pharmacy students' ability to identify potential drug-drug interactions. American Journal of Pharmaceutical Education 73(2): 27

Schneider, E.F.; Castleberry, A.N.; Vuk, J.; Stowe, C.D. 2014: Pharmacy students' ability to think about thinking. American Journal of Pharmaceutical Education 78(8): 148

Krueger, J.L. 2013: Pharmacy students' application of knowledge from the classroom to introductory pharmacy practice experiences. American Journal of Pharmaceutical Education 77(2): 31

Smith, L.; Saini, B.; Krass, I.; Chen, T.; Bosnic-Anticevich, S.; Sainsbury, E. 2007: Pharmacy students' approaches to learning in an Australian university. American Journal of Pharmaceutical Education 71(6): 120

Smith, L.; Krass, I.; Sainsbury, E.; Rose, G. 2010: Pharmacy students' approaches to learning in undergraduate and graduate entry programs. American Journal of Pharmaceutical Education 74(6): 106

Neville, M.W. 2014: Pharmacy students' attitudes about treating patients with alcohol addiction after attending a required mutual support group. American Journal of Pharmaceutical Education 78(2): 39

Shah, B.; Rahim, H.; Yin, H.; Bhavsar, J. 2009: Pharmacy students' attitudes toward a required public health course and developing a public health program. American Journal of Pharmaceutical Education 73(7): 134

Volmer, D.; Mäesalu, M.; Bell, J.S. 2008: Pharmacy students' attitudes toward and professional interactions with people with mental disorders. International Journal of Social Psychiatry 54(5): 402-413

Beall, J.W.; Broeseker, A.E. 2010: Pharmacy students' attitudes toward death and end-of-life care. American Journal of Pharmaceutical Education 74(6): 104

Adkins, D.M.; Mayhew, S.L.; Gavaza, P.; Rahman, S. 2012: Pharmacy students' attitudes toward geriatric nursing home patients. American Journal of Pharmaceutical Education 76(5): 81

El Hajj, M.S.; Hammad, A.S.; Afifi, H.M. 2014: Pharmacy students' attitudes toward pharmaceutical care in Qatar. Therapeutics and Clinical Risk Management 10: 121-129

Al-Arifi, M.N. 2009: Pharmacy students' attitudes toward pharmaceutical care in Riyadh region Saudi Arabia. Pharmacy World and Science: Pws 31(6): 677-681

Gavaza, P.; Bui, B. 2012: Pharmacy students' attitudes toward reporting serious adverse drug events. American Journal of Pharmaceutical Education 76(10): 194

Murphy, A.; Szumilas, M.; Rowe, D.; Landry, K.; Martin-Misener, R.; Kutcher, S.; Gardner, D. 2014: Pharmacy students' experiences in provision of community pharmacy mental health services. Canadian Pharmacists Journal: Cpj 147(1): 55-65

Fisher, C.L.; Wilson, S.A. 2010: Pharmacy students' exposure to a culture of safety and their communication of medication errors. American Journal of Pharmaceutical Education 74(9): 176a; Author Reply 176b

Taylor, S.J.; Maharaj, P.; Williams, K.; Sheldrake, C. 2009: Pharmacy students' intention to practise in a rural setting: measuring the impact of a rural curriculum, rural campus and rural placement on a predominantly metropolitan student cohort. Australian Journal of Rural Health 17(6): 305-309

Emmerton, L.; Jiang, H.; McKauge, L. 2014: Pharmacy students' interpretation of academic integrity. American Journal of Pharmaceutical Education 78(6): 119

Elkalmi, R.M.; Hassali, M.A.; Ibrahim, M.I.M.; Widodo, R.T.; Efan, Q.M.A.; Hadi, M.A. 2011: Pharmacy students' knowledge and perceptions about pharmacovigilance in Malaysian public universities. American Journal of Pharmaceutical Education 75(5): 96

Moeller, K.E.; Shireman, T.I.; Generali, J.; Rigler, S.; Mayorga, A. 2010: Pharmacy students' knowledge of black box warnings. American Journal of Pharmaceutical Education 74(1): 5

Urmie, J.M.; Farris, K.B.; Herbert, K.E. 2007: Pharmacy students' knowledge of the Medicare drug benefit and intention to provide Medicare medication therapy management services. American Journal of Pharmaceutical Education 71(3): 41

Ragland, D.; West, D. 2009: Pharmacy students' knowledge, attitudes, and behaviors regarding emergency contraception. American Journal of Pharmaceutical Education 73(2): 26

Naik, R.K.; Borrego, M.E.; Gupchup, G.V.; Dodd, M.; Sather, M.R. 2007: Pharmacy students' knowledge, attitudes, and evaluation of direct-to-consumer advertising. American Journal of Pharmaceutical Education 71(5): 86

Branch, C. 2013: Pharmacy students' learning and satisfaction with high-fidelity simulation to teach drug-induced dyspepsia. American Journal of Pharmaceutical Education 77(2): 30

Harrington, A.R.; Desselle, S.P.; Apgar, D.A.; Hesselbacher, E.; Pié, A.; Quesnel, A.; Warholak, T.L. 2013: Pharmacy students' opinions of direct-to-consumer advertising: a pilot study at one university. Research in Social and Administrative Pharmacy: Rsap 9(4): 458-466

Nykamp, D.; Murphy, J.E.; Marshall, L.L.; Bell, A. 2010: Pharmacy students' participation in a research experience culminating in journal publication. American Journal of Pharmaceutical Education 74(3): 47

Kotani, H.; Mizuno, T.; Kuwahara, H.; Ando, Y.; Ito, K.; Nimi, T.; Ohashi, M.; Asai, R.; Hida, H.; Hirabayashi, A.; Murosaki, C.; Kato, H.; Noda, Y.; Nabeshima, T. 2010: Pharmacy students' participation in medicinal education for children. Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan 130(6): 857-866

Rahim, H.; Shah, B. 2010: Pharmacy students' perceptions and emotional responses to aggressive incidents in pharmacy practice. American Journal of Pharmaceutical Education 74(4): 61

Kim, S.E.; Whittington, J.I.; Nguyen, L.M.; Ambrose, P.J.; Corelli, R.L. 2010: Pharmacy students' perceptions of a required senior research project. American Journal of Pharmaceutical Education 74(10): 190

Surratt, C.K.; Desselle, S.P. 2007: Pharmacy students' perceptions of a teaching evaluation process. American Journal of Pharmaceutical Education 71(1): 6

Wu, K.; Davison, L.; Heck Sheehan, A. 2012: Pharmacy students' perceptions of and attitudes towards peer assessment within a drug literature evaluation course. American Journal of Pharmaceutical Education 76(4): 62

Cooper, L.-A.; Vellurattil, R.P.; Quiñones-Boex, A. 2014: Pharmacy students' perceptions of cultural competence encounters during practice experiences. American Journal of Pharmaceutical Education 78(2): 31

Prescott, J.; Wilson, S.E.; Wan, K.-W. 2014: Pharmacy students' perceptions of natural science and mathematics subjects. American Journal of Pharmaceutical Education 78(6): 118

Scott, D.M.; Friesner, D.L.; Miller, D.R. 2010: Pharmacy students' perceptions of their preparedness to provide pharmaceutical care. American Journal of Pharmaceutical Education 74(1): 8

Holtzman, C.W.; Sifontis, N.M. 2014: Pharmacy students' perspectives on a PharmD/MPH dual degree program at a large metropolitan school of pharmacy. Pharmacy practice 12(1): 359

Gallimore, C.; George, A.K.; Brown, M.C. 2008: Pharmacy students' preferences for various types of simulated patients. American Journal of Pharmaceutical Education 72(1): 04

Fuller, S.; Horlen, C.; Cisneros, R.; Merz, T. 2007: Pharmacy students' reading ability and the readability of required reading materials. American Journal of Pharmaceutical Education 71(6): 111

Kopacek, K.B.; Dopp, A.L.; Dopp, J.M.; Vardeny, O.; Sims, J.J. 2010: Pharmacy students' retention of knowledge and skills following training in automated external defibrillator use. American Journal of Pharmaceutical Education 74(6): 109

Gilligan, A.M.; Warholak, T.L.; Murphy, J.E.; Hines, L.E.; Malone, D.C. 2011: Pharmacy students' retention of knowledge of drug-drug interactions. American Journal of Pharmaceutical Education 75(6): 110

Waskiewicz, R.A. 2011: Pharmacy students' test-taking motivation-effort on a low-stakes standardized test. American Journal of Pharmaceutical Education 75(3): 41

Anwar, M.; Norris, P.; Green, J.; Au, S.; Li, G.; Ma, M.; Prentice, R.; Shum, A.; Siaw, L.-A.; Yoo, S.; Zhang, S. 2015: Pharmacy students' use of and beliefs about traditional healthcare. Journal of Immigrant and Minority Health 17(3): 895-904

Hall, M.; Hanna, L-Anne.; Quinn, S. 2012: Pharmacy students' views of faculty feedback on academic performance. American Journal of Pharmaceutical Education 76(1): 5

Pittenger, A.L.; Starner, C.I.; Thompson, K.; Gleason, P.P. 2010: Pharmacy students' views of managed care pharmacy and PBMS: should there be more exposure to managed care in the pharmacy curriculum?. Journal of Managed Care Pharmacy: Jmcp 16(5): 346-354

Necyk, C.; Tsuyuki, R.T.; Boon, H.; Foster, B.C.; Legatt, D.; Cembrowski, G.; Murty, M.; Barnes, J.; Charrois, T.L.; Arnason, J.T.; Ware, M.A.; Rosychuk, R.J.; Vohra, S. 2014: Pharmacy study of natural health product adverse reactions (SONAR): a cross-sectional study using active surveillance in community pharmacies to detect adverse events associated with natural health products and assess causality. Bmj Open 4(3): E003431

Manasse, H.R.; Menighan, T.E. 2011: Pharmacy technician education, training, and certification: call for a single national standard and public accountability. Journal of the American Pharmacists Association: Japha 51(3): 326-327

Bess, D.T.; Carter, J.; DeLoach, L.; White, C.L. 2014: Pharmacy technician-to-pharmacist ratios: a state-driven safety and quality decision. Journal of the American Pharmacists Association: Japha 54(6): 648-651

Knight, H.; Edgerton, L.; Foster, R. 2010: Pharmacy technicians obtaining medication histories within the emergency department. American Journal of Health-System Pharmacy: Ajhp: Official Journal of the American Society of Health-System Pharmacists 67(7): 512-514

Benavides, S.; Rambaran, K.A. 2013: Pharmacy technicians: Expanding role with uniform expectations, education and limits in scope of practice. Journal of Research in Pharmacy Practice 2(4): 135-137

Raal, A.; Hinrikus, T.; Tankler, H. 2009: Pharmacy textbooks used at the University of Tartu/Dorpat 1802-1918. Die Pharmazie 64(4): 276-283

Gesoalde, N.S. 1947: Pharmacy today. New York State Pharmacist 22(12): 20

Scahill, S.; Harrison, J.; Sheridan, J. 2010: Pharmacy under the spotlight: New Zealand pharmacists' perceptions of current and future roles and the need for accreditation. International Journal of Pharmacy Practice 18(1): 59-62

Renberg, T.; Wichman Törnqvist, K.; Kälvemark Sporrong, S.; Kettis Lindblad, A.; Tully, M.P. 2011: Pharmacy users' expectations of pharmacy encounters: a Q-methodological study. Health Expectations: An International Journal of Public Participation in Health Care and Health Policy 14(4): 361-373

Zellmer, W.A. 2008: Pharmacy vision and leadership: revisiting the fundamentals. PharmacoTherapy 28(12): 1437-1442

Carpenter, L.A.; Edgar, Z.; Dang, C. 2011: Pharmacy waste, fraud, and abuse in health care reform. Journal of the American Pharmacists Association: Japha 51(2): E3-16

Lofwall, M.R.; Wunsch, M.J.; Walsh, S.L. 2010: Pharmacy willingness to partner with office-based opioid dependence treatment providers in conducting random buprenorphine pill counts. American Journal on Addictions 19(2): 195-196

Schneider, P.J. 2008: Pharmacy without borders. American Journal of Health-System Pharmacy: Ajhp: Official Journal of the American Society of Health-System Pharmacists 65(16): 1513-1519

Billings, D.L.; Walker, D.; Mainero del Paso, G.; Clark, K.A.; Dayananda, I. 2009: Pharmacy worker practices related to use of misoprostol for abortion in one Mexican state. Contraception 79(6): 445-451

Ngo, T.D.; Park, M.Hae.; Nguyen, T.H. 2012: Pharmacy workers' knowledge and provision of abortifacients in Ho Chi Minh City, Vietnam. International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics 117(2): 187-188

Wen, Y.; Guan, J.; Wu, Z.; Li, L.; Rotheram-Borus, M.Jane.; Lin, C.; Detels, R. 2009: Pharmacy workers' sexually transmitted diseases/human immunodeficiency virus knowledge in Fuzhou, China: implications for human immunodeficiency virus testing, treatment, and prevention strategies. Sexually Transmitted Diseases 36(4): 221-226

Fischelis, R.P. 1935: Pharmacy's Unfinished Tasks. Science 81(2100): 301-306

Carmichael, J.M. 2013: Pharmacy's bucket list: lean in. American Journal of Health-System Pharmacy: Ajhp: Official Journal of the American Society of Health-System Pharmacists 70(16): 1375-1382

Zellmer, W.A. 2010: Pharmacy's future: Transformation, diffusion, and imagination. American Journal of Health-System Pharmacy: Ajhp: Official Journal of the American Society of Health-System Pharmacists 67(14): 1199-1204

Zellmer, W.A. 2009: Pharmacy's organizations--key issues for future historians. Pharmacy in History 51(3): 128-133

Fishwick, S. 2008: Pharmacy's perfect prescription. Health Service Journal 118(6135): 18

Kehrer, J.P.; Eberhart, G.; Wing, M.; Horon, K. 2013: Pharmacy's role in a modern health continuum. Canadian Pharmacists Journal: Cpj 146(6): 321-324

Hamilton, L. 2009: Pharmacy's stars climb to reach our potential. Journal of the American Pharmacists Association: Japha 49(4): 482-485

Traynor, K. 2007: Pharmacy, public health intersect in Alabama disaster plans. American Journal of Health-System Pharmacy: Ajhp: Official Journal of the American Society of Health-System Pharmacists 64(19): 1998-1999

Cain, J.; Romanelli, F.; Fox, B. 2010: Pharmacy, social media, and health: Opportunity for impact. Journal of the American Pharmacists Association: Japha 50(6): 745-751

David, A. 1953: Data on the decomposition of orthoboric acid, and boric acid solutions. A Gyogyszeresz 8(8): 144-145

Anderson, S. 2008: Pharmacy, trade and empire: medicines and the English East India Company 1600 to 1858. Pharmaceutical Historian 38(2): 23-29

Marra, F.; Kaczorowski, J.; Gastonguay, L.; Marra, C.A.; Lynd, L.D.; Kendall, P. 2014: Pharmacy-based Immunization in Rural Communities Strategy (PhICS): a community cluster-randomized trial. Canadian Pharmacists Journal: Cpj 147(1): 33-44

Michie, L.; Cameron, S.T.; Glasier, A.; Larke, N.; Muir, A.; Lorimer, A. 2014: Pharmacy-based interventions for initiating effective contraception following the use of emergency contraception: a pilot study. Contraception 90(4): 447-453

Fischer, M.A.; Choudhry, N.K.; Bykov, K.; Brill, G.; Bopp, G.; Wurst, A.M.; Shrank, W.H. 2014: Pharmacy-based interventions to reduce primary medication nonadherence to cardiovascular medications. Medical Care 52(12): 1050-1054

Lippi, G.; Siest, G.ér.; Plebani, M. 2008: Pharmacy-based laboratory services: past or future and risk or opportunity?. Clinical Chemistry and Laboratory Medicine 46(4): 435-436

Smith, S.B.; Mango, M.D. 2013: Pharmacy-based medication reconciliation program utilizing pharmacists and technicians: a process improvement initiative. Hospital Pharmacy 48(2): 112-119

Walker, N.; Doughty, R.; Parag, V.; Harrison, J.; Bennett, M.; Freedman, B. 2014: Pharmacy-based screening for atrial fibrillation in high-risk Maori and Pacific populations. New Zealand Medical Journal 127(1398): 128-131

Rani, R. 2008: Pharmacy-based sexual health services and clinical governance. Journal of Family Planning and Reproductive Health Care 34(4): 274

Warden, B.A.; Freels, J.Pryor.; Furuno, J.P.; Mackay, J. 2014: Pharmacy-managed program for providing education and discharge instructions for patients with heart failure. American journal of health-system pharmacy: AJHP: official journal of the American Society of Health-System Pharmacists 71(2): 134-139

Tessier, E.G.; Henneman, E.A.; Nathanson, B.; Plotkin, K.; Heelon, M. 2010: Pharmacy-nursing intervention to improve accuracy and completeness of medication histories. American Journal of Health-System Pharmacy: Ajhp: Official Journal of the American Society of Health-System Pharmacists 67(8): 607-611

Moya Gómez, P.; Cía Lecumberri, J.J. 2008: Pharmacy-provided management of medicinal gases. Farmacia Hospitalaria: Organo Oficial de Expresion Cientifica de la Sociedad Espanola de Farmacia Hospitalaria 32(4): 255-256

O'Hanlon, S. 2013: Pharmacy. a fully integrated patient care team. Health Service Journal 123(6363): 22-23

Moore, A. 2012: Pharmacy. Change the script. Health Service Journal 122(6329): Suppl: 10-11

Kreimer, S. 2007: Pharmacy. Medicare drug plan poses challenges for treating home patients. Hospitals and Health Networks 81(7): 33

Moore, A. 2012: Integrated care. Together we stand. Health Service Journal 122(6329): Suppl: 14-15

Patel, A. 2007: Pharmacy: no longer a "second choice" career. American Journal of Pharmaceutical Education 71(4): 74

Isaacs, D. 2009: Pharmageddon. Journal of Paediatrics and Child Health 45(9): 479-480

Citrome, L.; Karagianis, J.; Maguire, G.A.; Nierenberg, A.A. 2014: Pharmaism: a tale of two perspectives. International Journal of Clinical Practice 68(6): 659-661

Shimizu, Y.; Tomino, Y. 2012: Pharmakokinetics of hydrophobic drugs: hepatic metabolism and excretion. Nihon Jinzo Gakkai Shi 54(7): 972-976

Dittrich, P.; Ostrowski, J.; Kukovetz, W.R. 1982: Pharmakokinetik von 7,3', 4'-Tri-O-(2-hydroxyethyl)-rutin (Troxerutin) nach oraler Applikation am Menschen. Planta Medica 45(3): 146

Pliasunova, M.M.; Antelava, N.A.; Bekaia, G.L.; Imanishvili, T.Z.; Kvachadze, I.D. 2013: Pharmakological characteristic of some amide local anesthetics, currently used in dental clinics. Georgian Medical News 223: 65-71

Boominathan, R.; Devi, B.P.; Mandal, S.C. 2005: Pharmamacgnostical evaluation of ionldium suffrlitlcosam ging (family: violaceae). Ancient Science of Life 25(1): 34-38

Biron, P.; Plaisance, M.; Lévesque, P. 2007: Pharmas-co-dependence exposed: would it be time to say, "no thanks"?. Canadian Family Physician Medecin de Famille Canadien 53(10): 1635-1637; 1643-1645

Schoettler, P.; Dingermann, T.; Schubert-Zsilavecz, M. 2009: Pharmazie in unserer Zeit 1/2009. Pharmazie in Unserer Zeit 38(1): 3

Holzgrabe, U.; Schlitzer, M.; Steinmetzer, T. 2011: Pharmazie in unserer Zeit 2/2011. Pharmazie in Unserer Zeit 40(2): 95

Link, A.; Schubert-Zsilavecz, M. 2009: Pharmazie in unserer Zeit 3/2009. Pharmazie in Unserer Zeit 38(3): 201

Marschalek, R.; Dingermann, T. 2012: Pharmazie in unserer Zeit 3/2012. Pharmazie in Unserer Zeit 41(3): 179

Dingermann, T.; Laufer, S.; Winckler, T. 2008: Pharmazie in unserer Zeit 5/2008. Pharmazie in Unserer Zeit 37(5): 349

Shankar, P.R. 2008: PharmedOut. Singapore Medical Journal 49(4): 363-365

Koes, D.R.; Camacho, C.J. 2011: Pharmer: efficient and exact pharmacophore search. Journal of Chemical Information and Modeling 51(6): 1307-1314

Liénard, D.; Sourrouille, C.; Gomord, V.ér.; Faye, L.ïc. 2007: Pharming and transgenic plants. Biotechnology Annual Review 13: 115-147

Baer-Dubowska, W.; Majchrzak-Celińska, A.; Cichocki, M.ł 2011: Pharmocoepigenetics: a new approach to predicting individual drug responses and targeting new drugs. Pharmacological Reports: Pr 63(2): 293-304

Kudo, Y.; Komuro, I.; Akazawa, H. 2007: Pharmocological therapeutics for chronic heart failure--how to use ARB (angiotensin receptor blocker. Nihon Rinsho. Japanese Journal of Clinical Medicine 65(Suppl 5): 84-89

Garten, Y.; Altman, R.B. 2009: Pharmspresso: a text mining tool for extraction of pharmacogenomic concepts and relationships from full text. Bmc Bioinformatics 10(Suppl 2): S6

Laroche, R.; Maistre, B. 2011: Pharo School - le Pharo. Medecine Tropicale: Revue du Corps de Sante Colonial 71(1): 17-20

Mocco, J.; Darkhabani, Z.; Levy, E.I. 2009: Pharos neurovascular intracranial stent: elective use for a symptomatic stenosis refractory to medical therapy. Catheterization and Cardiovascular Interventions: Official Journal of the Society for Cardiac Angiography and Interventions 74(4): 642-646

Belov, B.S. 2013: Pharyngeal A-streptococcal infection encountered in the practical work of an internal medicine specialist. Vestnik Otorinolaringologii 3: 39-43

Karlsson, A.; Österlund, A.; Forssén, A. 2011: Pharyngeal Chlamydia trachomatis is not uncommon any more. Scandinavian Journal of Infectious Diseases 43(5): 344-348

Harmer, W.D. 1914: Pharyngeal Cyst. Proceedings of the Royal Society of Medicine 7(Laryngol Sect): 97-98

Kelson, W.H. 1919: Pharyngeal Diverticula with Notes of Two Cases-in one the Pouch was Removed under Local, in the other under General, Anaesthesia. Proceedings of the Royal Society of Medicine 12(Laryngol Sect): 248-250

Kelson, W.H. 1919: Pharyngeal Diverticula with Notes of Two Cases-in one the Pouch was Removed under Local, in the other under General, Anæsthesia. Proceedings of the Royal Society of Medicine 12(Laryngol Sect): 248-250

Law, H. 1920: Pharyngeal Diverticuli; Report of Two Cases. Proceedings of the Royal Society of Medicine 13(Laryngol Sect): 108-113

Kisch, H. 1927: Pharyngeal Diverticulum. Proceedings of the Royal Society of Medicine 20(10): 1623-1626

Ramachandran, R.B.; Swash, M. 2004: Pharyngeal Dysphagia in dermatomyositis: responsive to cyclophosphamide. Journal of Clinical Neuromuscular Disease 5(3): 166-167

Harmer, W.D. 1915: Pharyngeal Fistula in an Old man after Operation on Abscess in the Neck. Proceedings of the Royal Society of Medicine 8(Laryngol Sect): 108

Badgerow, G. 1925: Pharyngeal Growth in a man aged 70. Proceedings of the Royal Society of Medicine 18(Laryngol Sect): 54

Noguchi, Y. 2009: Pharyngeal Neisseria gonorrhoeae and Chlamydia trachomatis infections. Nihon Rinsho. Japanese Journal of Clinical Medicine 67(1): 173-176

Takahashi, S.; Kurimura, Y.; Hashimoto, J.; Takeyama, K.; Koroku, M.; Tanda, H.; Nishimura, M.; Tsukamoto, T. 2008: Pharyngeal Neisseria gonorrhoeae detection in oral-throat wash specimens of male patients with urethritis. Journal of Infection and Chemotherapy: Official Journal of the Japan Society of ChemoTherapy 14(6): 442-444

Robin, I. 1959: Pharyngeal Pouch. Proceedings of the Royal Society of Medicine 52(6): 479

Hill, W. 1918: Pharyngeal Pouch treated by Diverticulo-pexy. Proceedings of the Royal Society of Medicine 11(Laryngol Sect): 60-63

Finzi, N.S. 1917: Pharyngeal Pouches. Proceedings of the Royal Society of Medicine 10(Electro Ther Sect): 63-76

Faulder, T.J.; Harmer, W.D. 1912: Pharyngeal Tuberculosis; Tuberculous Lesions of other Parts; Treatment by Injections of Tuberculin. Proceedings of the Royal Society of Medicine 5(Laryngol Sect): 55-57

Tamplin, E.C. 1933: Pharyngeal Tumour. Proceedings of the Royal Society of Medicine 26(3): 239-240

Neilson, D.F. 1932: Pharyngeal Ulceration (Bilateral). Case for Diagnosis. Proceedings of the Royal Society of Medicine 25(4): 450

Korkis, F.B. 1948: Pharyngeal abscesses in young children. Practitioner 161(963): 199-202

Leonard, R.; Belafsky, P.; McKenzie, S. 2008: Pharyngeal adaptation in Zenker's diverticulum: the "faux pharyngoesophageal segment". Otolaryngology--Head and Neck Surgery: Official Journal of American Academy of Otolaryngology-Head and Neck Surgery 139(3): 424-428

Zang, H.-R.; Li, L.-F.; Zhou, B.; Li, Y.-C.; Wang, T.; Han, D.-M. 2012: Pharyngeal aerodynamic characteristics of obstructive sleep apnea/hypopnea syndrome patients. Chinese Medical Journal 125(17): 3039-3043

Kim, J.-S.; Kim, J.K.; Hong, S.-C.; Cho, J.H. 2010: Pharyngeal airway changes after sagittal split ramus osteotomy of the mandible: a comparison between genders. Journal of Oral and Maxillofacial Surgery: Official Journal of the American Association of Oral and Maxillofacial Surgeons 68(8): 1802-1806

Tuncer, B.B.ş; Kaygisiz, E.; Tuncer, C.; Yüksel, S. 2009: Pharyngeal airway dimensions after chin cup treatment in Class IIi malocclusion subjects. Journal of Oral Rehabilitation 36(2): 110-117

Mislik, B.; Hänggi, M.P.; Signorelli, L.; Peltomäki, T.A.; Patcas, R. 2014: Pharyngeal airway dimensions: a cephalometric, growth-study-based analysis of physiological variations in children aged 6-17. European Journal of Orthodontics 36(3): 331-339

Takemoto, Y.; Saitoh, I.; Iwasaki, T.; Inada, E.; Yamada, C.; Iwase, Y.; Shinkai, M.; Kanomi, R.; Hayasaki, H.; Yamasaki, Y. 2011: Pharyngeal airway in children with prognathism and normal occlusion. Angle Orthodontist 81(1): 75-80

Dua, K.; Surapaneni, S.N.; Kuribayashi, S.; Hafeezullah, M.; Shaker, R. 2011: Pharyngeal airway protective reflexes are triggered before the maximum volume of fluid that the hypopharynx can safely hold is exceeded. American Journal of Physiology. Gastrointestinal and Liver Physiology 301(2): G197-G202

Prado, F.B.; Rossi, A.C.; Freire, A.R.; Groppo, F.C.; De Moraes, M.; Caria, P.H.F. 2012: Pharyngeal airway space and frontal and sphenoid sinus changes after maxillomandibular advancement with counterclockwise rotation for Class Ii anterior open bite malocclusions. Dento Maxillo Facial Radiology 41(2): 103-109

Aydemir, H.; Memikoğlu, U.; Karasu, H. 2012: Pharyngeal airway space, hyoid bone position and head posture after orthognathic surgery in Class IIi patients. Angle Orthodontist 82(6): 993-1000

Efendiyeva, R.; Aydemir, H.; Karasu, H.; Toygar-Memikoğlu, U. 2014: Pharyngeal airway space, hyoid bone position, and head posture after bimaxillary orthognathic surgery in Class IIi patients: long-term evaluation. Angle Orthodontist 84(5): 773-781

Grauer, D.; Cevidanes, L.S.H.; Styner, M.A.; Ackerman, J.L.; Proffit, W.R. 2009: Pharyngeal airway volume and shape from cone-beam computed tomography: relationship to facial morphology. American Journal of Orthodontics and Dentofacial Orthopedics: Official Publication of the American Association of Orthodontists its Constituent Societies and the American Board of Orthodontics 136(6): 805-814

Hill, W. 1926: Pharyngeal and Oesophageal Diverticula. British Medical Journal 2(3441): 1163-1169

Godar, D.E.; Tang, R.; Merrill, S.J. 2014: Pharyngeal and cervical cancer incidences significantly correlate with personal UV doses among whites in the United States. Anticancer Research 34(9): 4993-4999

Huang, Y-jiu.; Bao, X-li.; Liu, J. 2013: Pharyngeal and laryngeal syphilis-report of three cases. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 48(1): 69-70

Bali, R.; Sharma, P.; Gupta, K.; Nagrath, S. 2013: Pharyngeal and peritonsillar abscess due to Leclercia adecarboxylata in an immunocompetant patient. Journal of Infection in Developing Countries 7(1): 46-50

Ball, S.L.; Kwong, F.N.K.; Young, F.; Robson, A.K. 2014: Pharyngeal angiosarcoma following multimodal treatment for oropharyngeal squamous cell carcinoma. Annals of the Royal College of Surgeons of England 96(2): E5-E6

Proctor, M.I.; Shadle, C.H.; Iskarous, K. 2010: Pharyngeal articulation in the production of voiced and voiceless fricatives. Journal of the Acoustical Society of America 127(3): 1507-1518

Adair, M. 1948: Pharyngeal bursa associated with cleft palate; report of two cases. Plastic and Reconstructive Surgery 3(4): 479-480

Kyper, F.T.; Cross, R.J. 1948: Pharyngeal bursitis; a case report. Bulletin of the School of Medicine 33(1): 35-39

Saito, M.; Yamashita, K.; Tanuma, T.; Kaneto, H.; Murakami, K.; Onodera, K.; Shimizu, H.; Sakamoto, H.; Hosokawa-Motoya, M.; Arimura, Y.; Shinomura, Y. 2013: Pharyngeal cancer surveillance using narrow band imaging during conventional upper gastrointestinal endoscopy. Digestion 88(4): 229-234

Maffei, C.; Gonçalves, M.I.R.; de Mello, M.ça.M.; Kluppel, J.h.; Camargo, P.A.M. 2007: Pharyngeal cervical neurinoma: dysphonia and dysphagia. Brazilian Journal of Otorhinolaryngology 73(5): 718

Heiser, C.; Zimmermann, I.; Sommer, J.U.; Hörmann, K.; Herr, R.M.; Stuck, B.A. 2013: Pharyngeal chemosensitivity in patients with obstructive sleep apnea and healthy subjects. Chemical Senses 38(7): 595-603

Zhi, K. 2008: Pharyngeal choristoma with squamous epithelium in an infant. Otolaryngology--Head and Neck Surgery: Official Journal of American Academy of Otolaryngology-Head and Neck Surgery 139(1): 174-175

Yagupsky, P.; Porat, N.; Pinco, E. 2009: Pharyngeal colonization by Kingella kingae in children with invasive disease. Pediatric Infectious Disease Journal 28(2): 155-157

Tarnowska, C.ła.; Grochowska-Bohatyrewicz, E.; Bień, S.; Sieczka, J.ła.; Jaworowska, E.; Lubiński, J. 2010: Pharyngeal constrictor muscles closure after total laryngectomy is that really beneficial?. Otolaryngologia Polska 64(1): 37-42

Albin, M.S. 2013: Pharyngeal cooling, brain temperature reduction and a neglect of history. Anesthesiology 118(2): 467-469

Go, L.-m.; Barton, A.K.; Ohnesorge, B. 2014: Pharyngeal diameter in various head and neck positions during exercise in sport horses. Bmc Veterinary Research 10: 117

Belafsky, P.C.; Rees, C.J.; Allen, J.; Leonard, R.J. 2010: Pharyngeal dilation in cricopharyngeus muscle dysfunction and Zenker diverticulum. Laryngoscope 120(5): 889-894

Lundkvist, K.; Friberg, D. 2010: Pharyngeal disturbances in OSAS patients before and 1 year after UPPP. Acta Oto-Laryngologica 130(12): 1399-1405

Grant, P.D.; Morgan, D.E.; Scholz, F.J.; Canon, C.L. 2009: Pharyngeal dysphagia: what the radiologist needs to know. Current Problems in Diagnostic Radiology 38(1): 17-32

Yu, W-Nien.; Chen, C-Jung.; Chen, C-Ming. 2014: Pharyngeal entomophthoromycosis. Journal of the Chinese Medical Association: Jcma 77(6): 337-340

Dali, H.; Barry, B.; Wassef, M.; Mansouri, D.; Hourseau, M.; Hénin, D.; Soufan, R. 2011: Pharyngeal fibrovascular polyp. Annales de Pathologie 31(3): 211-213

Chegar, B.E.; Shprintzen, R.J.; Curtis, M.S.; Tatum, S.A. 2007: Pharyngeal flap and obstructive apnea: maximizing speech outcome while limiting complications. Archives of Facial Plastic Surgery 9(4): 252-259

Sullivan, S.R.; Marrinan, E.M.; Mulliken, J.B. 2010: Pharyngeal flap outcomes in nonsyndromic children with repaired cleft palate and velopharyngeal insufficiency. Plastic and Reconstructive Surgery 125(1): 290-298

Collins, J.; Cheung, K.; Farrokhyar, F.; Strumas, N. 2012: Pharyngeal flap versus sphincter pharyngoplasty for the treatment of velopharyngeal insufficiency: a meta-analysis. Journal of Plastic Reconstructive and Aesthetic Surgery: Jpras 65(7): 864-868

Noll, L.; Rommel, N.; Davidson, G.P.; Omari, T.I. 2011: Pharyngeal flow interval: a novel impedance-based parameter correlating with aspiration. Neurogastroenterology and Motility: the Official Journal of the European Gastrointestinal Motility Society 23(6): 551-E206

Cedborg, A.I.H.år.; Sundman, E.; Bodén, K.; Hedström, H.W.; Kuylenstierna, R.; Ekberg, O.; Eriksson, L.I. 2014: Pharyngeal function and breathing pattern during partial neuromuscular block in the elderly: effects on airway protection. Anesthesiology 120(2): 312-325

Weinstock, H.; Workowski, K.A. 2009: Pharyngeal gonorrhea: an important reservoir of infection?. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 49(12): 1798-1800

Sathia, L.; Ellis, B.; Phillip, S.; Winston, A.; Smith, A. 2007: Pharyngeal gonorrhoea - is dual therapy the way forward?. International Journal of Std and Aids 18(9): 647-648

Kinghorn, G. 2010: Pharyngeal gonorrhoea: a silent cause for concern. Sexually Transmitted Infections 86(6): 413-414

Cone, B.M.; Taweevisit, M.; Shenoda, S.; Sobol, S.; Schemankewitz, E.; Shehata, B.M. 2012: Pharyngeal hairy polyps: five new cases and review of the literature. Fetal and Pediatric Pathology 31(3): 184-189

Kreckel, V.; Langwara, H. 2009: Pharyngeal hemorrhaging due to iatrogenic false aneurysm. Complication after cannulation of the internal jugular vein. Der Anaesthesist 58(3): 259-261

Siraj, F.; Manucha, V. 2010: Pharyngeal histoplasmosis presenting as a tumor mass in an immunocompetent host. Journal of Global Infectious Diseases 2(1): 70-71

Leopold, J.S. 1949: Pharyngeal injury caused by ingestion of glass chipped from baby-food container. Journal of Pediatrics 35(3): 373-375

Hirabayashi, Y. 2007: Pharyngeal injury related to GlideScope videolaryngoscope. Otolaryngology--Head and Neck Surgery: Official Journal of American Academy of Otolaryngology-Head and Neck Surgery 137(1): 175-176

Abdel-Latif, M.E.; Osborn, D.A. 2011: Pharyngeal instillation of surfactant before the first breath for prevention of morbidity and mortality in preterm infants at risk of respiratory distress syndrome. Cochrane Database of Systematic Reviews 2011(3): Cd008311

Hauber, H.-P.; Rüller, S.; Müller, E.; Hansen, E.; Zabel, P. 2011: Pharyngeal lavage lymphocytosis in patients with obstructive sleep apnea: a preliminary observation. Plos one 6(1): E16277

Harel, I.; Maezawa, Y.; Avraham, R.; Rinon, A.; Ma, H.-Y.; Cross, J.W.; Leviatan, N.; Hegesh, J.; Roy, A.; Jacob-Hirsch, J.; Rechavi, G.; Carvajal, J.; Tole, S.; Kioussi, C.; Quaggin, S.; Tzahor, E. 2012: Pharyngeal mesoderm regulatory network controls cardiac and head muscle morphogenesis. Proceedings of the National Academy of Sciences of the United States of America 109(46): 18839-18844

Ni, K.; Li, S.; Xia, Q.; Zang, N.; Deng, Y.; Xie, X.; Luo, Z.; Luo, Y.; Wang, L.; Fu, Z.; Liu, E. 2012: Pharyngeal microflora disruption by antibiotics promotes airway hyperresponsiveness after respiratory syncytial virus infection. Plos one 7(7): E41104

Huckabee, M.-L.; Lamvik, K.; Jones, R. 2014: Pharyngeal mis-sequencing in dysphagia: characteristics, rehabilitative response, and etiological speculation. Journal of the Neurological Sciences 343(1-2): 153-158

Thangaswamy, C.Rajeswari. 2008: Pharyngeal morbidity and the high intracuff pressure of classic laryngeal mask airway. Anesthesia and analgesia 107(3): 1083-4; author reply 1084

Morinaga, M.; Nakata, S.; Yasuma, F.; Noda, A.; Yagi, H.; Tagaya, M.; Sugiura, M.; Teranishi, M.; Nakashima, T. 2009: Pharyngeal morphology: a determinant of successful nasal surgery for sleep apnea. Laryngoscope 119(5): 1011-1016

Fukuda, M.; Oishi, M.; Hiraishi, T.; Saito, A.; Fujii, Y. 2012: Pharyngeal motor evoked potentials elicited by transcranial electrical stimulation for intraoperative monitoring during skull base surgery. Journal of Neurosurgery 116(3): 605-610

Benjamino, K.P.; Birchard, S.J.; Niles, J.D.; Penrod, K.D. 2012: Pharyngeal mucoceles in dogs: 14 cases. Journal of the American Animal Hospital Association 48(1): 31-35

Di Giacinto, I.; Adversi, M.; Pigna, A.; Garroni, M.; Melotti, R.M. 2013: Pharyngeal mucosal injury associated with subcutaneous emphysema caused by laryngeal tube. Minerva Anestesiologica 79(11): 1313-1314

Slaughter, D.P.; DePEYSTER, F.A. 1949: Pharyngeal neurilemmomas of cranial nerve origin; medical displacement of the internal carotid artery as a diagnostic sign. Archives of Surgery 59(3): 386-397

Lévy, P.; Pépin, J.-L.; Dematteis, M. 2012: Pharyngeal neuropathy in obstructive sleep apnea: where are we going?. American Journal of Respiratory and Critical Care Medicine 185(3): 241-243

Engström, J.; Hedenstierna, G.ör.; Larsson, A. 2010: Pharyngeal oxygen administration increases the time to serious desaturation at intubation in acute lung injury: an experimental study. Critical Care 14(3): R93

Desjardin, M.; Roman, S.; des Varannes, S.Bruley.; Gourcerol, G.; Coffin, B.; Ropert, A.; Mion, Fçois.; Zerbib, F. 2013: Pharyngeal pH alone is not reliable for the detection of pharyngeal reflux events: A study with oesophageal and pharyngeal pH-impedance monitoring. United European Gastroenterology Journal 1(6): 438-444

Worrell, S.G.; DeMeester, S.R.; Greene, C.L.; Oh, D.S.; Hagen, J.A. 2013: Pharyngeal pH monitoring better predicts a successful outcome for extraesophageal reflux symptoms after antireflux surgery. Surgical Endoscopy 27(11): 4113-4118

Ulualp, S.O.; Rodriguez, S.; Cunningham, S.; Shen, J. 2007: Pharyngeal pH monitoring in infants with laryngitis. Otolaryngology--Head and Neck Surgery: Official Journal of American Academy of Otolaryngology-Head and Neck Surgery 137(5): 776-779

Appadurai, I.R.; Tomkinson, A. 2007: Pharyngeal packing during ENT surgery. Anaesthesia 62(6): 633

Erkalp, K.; Korkut, Y.A.; Meric, A.; Kahya, V.; Gedikli, O.; Su, O.K.; Saitoglu, L. 2010: Pharyngeal packing is a predisposing factor for postoperative aphthous stomatitis in nasal surgery. Otolaryngology--Head and Neck Surgery: Official Journal of American Academy of Otolaryngology-Head and Neck Surgery 142(5): 672-676

Restivo, D.A.; Solaro, C.; Maimone, D.; Pavone, A.; Marchese-Ragona, R. 2011: Pharyngeal painful tonic spasms: paroxysmal painful swallowing. Annals of Internal Medicine 155(9): 649-650

Svetlikova, M.; Starek, I.; Spenerova, M.; Potesil, J.; Sulla, I.; Hucko, C.; Mihal, V.; Balik, V. 2014: Pharyngeal perforation after blunt cervical trauma in child. International Journal of Pediatric Otorhinolaryngology 78(1): 5-9

Knight, R.B.; Webb, D.E.; P Coppola, C. 2009: Pharyngeal perforation masquerading as esophageal atresia. Journal of Pediatric Surgery 44(11): 2216-2218

Al-Jarabah, M.; Coulston, J.; Hewin, D. 2008: Pharyngeal perforation secondary to electrical shock from a Taser gun. Emergency Medicine Journal: Emj 25(6): 378

Heustis, R.J.; Ng, H.K.; Brand, K.J.; Rogers, M.C.; Le, L.T.; Specht, C.A.; Fuhrman, J.A. 2012: Pharyngeal polysaccharide deacetylases affect development in the nematode C. elegans and deacetylate chitin in vitro. Plos one 7(7): E40426

Nelson, L.L.; Coelho, J.C.; Mietelka, K.; Langohr, I.M. 2012: Pharyngeal pouch and cleft remnants in the dog and cat: a case series and review. Journal of the American Animal Hospital Association 48(2): 105-112

Yeo, J.C.L.; Mackenzie, K. 2010: Pharyngeal pouch surgery in north Glasgow: NICE (National Institute for Health and Clinical Excellence) practice or not?. Journal of Laryngology and Otology 124(5): 533-537

Colnaghi, M.; Matassa, P.G.; Fumagalli, M.; Messina, D.; Mosca, F. 2008: Pharyngeal pressure value using two continuous positive airway pressure devices. Archives of Disease in Childhood. Fetal and Neonatal Edition 93(4): F302-F304

Macrae, P.R.; Myall, D.J.; Jones, R.D.; Huckabee, M-Lee. 2011: Pharyngeal pressures during swallowing within and across three sessions: within-subject variance and order effects. Dysphagia 26(4): 385-391

Kelly, A.M.; Macfarlane, K.; Ghufoor, K.; Drinnan, M.J.; Lew-Gor, S. 2008: Pharyngeal residue across the lifespan: a first look at what's normal. Clinical Otolaryngology: Official Journal of Ent-Uk ; Official Journal of Netherlands Society for Oto-Rhino-Laryngology and Cervico-Facial Surgery 33(4): 348-351

Leconte, J. 1886: Pharyngeal respiratory movements of adult amphibia under water. Science 7(172): 462

Doll, H.; Truebel, H.; Kipfmueller, F.; Schaefer, U.; Neugebauer, E.A.M.; Wirth, S.; Maegele, M. 2009: Pharyngeal selective brain cooling improves neurofunctional and neurocognitive outcome after fluid percussion brain injury in rats. Journal of Neurotrauma 26(2): 235-242

Doll, H.; Maegele, M.; Bohl, J.ür.; Störkel, S.; Kipfmueller, F.; Schaefer, U.; Angelov, D.; Wirth, S.; Truebel, H. 2010: Pharyngeal selective brain cooling is associated with reduced CNS cortical lesion after experimental traumatic brain injury in rats. Journal of Neurotrauma 27(12): 2245-2254

Locatelli, F.; Pozzi, M.; Avantaggiato, P.; Lanfranchi, M.; Tufarulo, L.; Amorelli, V.; Rizzi, G.; Radice, S.; Galbiati, S.; Clementi, E.; Strazzer, S. 2014: Pharyngeal spasticity due to dantrolene. Journal of Clinical Pharmacy and Therapeutics 39(4): 449-451

Ongkasuwan, J.; Yung, K.C.; Courey, M.S. 2012: Pharyngeal stasis of secretions in patients with Zenker diverticulum. Otolaryngology--Head and Neck Surgery: Official Journal of American Academy of Otolaryngology-Head and Neck Surgery 146(3): 426-429

Şirinoğlu, H.; Ersoy, B.; Tezel, E. 2012: Pharyngeal suturing made easier and safer by the Peruvian fisherman's knot. Journal of Craniofacial Surgery 23(3): 948

Hoffman, M.R.; Ciucci, M.R.; Mielens, J.D.; Jiang, J.J.; McCulloch, T.M. 2010: Pharyngeal swallow adaptations to bolus volume measured with high-resolution manometry. Laryngoscope 120(12): 2367-2373

Jäghagen, E.Levring.; Bodin, I.; Isberg, A. 2008: Pharyngeal swallowing dysfunction following treatment for oral and pharyngeal cancer--association with diminished intraoral sensation and discrimination ability. Head and Neck 30(10): 1344-1351

Morinière, S.; Boiron, M.èl.; Brunereau, L.; Beutter, P.; Patat, F.éd.ér. 2011: Pharyngeal swallowing sound profile assessed after partial and total laryngectomy. Dysphagia 26(4): 366-373

Domenis, D.R.; Granzotti, R.B.; Sobreira, C.F.; Dantas, R.O. 2015: Pharyngeal transit in patients with chronic progressive external ophthalmoplegia. International Journal of Speech-Language Pathology 17(4): 384-389

Kharoubi, S. 2008: Pharyngeal tuberculosis. Annales d'Oto-Laryngologie et de Chirurgie Cervico Faciale: Bulletin de la Societe d'Oto-Laryngologie des Hopitaux de Paris 125(4): 218-223

Fang, G.; Zhang, L.; Wang, C.; Xiao, J.; Fu, Q.; Zhao, H. 2014: Pharyngeal ulcer in patients with acquired immune deficiency syndrome. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 49(2): 125-130

Nestler, C.; Reske, A.P.; Reske, A.W.; Pethke, H.; Koch, T. 2013: Pharyngeal wall injury during videolaryngoscopy-assisted intubation. Anesthesiology 118(3): 709

Domer, A.S.; Leonard, R.; Belafsky, P.C. 2014: Pharyngeal weakness and upper esophageal sphincter opening in patients with unilateral vocal fold immobility. Laryngoscope 124(10): 2371-2374

Efthymiou, M.; Raftopoulos, S.; Kortan, P. 2012: Pharyngeal webs in a patient with dysphagia and Behcet's disease. Endoscopy 44 Suppl 2 Uctn: E374

Rubin, J.E.; Chirino-Trejo, M. 2010: Pharyngeal, rectal and nasal colonization of clinically healthy dogs with Staphylococcus aureus. Veterinary Microbiology 143(2-4): 440-441

Basiri, K.; Fatehi, F.; Derakhshan, F. 2009: Pharyngeal-cervical-brachial variant of Guillain-Barre syndrome in a patient with thalassemia intermedia. Neurosciences 14(1): 71-74

Rajadhyaksha, A.; Mehra, S. 2012: Pharyngeal-cervical-brachial variant of Guillain-Barre syndrome with predominant bulbar palsy as the initial presentation of systemic lupus erythematosus and lupus nephritis: a case report. International Journal of Rheumatic Diseases 15(6): E162-E164

Más-Lázaro, C.; García-Pastor, A.; Díaz-Insa, S.; Moltó-Jordà, J.M.; Lacruz-Ballester, L. 2008: Pharyngeal-cervical-brachial variant of Guillain-Barré syndrome: a well-defined clinical condition with a heterogeneous immunological profile. Revista de Neurologia 47(11): 579-581

Thapa, R.; Biswas, B.; Mallick, D.; Mukherjee, S. 2009: Pharyngeal-cervical-brachial variant of pediatric Guillain-Barré syndrome with antecedent acute hepatitis a virus infection. Journal of Child Neurology 24(7): 865-867

Weber, R. 2014: Pharyngitis. Primary Care 41(1): 91-98

Alcaide, M.L.; Bisno, A.L. 2007: Pharyngitis and epiglottitis. Infectious Disease Clinics of North America 21(2): 449-69 Vii

Martin, J.M. 2010: Pharyngitis and streptococcal throat infections. Pediatric Annals 39(1): 22-27

Matthys, J.; De Meyere, M. 2011: Pharyngitis guidelines. Clinical Therapeutics 33(7): 990; Author Reply 990-1

Ruel, J. 2010: Pharyngitis in the convenient care setting. Advance for Nurse Practitioners 18(2): 34

Kutuya, N.; Kurosaki, Y.; Suzuki, K.; Takata, K.; Shiraihshi, A. 2008: Pharyngitis of infectious mononucleosis: computed tomography findings. Radiation Medicine 26(4): 248-251

Guha, G.; Gupta, S.; Chakraborty, S. 2005: Pharyngo oesophageal strictures and its reconstruction by delto pectoral flaps. Indian Journal of Otolaryngology and Head and Neck Surgery: Official Publication of the Association of Otolaryngologists of India 57(3): 229-234

Shephard, J.H. 1939: Pharyngo-Esophageal Diverticula: Modified Technique for One-Stage Operation. California and Western Medicine 51(3): 156-159

Tillotson, J.E. 1937: Pharyngo-Esophageal Diverticulum. California and Western Medicine 46(2): 111-112

Ziegelman, E.F. 1935: Pharyngo-Esophageal Diverticulum Pulsion Type. California and Western Medicine 42(2): 85-90

Sayles, M.; Koonce, S.L.; Harrison, L.; Beasley, N.; McRae, A.R.; Grant, D.G. 2014: Pharyngo-cutaneous fistula complicating laryngectomy in the chemo-radiotherapy organ-preservation epoch. European Archives of Oto-Rhino-Laryngology: Official Journal of the European Federation of Oto-Rhino-Laryngological Societies: Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery 271(6): 1765-1769

Iglesias-Moreno, M.ía.C.; Gimeno-Hernández, J.ús.; Gómez-Serrano, M.; Carricondo, F.; Gil-Loyzaga, P.; Poch-Broto, J.ín. 2011: Pharyngo-cutaneous fistula: an old problem revisited. Acta Oto-Laryngologica 131(12): 1311-1318

Blain, A. 1949: Pharyngo-esophageal diverticulectomy; advantages of the two-stage operation for large pulsion diverticula. Alexander Blain Hospital Bulletin 8(2): 57-68

Lahey, F.H. 1946: Pharyngo-esophageal diverticulum; its management and complications. Annals of Surgery 124: 617-636

Rommel, N. 2011: Pharyngo-esophageal motility in neurologically impaired children. Journal of Pediatric Gastroenterology and Nutrition 53(Suppl 2): S21-S22

Davis, H.J. 1909: Pharyngo-keratosis of five months' duration in a man aged 34; the Secretion swarming with Diphtheria Bacilli. Proceedings of the Royal Society of Medicine 2(Laryngol Sect): 127-129

Hill, W. 1916: Pharyngo-laryngeal Carcinoma. Proceedings of the Royal Society of Medicine 9(Laryngol Sect): 57

Parotto, M.; Micaglio, M.; Ori, C.; Trevisanuto, D. 2009: Pharyngo-laryngeal discomfort after breast surgery: comparison between orotracheal intubation and laryngeal mask. Breast 18(1): 1

Irjala, H.; Matar, N.; Remacle, M.; Georges, L. 2011: Pharyngo-laryngeal examination with the narrow band imaging technology: early experience. European Archives of Oto-Rhino-Laryngology: Official Journal of the European Federation of Oto-Rhino-Laryngological Societies: Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery 268(6): 801-806

Iriarte, J.; Palma, J-Alberto.; Fernandez, S.; Urrestarazu, E.; Alegre, M.; Artieda, J.; Baptista, P. 2013: Pharyngo-laryngoscopic video-recording in obstructive sleep apnea during natural N2 sleep. A case report of a non-complete obstructive mechanism. Sleep Medicine 14(2): 217-219

Graham, R.B.; Sugrue, P.A.; Rahme, R.J.; Batjer, H.H.; Bendok, B.R. 2013: Pharyngo-occipital artery variant arising from the internal carotid artery impacting surgical technique during carotid endarterectomy. Journal of Neurointerventional Surgery 5(3): E14

Cohen, J.é E.; Leker, R.R.; Moshe Gomori, J.; Itshayek, E. 2014: Pharyngo-occipital artery variant arising proximal to occluded internal carotid artery: the risk of an unnecessary endarterectomy. Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia 21(3): 529-531

Oishi Konari, M.; Zapater Latorre, E.; Mosquera Lloreda, N.; Basterra Alegría, J. 2013: Pharyngocele. Acta Otorrinolaringologica Espanola 64(5): 369-370

Tsutsumi, H. 2007: Pharyngoconjunctival fever (PCF)--adenovirus infection. Nihon Rinsho. Japanese Journal of Clinical Medicine 65(Suppl 3): 304-308

Vaidya, R. 2009: Pharyngocutaneous fistula after anterior cervical spine surgery. European Spine Journal: Official Publication of the European Spine Society the European Spinal Deformity Society and the European Section of the Cervical Spine Research Society 18(5): 591-592

Saki, N.; Nikakhlagh, S.; Kazemi, M. 2008: Pharyngocutaneous fistula after laryngectomy: incidence, predisposing factors, and outcome. Archives of Iranian Medicine 11(3): 314-317

Calli, C.; Pinar, E.; Oncel, S. 2011: Pharyngocutaneous fistula after total laryngectomy: Less common with mechanical stapler closure. Annals of Otology Rhinology and Laryngology 120(5): 339-344

Benson, E.M.; Hirata, R.M.; Thompson, C.B.; Ha, P.K.; Fakhry, C.; Saunders, J.R.; Califano, J.A.; Arnaoutakis, D.; Levine, M.; Tang, M.; Neuner, G.; Messing, B.P.; Blanco, R.G.F. 2015: Pharyngocutaneous fistula after total laryngectomy: a single-institution experience, 2001-2012. American journal of otolaryngology 36(1): 24-31

Pinar, E.; Oncel, S.; Calli, C.; Guclu, E.; Tatar, B. 2008: Pharyngocutaneous fistula after total laryngectomy: emphasis on lymph node metastases as a new predisposing factor. Journal of Otolaryngology - Head and Neck Surgery 37(3): 312-318

Güçlü, E.; Pinar, E.; Oncel, S.; Calli, C.ğl. 2007: Pharyngocutaneous fistula after total laryngectomy: incidence and analysis of risk factors. Kulak Burun Bogaz Ihtisas Dergisi: Kbb 17(5): 260-264

Akduman, D.; Naiboğlu, B.ş; Uslu, C.; Oysu, C.ğa.; Tek, A.; Sürmeli, M.; Kiliçarslan, Y.; Yanilmaz, M. 2008: Pharyngocutaneous fistula after total laryngectomy: incidence, predisposing factors, and treatment. Kulak Burun Bogaz Ihtisas Dergisi: Kbb 18(6): 349-354

Dedivitis, R.ér.A.; Aires, F.T.; Cernea, C.R.; Brandão, L.G. 2015: Pharyngocutaneous fistula after total laryngectomy: systematic review of risk factors. Head and Neck 37(11): 1691-1697

Rzepakowska, A.; Osuch-Wójcikiewicz, E.; Ochal-Choińska, A.; Bruzgielewicz, A.; Chęciński, P.; Nyckowska, J.; Szwedowicz, Pł. 2011: Pharyngocutaneous fistula as a complication after total laryngectomy--clinical study and literature review. Otolaryngologia Polska 65(5 Suppl): 22-30

Stathas, T.; Mallis, A.; Mastronikolis, N.S.; Naxakis, S.S.; Dimaka, K.; Panogeorgou, T.; Stavrou, S.; Margaritis, V.; Kourousis, C.; Papadas, T.A. 2011: Pharyngocutaneous fistula complicating laryngectomy: can metronidazole help?. Orl; Journal for Oto-Rhino-Laryngology and its Related Specialties 73(6): 291-294

Dedivitis, R.A.; Ribeiro, K.C.B.; Castro, M.A.F.; Nascimento, P.C. 2007: Pharyngocutaneous fistula following total laryngectomy. Acta Otorhinolaryngologica Italica: Organo Ufficiale Della Societa Italiana di Otorinolaringologia e Chirurgia Cervico-Facciale 27(1): 2-5

Ming, W.; Hua, Q.; Zhan, H. 2008: Pharyngocutaneous fistula following total laryngectomy in patients with advanced stage hypopharyngeal or laryngeal carcinomas. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 22(12): 542-543

Palomar-Asenjo, V.íc.; Sarroca Capell, E.; Tobías Gómez, S.; Pérez Hernández, I.; Palomar-García, V.íc. 2008: Pharyngocutaneous fistula following total laryngectomy. a case-control study of risk factors implicated in its onset. Acta Otorrinolaringologica Espanola 59(10): 480-484

Galli, J.; Valenza, V.; Parrilla, C.; Galla, S.; Marchese, M.R.; Castaldi, P.; Almadori, G.; Paludetti, G. 2009: Pharyngocutaneous fistula onset after total laryngectomy: scintigraphic analysis. Acta Otorhinolaryngologica Italica: Organo Ufficiale Della Societa Italiana di Otorinolaringologia e Chirurgia Cervico-Facciale 29(5): 242-244

Kızıl, Y.; Aydil, U.; Cebeci, S.ül.; Köybaşıoğlu, A.; Yılmaz, M.; Inal, E.ğa. 2013: Pharyngocutaneous fistula rates after total laryngectomy in the organ preservation era. Kulak Burun Bogaz Ihtisas Dergisi: Kbb 23(1): 10-14

De Santana, M.E.; Sawada, N.O. 2008: Pharyngocutaneous fistulae after total laryngectomy: a systematic review. Revista Latino-Americana de Enfermagem 16(4): 772-778

Gonçalves, A.J.é; de Souza, J.A.L.; Menezes, M.B.; Kavabata, N.K.; Suehara, A.B.; Lehn, C.N. 2009: Pharyngocutaneous fistulae following total laryngectomy comparison between manual and mechanical sutures. European Archives of Oto-Rhino-Laryngology: Official Journal of the European Federation of Oto-Rhino-Laryngological Societies: Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery 266(11): 1793-1798

Joanes, V.; Belinchón, J. 2008: Pharyngoesophageal diverticulum following cervical corpectomy and plating. Case report. Journal of Neurosurgery. Spine 9(3): 258-260

Almre, I.; Asser, A.; Laisaar, T. 2014: Pharyngoesophageal diverticulum perforation 18 years after anterior cervical fixation. Interactive Cardiovascular and Thoracic Surgery 18(2): 240-241

Singaporewalla, R.M.; Mukherjee, J.J.; Thamboo, T.P.; Cheah, W.K. 2011: Pharyngoesophageal diverticulum resembling a thyroid nodule on ultrasound. Head and Neck 33(12): 1800-1803

Aquino, J.é L.B.d.; Said, M.M.; Chagas, J.é F.S.; Leandro-Merhi, V.ân.A.; Gallo-Junior, E.éb.J.é; Cecchino, G.N.; Assunção, M.T. 2012: Pharyngoesophageal diverticulum surgical therapy using linear stapling device. Arquivos Brasileiros de Cirurgia Digestiva: Abcd 25(2): 91-95

Tian, H.; Yuan, W.; Johnson, J.S.; Chen, H.; Chen, D. 2011: Pharyngoesophageal diverticulum: a delayed complication of anterior cervical spine surgery. European Spine Journal: Official Publication of the European Spine Society the European Spinal Deformity Society and the European Section of the Cervical Spine Research Society 20(Suppl 2): S211-S216

Henry, M.A.C.d.A.; Lerco, M.M.; Tagliarini, J.é V.; Castilho, E.C.; Novaes, F.T.; Lamonica, V.C. 2013: Pharyngoesophageal diverticulum: evaluation of treatment results. Revista do Colegio Brasileiro de Cirurgioes 40(2): 104-109

Rezaii, J.; Esfandiari, K.; Abdolrazzaghi, H.A.; Tavakoli, H.; Ashegh, H.; Rashidi, A.; Abouzari, M. 2007: Pharyngoesophageal foreign bodies: a report of 10-year experience. Clinical Otolaryngology: Official Journal of Ent-Uk ; Official Journal of Netherlands Society for Oto-Rhino-Laryngology and Cervico-Facial Surgery 32(3): 216-217

Berteşteanu, S.V.G.; Popescu, C.R.; Grigore, R.; Popescu, B. 2012: Pharyngoesophageal junction neoplasia--therapeutic management. Chirurgia 107(1): 33-38

Denewer, A.; Khater, A.; Hafez, M.T.; Hussein, O.; Roshdy, S.; Shahatto, F.; Elnahas, W.; Kotb, S.; Mowafy, K. 2014: Pharyngoesophageal reconstruction after resection of hypopharyngeal carcinoma: a new algorithm after analysis of 142 cases. World Journal of Surgical Oncology 12: 182

Yu, P.; Hanasono, M.M.; Skoracki, R.J.; Baumann, D.P.; Lewin, J.S.; Weber, R.S.; Robb, G.L. 2010: Pharyngoesophageal reconstruction with the anterolateral thigh flap after total laryngopharyngectomy. Cancer 116(7): 1718-1724

Liu, D.; Guan, J.; He, H. 2010: Pharyngogastric or pharyngocolonic anastomosis in esophageal reconstruction for hypopharyngeal cancer or esophageal disease. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 24(3): 122-125

Behranwala, K.A.; Fullard, M.; Livingstone, J.I. 2010: Pharyngojejunal tubes for feeding after upper gastrointestinal surgery: the way forward. Annals of the Royal College of Surgeons of England 92(6): 529

Omura, K.; Yokoi, K.; Hirano, Y.; Inaki, N.; Watanabe, G. 2007: Pharyngojejunostomy with the creation of a funnel-shaped jejunal stump during reconstruction of the cervical esophagus using a free jejunal graft. Journal of Surgical Oncology 96(7): 630-632

Dufour, X. 2011: Pharyngolaryngeal diseases and medicine. La Revue de Medecine Interne 32(Suppl 1): S9-11

Torretta, S.; Gaffuri, M.; Recalcati, S.; Marzano, A.V.; Cantarella, G.; Iofrida, E.; Pignataro, L. 2013: Pharyngolaryngeal location of Kaposi's sarcoma with airway obstruction in an HIV-negative patient. Tumori 99(5): E208-E210

El-Orbany, M. 2014: Pharyngolaryngeal morbidity after tracheal intubation. Acta Anaesthesiologica Scandinavica 58(1): 127

Ohki, M.; Komiyama, S.; Tayama, N. 2015: Pharyngolaryngeal paralysis in a patient with pharyngeal tuberculosis. Auris Nasus Larynx 42(1): 63-67

Petrova, L.G.; Chaĭkovskiĭ, V.V.; Rybak, P.R. 2013: Pharyngolaryngeal reflux as one of the causes of chronic excretory otitis media. Vestnik Otorinolaringologii 1: 19-21

Nishimura, K.; Fujita, H.; Tanaka, T.; Matono, S.; Nagano, T.; Murata, K.; Umeno, H.; Yanagawa, T.; Shirouzu, K. 2010: Pharyngolaryngeal reflux in patients who underwent cervical esophago-gastrostomy following esophagectomy. Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus 23(5): 353-360

Braun, J.Jacques.; Imperiale, A.; Schultz, P.; Molard, A.; Charpiot, A.; Gentine, Aé. 2008: Pharyngolaryngeal sarcoidosis: report of 12 cases. Otolaryngology--Head and Neck Surgery: Official Journal of American Academy of Otolaryngology-Head and Neck Surgery 139(3): 463-465

Chen, P-Shao.; Lin, Y-Yung.; Huang, B-Rong. 2012: Pharyngolaryngeal zoster: a case report. Archives of Otolaryngology--Head and Neck Surgery 138(6): 592-595

Nisa, L.ís. 2013: Pharyngolaryngeal zoster: indeed challenging, but also dreadful. American Journal of Otolaryngology 34(6): 766

Babar-Craig, H.; Clarke, P.M.; Wood, S.H. 2008: Pharyngolaryngectomy using a free jejunal graft: a new anastomosis technique. Clinical Otolaryngology: Official Journal of Ent-Uk ; Official Journal of Netherlands Society for Oto-Rhino-Laryngology and Cervico-Facial Surgery 33(2): 130-133

Reumueller, A.; Leonhard, M.; Mancusi, G.; Gaechter, J.N.; Bigenzahn, W.; Schneider-Stickler, B. 2011: Pharyngolaryngectomy with free jejunal autograft reconstruction and tracheoesophageal voice restoration: Indications for replacements, microbial colonization, and indwelling times of the Provox 2 voice prostheses. Head and Neck 33(8): 1144-1153

Panizza, B. 2007: Pharyngolaryngectomy: still a necessary surgical evil. ANZ Journal of Surgery 77(11): 932

Huscher, C.; Mingoli, A.; Mereu, A.; Sgarzini, G. 2012: Pharyngolaryngo-esophagectomy with laparoscopic gastric pull-up: a reappraisal for the pharyngoesophageal junction cancer. Annals of Surgical Oncology 19(9): 2980

Afrashi, A. 2015: Pharyngolateral ferromagnetic prosthesis (PFP) for treatment of obstructive sleep apnea. European Archives of Oto-Rhino-Laryngology: Official Journal of the European Federation of Oto-Rhino-Laryngological Societies: Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery 272(9): 2573-2574

Chan, E.Y.T.; Ng, D.K.K.; Chow, P.Y.; Kwok, K.L. 2007: Pharyngomalacia as a cause of severe neonatal stridor. Singapore Medical Journal 48(9): e246-e247

Andersson, E.-M.; Sandvik, L.; Tørdal, I.B.; Abyholm, F. 2010: Pharyngoplasty after primary repair of clefts of the secondary palate. Scandinavian Journal of Plastic and Reconstructive Surgery and Hand Surgery 44(1): 26-30

Junior, J.E.L.; Tanikawa, D.Y.S.; Rocha, D.óg.L.; Alonso, N. 2012: Pharyngoplasty applied to velopharyngeal insufficiency: efficacy versus morbidity. Plastic and Reconstructive Surgery 129(6): 1015e-1017e

Rueth, N.M.; Lee, N.; Groth, S.S.; Stranberg, S.C.; Maddaus, M.A.; D'Cunha, J.; Andrade, R.S. 2010: Pharyngostomy tubes for gastric conduit decompression. Journal of Thoracic and Cardiovascular Surgery 140(2): 373-376

Stjernquist-Desatnik, A.; Orrling, A. 2009: Pharyngotonsillitis. Periodontology 2000 49: 140-150

Balbani, A.P.S.; Montovani, J.C.; Carvalho, L.R.d. 2009: Pharyngotonsillitis in children: view from a sample of pediatricians and otorhinolaryngologists. Brazilian Journal of Otorhinolaryngology 75(1): 139-146

Mirghani, H.ït.; Leymarie, N.; Amen, F.; Qassemyar, Q.; Leclère, F.M.; Kolb, F. 2014: Pharyngotracheal fistula closure using the internal mammary artery perforator island flap. Laryngoscope 124(5): 1106-1111

Rolleston, J.D. 1913: Pharynx and Larynx from Fatal Case of Haemorrhage from Throat. Proceedings of the Royal Society of Medicine 6(Sect Study Dis Child): 42-45

Rolleston, J.D. 1913: Pharynx and Larynx from Fatal Case of Hæmorrhage from Throat. Proceedings of the Royal Society of Medicine 6(Sect Study Dis Child): 42-45

Matulić, Z.; Skitarelić, N.; Knez, M. 2007: Pharynx and cervical esophagus reconstruction with pectoralis major flap. Acta Medica Croatica: Casopis Hravatske Akademije Medicinskih Znanosti 61(2): 201-205

Jain, A. 2010: Phase 0 (zero) clinical trials: a myth or reality?. Indian Journal of Cancer 47(1): 70

Schellens, J.H.M. 2009: Phase 0 (zero) clinical trials: more than zero benefit?. European Journal of Cancer 45(5): 728-729

Rani, P.Usha.; Naidu, M.U.R. 2008: Phase 0 - Microdosing strategy in clinical trials. Indian Journal of Pharmacology 40(6): 240-242

Döring, B.; Petzinger, E. 2014: Phase 0 and phase IIi transport in various organs: combined concept of phases in xenobiotic transport and metabolism. Drug Metabolism Reviews 46(3): 261-282

Reid, J.M.; Walden, C.A.; Qin, R.; Ziegler, K.L.Allen.; Haslam, J.L.; Rajewski, R.A.; Warndahl, R.; Fitting, C.L.; Boring, D.; Szabo, E.; Crowell, J.; Perloff, M.; Jong, L.; Bauer, B.A.; Mandrekar, S.J.; Ames, M.M.; Limburg, P.J. 2011: Phase 0 clinical chemoprevention trial of the Akt inhibitor SR13668. Cancer Prevention Research 4(3): 347-353

Kummar, S.; Kinders, R.; Gutierrez, M.E.; Rubinstein, L.; Parchment, R.E.; Phillips, L.R.; Ji, J.; Monks, A.; Low, J.A.; Chen, A.; Murgo, A.J.; Collins, J.; Steinberg, S.M.; Eliopoulos, H.; Giranda, V.L.; Gordon, G.; Helman, L.; Wiltrout, R.; Tomaszewski, J.E.; Doroshow, J.H. 2009: Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 27(16): 2705-2711

Wei, X.; Zhang, Z.; Xie, Y.; Wang, Y. 2011: Phase 0 clinical trials and post-marketed re-evaluation of clinical safety in injection of traditional Chinese medicine. Zhongguo Zhong Yao Za Zhi 36(20): 2874-2876

Kinders, R.; Parchment, R.E.; Ji, J.; Kummar, S.; Murgo, A.J.; Gutierrez, M.; Collins, J.; Rubinstein, L.; Pickeral, O.; Steinberg, S.M.; Yang, S.; Hollingshead, M.; Chen, A.; Helman, L.; Wiltrout, R.; Simpson, M.; Tomaszewski, J.E.; Doroshow, J.H. 2007: Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice. Molecular Interventions 7(6): 325-334

Gupta, U.C.; Bhatia, S.; Garg, A.; Sharma, A.; Choudhary, V. 2011: Phase 0 clinical trials in oncology new drug development. Perspectives in Clinical Research 2(1): 13-22

Takimoto, C.H. 2009: Phase 0 clinical trials in oncology: a paradigm shift for early drug development?. Cancer ChemoTherapy and Pharmacology 63(4): 703-709

Pocard, M.; Soria, J.-C.; Aldaz-Carroll, L.; Bellet, D. 2010: Phase 0 clinical trials in oncology: an exploratory methodology for constructing a study with patients undergoing surgery for metastatic disease. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 28(30): 4551-4553

Mendoza, L. 2011: Phase 0 clinical trials will overcome stagnation of anticancer drug development?. Klinicka Onkologie: Casopis Ceske a Slovenske Onkologicke Spolecnosti 24(2): 143-145

LoRusso, P.M. 2009: Phase 0 clinical trials: an answer to drug development stagnation?. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 27(16): 2586-2588

Ye, F.; Ma, D.-S.; Wang, J.; Qiao, Z.-H. 2018: Clinical Study of Patients with Myelodysplastic Syndrome Transformed into Acute Myeloid Leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 26(1): 202-207

Hill, T.P. 2012: Phase 0 clinical trials: towards a more complete ethics critique. Ecancermedicalscience 6: 248

Picat, M-Quitterie.; Houédé, N.; Chamorey, E.; Mathoulin-Pélissier, S. 2011: Phase 0 exploratory clinical trials: literature review 2006-2009. Bulletin du cancer 98(7): 753-759

Sarich, T.C.; Connelly, M.A.; Schranz, D.B.; Ghosh, A.; Manitpisitkul, P.; Leary, E.T.; Rothenberg, P.; Demarest, K.T.; Damiano, B.P. 2012: Phase 0 study of the inhibition of cholesteryl ester transfer protein activity by JNJ-28545595 in plasma from normolipidemic and dyslipidemic humans. International Journal of Clinical Pharmacology and Therapeutics 50(8): 584-594

Zanon, C. 2008: Phase 0 trial as first human study in translational research in medical technology. Tumori 94(4): 626-627

McBride, D. 2007: Phase 0 trials speed early drug development. Ons Connect 22(9): 21

Eliopoulos, H.; Giranda, V.; Carr, R.; Tiehen, R.; Leahy, T.; Gordon, G. 2008: Phase 0 trials: an industry perspective. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 14(12): 3683-3688

Kummar, S.; Doroshow, J.H. 2011: Phase 0 trials: expediting the development of chemoprevention agents. Cancer Prevention Research 4(3): 288-292

Caramori, C.Antonio. 2013: Phase 0, Phase I in clinical research and the registering of publications. Revista Brasileira de Cirurgia Cardiovascular: Orgao Oficial da Sociedade Brasileira de Cirurgia Cardiovascular 28(3): 414-417

Denmeade, S.R.; Egerdie, B.; Steinhoff, G.; Merchant, R.; Abi-Habib, R.; Pommerville, P. 2011: Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. European Urology 59(5): 747-754

Wakui, H.; Yamamoto, N.; Nakamichi, S.; Tamura, Y.; Nokihara, H.; Yamada, Y.; Tamura, T. 2014: Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors. Cancer ChemoTherapy and Pharmacology 73(3): 511-516

Ciunci, C.A.; Perini, R.F.; Avadhani, A.N.; Kang, H.C.; Sun, W.; Redlinger, M.; Harlacker, K.; Flaherty, K.T.; Giantonio, B.J.; Rosen, M.A.; Divgi, C.R.; Song, H.K.; Englander, S.; Troxel, A.; Schnall, M.; O'Dwyer, P.J. 2014: Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer. Cancer 120(1): 77-85

Karp, J.E.; Smith, B.D.; Resar, L.S.; Greer, J.M.; Blackford, A.; Zhao, M.; Moton-Nelson, D.; Alino, K.; Levis, M.J.; Gore, S.D.; Joseph, B.; Carraway, H.; McDevitt, M.A.; Bagain, L.; Mackey, K.; Briel, J.; Doyle, L.A.; Wright, J.J.; Rudek, M.A. 2011: Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. Blood 117(12): 3302-3310

Levy, A.S.; Meyers, P.A.; Wexler, L.H.; Jakacki, R.; Angiolillo, A.; Ringuette, S.N.; Cohen, M.B.; Gorlick, R. 2009: Phase 1 and pharmacokinetic study of concurrent carboplatin and irinotecan in subjects aged 1 to 21 years with refractory solid tumors. Cancer 115(1): 207-216

Saba, N.F.; Hurwitz, S.J.; Magliocca, K.; Kim, S.; Owonikoko, T.K.; Harvey, D.; Ramalingam, S.S.; Chen, Z.; Rogerio, J.; Mendel, J.; Kono, S.A.; Lewis, C.; Chen, A.Y.; Higgins, K.; El-Deiry, M.; Wadsworth, T.; Beitler, J.J.; Shin, D.M.; Sun, S.-Y.; Khuri, F.R. 2014: Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck. Cancer 120(24): 3940-3951

Ramalingam, S.S.; Harvey, R.D.; Saba, N.; Owonikoko, T.K.; Kauh, J.; Shin, D.M.; Sun, S.-Y.; Strychor, S.; Tighiouart, M.; Egorin, M.J.; Fu, H.; Khuri, F.R. 2010: Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer. Cancer 116(16): 3903-3909

Plummer, R.; Attard, G.; Pacey, S.; Li, L.; Razak, A.; Perrett, R.; Barrett, M.; Judson, I.; Kaye, S.; Fox, N.L.; Halpern, W.; Corey, A.; Calvert, H.; de Bono, J. 2007: Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 13(20): 6187-6194

Maté, L.; Virkel, G.; Lifschitz, A.; Sallovitz, J.; Ballent, M.; Lanusse, C. 2010: Phase 1 and phase 2 metabolic activities along the small intestine in adult male sheep. Journal of Veterinary Pharmacology and Therapeutics 33(6): 537-545

Carvalho, V.O. 2011: Phase 1 cardiovascular rehabilitation: be aggressive?. Journal of Cardiothoracic Surgery 6: 140

Gandy, J.J.; Meeding, J.P.; Snyman, J.R.é; van Rensburg, C.E.J. 2012: Phase 1 clinical study of the acute and subacute safety and proof-of-concept efficacy of carbohydrate-derived fulvic acid. Clinical Pharmacology: Advances and Applications 4: 7-11

Hamilton, E.; Blackwell, K.; Hobeika, A.C.; Clay, T.M.; Broadwater, G.; Ren, X.-R.; Chen, W.; Castro, H.; Lehmann, F.; Spector, N.; Wei, J.; Osada, T.; Lyerly, H.K.; Morse, M.A. 2012: Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected. Journal of Translational Medicine 10: 28

Liss, M.A.; Morales, B.; Skarecky, D.; Ahlering, T.E. 2014: Phase 1 clinical trial of Vesicare™ (solifenacin) in the treatment of urinary incontinence after radical prostatectomy. Journal of Endourology 28(10): 1241-1245

Phuphanich, S.; Supko, J.G.; Carson, K.A.; Grossman, S.A.; Burt Nabors, L.; Mikkelsen, T.; Lesser, G.; Rosenfeld, S.; Desideri, S.; Olson, J.J. 2010: Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma. Journal of Neuro-Oncology 100(1): 95-103

Kim, K.H.; Horn, T.D.; Pharis, J.; Kincannon, J.; Jones, R.; O'Bryan, K.; Myers, J.; Nakagawa, M. 2010: Phase 1 clinical trial of intralesional injection of Candida antigen for the treatment of warts. Archives of Dermatology 146(12): 1431-1433

Kabawat, M.; de Souza, R.F.; Badaró, M.íc.M.; de Koninck, L.; Barbeau, J.; Rompré, P.; Emami, E. 2014: Phase 1 clinical trial on the effect of palatal brushing on denture stomatitis. International Journal of Prosthodontics 27(4): 311-319

Ghosh, S.M.; Ghosh, R.K. 2010: Phase 1 clinical trial: growing role of anesthetists in India. Journal of Postgraduate Medicine 56(4): 333-335

Subbiah, V.; Kurzrock, R. 2011: Phase 1 clinical trials for sarcomas: the cutting edge. Current Opinion in Oncology 23(4): 352-360

Vaklavas, C.; Tsimberidou, A-Maria.; Wen, S.; Hong, D.; Wheler, J.; Ng, C.S.; Naing, A.; Uehara, C.; Wolff, R.A.; Kurzrock, R. 2011: Phase 1 clinical trials in 83 patients with pancreatic cancer: The M. D. Anderson Cancer Center experience. Cancer 117(1): 77-85

Godskesen, T.; Nygren, P.; Nordin, K.; Hansson, M.; Kihlbom, U. 2013: Phase 1 clinical trials in end-stage cancer: patient understanding of trial premises and motives for participation. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer 21(11): 3137-3142

Lindberg, D. 2012: Phase 1 clinical trials nursing: determining safety and side effects on the road approval. Ons Connect 27(7): 10-14

Tanihara, H.; Inoue, T.; Yamamoto, T.; Kuwayama, Y.; Abe, H.; Araie, M.; Azuma, J.; Ando, M. 2013: Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115. JAMA Ophthalmology 131(10): 1288-1295

Smith, L.R.; Wloch, M.K.; Ye, M.; Reyes, L.R.; Boutsaboualoy, S.; Dunne, C.E.; Chaplin, J.A.; Rusalov, D.; Rolland, A.P.; Fisher, C.L.; Al-Ibrahim, M.S.; Kabongo, M.L.; Steigbigel, R.; Belshe, R.B.; Kitt, E.R.; Chu, A.H.; Moss, R.B. 2010: Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza a virus H5 hemagglutinin. Vaccine 28(13): 2565-2572

Mukai, H.; Saeki, T.; Shimada, K.; Naito, Y.; Matsubara, N.; Nakanishi, T.; Obaishi, H.; Namiki, M.; Sasaki, Y. 2015: Phase 1 combination study of eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer. Investigational new Drugs 33(1): 119-127

Sun, R.; Tian, L.; Fang, X.; Du, X.; Zhu, B.; Song, Z.; Xu, X.; Qin, X. 2017: Clinical study of post-stroke upper limb spasmodic hemiplegia treated with jingou diaoyu needling technique and Bobath therapy. Zhongguo Zhen Jiu 37(4): 372-376

Salazar, R.; Morales, S.; Gil-Martín, M.; Aguirre, E.; Oaknin, A.; Garcia, M.; Callies, S.; Wickremsinhe, E.R.; Benhadji, K.A.; Llombart, A. 2014: Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors. Cancer ChemoTherapy and Pharmacology 73(6): 1205-1215

Advani, S.H.; Achrekar, S.D.; Doval, D.C.; Raghunadharao, D.; Wilhelm, F.E.; Acharya, M. 2014: Phase 1 dose escalation study of rigosertib by 2-, 4-, or 8-hour infusion twice-weekly in patients with advanced cancer. Indian Journal of Cancer 51(1): 40-44

Van Gurp, E.; Weimar, W.; Gaston, R.; Brennan, D.; Mendez, R.; Pirsch, J.; Swan, S.; Pescovitz, M.D.; Ni, G.; Wang, C.; Krishnaswami, S.; Chow, V.; Chan, G. 2008: Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics. American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 8(8): 1711-1718

Soria, J.C.; Massard, C.; Magné, N.; Bader, T.; Mansfield, C.D.; Blay, J.Y.; Bui, B.N.; Moussy, A.; Hermine, O.; Armand, J.P. 2009: Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers. European Journal of Cancer 45(13): 2333-2341

Plummer, R.; Stephens, P.; Aissat-Daudigny, L.; Cambois, A.; Moachon, G.; Brown, P.D.; Campone, M. 2014: Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors. Cancer ChemoTherapy and Pharmacology 74(2): 257-265

Goldman, J.W.; Laux, I.; Chai, F.; Savage, R.E.; Ferrari, D.; Garmey, E.G.; Just, R.G.; Rosen, L.S. 2012: Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib. Cancer 118(23): 5903-5911

Rini, B.I.; Stein, M.; Shannon, P.; Eddy, S.; Tyler, A.; Stephenson, J.J.; Catlett, L.; Huang, B.; Healey, D.; Gordon, M. 2011: Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 117(4): 758-767

Hemmerling, A.; Harrison, W.; Schroeder, A.; Park, J.; Korn, A.; Shiboski, S.; Cohen, C.R. 2009: Phase 1 dose-ranging safety trial of Lactobacillus crispatus CTV-05 for the prevention of bacterial vaginosis. Sexually Transmitted Diseases 36(9): 564-569

Raza, A.; Galili, N.; Mulford, D.; Smith, S.E.; Brown, G.L.; Steensma, D.P.; Lyons, R.M.; Boccia, R.; Sekeres, M.A.; Garcia-Manero, G.; Mesa, R.A. 2012: Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS). Journal of Hematology and Oncology 5: 18

Norris, R.E.; Shusterman, S.; Gore, L.; Muscal, J.A.; Macy, M.E.; Fox, E.; Berkowitz, N.; Buchbinder, A.; Bagatell, R. 2014: Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors. Pediatric Blood and Cancer 61(10): 1792-1797

Burris, H.A.; Rosen, L.S.; Rocha-Lima, C.M.; Marshall, J.; Jones, S.; Cohen, R.B.; Kunkel, L.A.; Loo, D.; Baughman, J.; Stewart, S.J.; Lewis, N. 2010: Phase 1 experience with an anti-glycotope monoclonal antibody, RAV12, in recurrent adenocarcinoma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 16(5): 1673-1681

Tsimberidou, A.M.; Rudek, M.A.; Hong, D.; Ng, C.S.; Blair, J.; Goldsweig, H.; Kurzrock, R. 2010: Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors. Cancer ChemoTherapy and Pharmacology 65(2): 235-241

Mita, M.M.; Spear, M.A.; Yee, L.K.; Mita, A.C.; Heath, E.I.; Papadopoulos, K.P.; Federico, K.C.; Reich, S.D.; Romero, O.; Malburg, L.; Pilat, M.; Lloyd, G.K.; Neuteboom, S.T.C.; Cropp, G.; Ashton, E.; LoRusso, P.M. 2010: Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid tumors or lymphomas. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 16(23): 5892-5899

Mohamadnejad, M.; Namiri, M.; Bagheri, M.; Hashemi, S.M.; Ghanaati, H.; Zare Mehrjardi, N.; Kazemi Ashtiani, S.; Malekzadeh, R.; Baharvand, H. 2007: Phase 1 human trial of autologous bone marrow-hematopoietic stem cell transplantation in patients with decompensated cirrhosis. World Journal of Gastroenterology 13(24): 3359-3363

Raza, A.; Galili, N.; Smith, S.; Godwin, J.; Lancet, J.; Melchert, M.; Jones, M.; Keck, J.G.; Meng, L.; Brown, G.L.; List, A. 2009: Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome. Blood 113(26): 6533-6540

Thomas, D.A.; Kantarjian, H.M.; Stock, W.; Heffner, L.T.; Faderl, S.; Garcia-Manero, G.; Ferrajoli, A.; Wierda, W.; Pierce, S.; Lu, B.; Deitcher, S.R.; O'Brien, S. 2009: Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia. Cancer 115(23): 5490-5498

Hackett, A.; Palmer, S.; Farrants, J. 2009: Phase 1 of an investigation into the levels of stress in United Kingdom hospice services. International Journal of Palliative Nursing 15(2): 66-72

Miller, F.G.; Joffe, S. 2013: Phase 1 oncology trials and informed consent. Journal of Medical Ethics 39(12): 761-764

Chiorean, E.G.; Schneider, B.P.; Akisik, F.M.; Perkins, S.M.; Anderson, S.; Johnson, C.S.; DeWitt, J.; Helft, P.; Clark, R.; Johnston, E.L.; Spittler, A.J.; Deluca, J.; Bu, G.; Shahda, S.; Loehrer, P.J.; Sandrasegaran, K.; Cardenes, H.R. 2014: Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer. International Journal of Radiation Oncology Biology Physics 89(2): 284-291

Johnson, F.M.; Agrawal, S.; Burris, H.; Rosen, L.; Dhillon, N.; Hong, D.; Blackwood-Chirchir, A.; Luo, F.R.; Sy, O.; Kaul, S.; Chiappori, A.A. 2010: Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Cancer 116(6): 1582-1591

Sheaves, B.; Jones, R.B.; Williamson, G.R.; Chauhan, R. 2011: Phase 1 pilot study of e-mail support for people with long term conditions using the Internet. Bmc Medical Informatics and Decision Making 11: 20

McGowan, I.; Gomez, K.; Bruder, K.; Febo, I.; Chen, B.A.; Richardson, B.A.; Husnik, M.; Livant, E.; Price, C.; Jacobson, C. 2011: Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004). Aids 25(8): 1057-1064

Jones, S.F.; Infante, J.R.; Spigel, D.R.; Peacock, N.W.; Thompson, D.S.; Greco, F.A.; McCulloch, W.; Burris, H.A. 2012: Phase 1 results from a study of romidepsin in combination with gemcitabine in patients with advanced solid tumors. Cancer Investigation 30(6): 481-486

Bégin, P.; Dominguez, T.; Wilson, S.P.; Bacal, L.; Mehrotra, A.; Kausch, B.; Trela, A.; Tavassoli, M.; Hoyte, E.; O'Riordan, G.; Blakemore, A.; Seki, S.; Hamilton, R.G.; Nadeau, K.C. 2014: Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab. Allergy Asthma and Clinical Immunology: Official Journal of the Canadian Society of Allergy and Clinical Immunology 10(1): 7

Vasan, S.; Schlesinger, S.J.; Chen, Z.; Hurley, A.; Lombardo, A.; Than, S.; Adesanya, P.; Bunce, C.; Boaz, M.; Boyle, R.; Sayeed, E.; Clark, L.; Dugin, D.; Boente-Carrera, M.; Schmidt, C.; Fang, Q.; LeiBa; Huang, Y.; Zaharatos, G.J.; Gardiner, D.F.; Caskey, M.; Seamons, L.; Ho, M.; Dally, L.; Smith, C.; Cox, J.; Gill, D.; Gilmour, J.; Keefer, M.C.; Fast, P.; Ho, D.D. 2010: Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine. Plos one 5(1): E8816

Vasan, S.; Schlesinger, S.J.; Huang, Y.; Hurley, A.; Lombardo, A.; Chen, Z.; Than, S.; Adesanya, P.; Bunce, C.; Boaz, M.; Boyle, R.; Sayeed, E.; Clark, L.; Dugin, D.; Schmidt, C.; Song, Y.; Seamons, L.; Dally, L.; Ho, M.; Smith, C.; Markowitz, M.; Cox, J.; Gill, D.K.; Gilmour, J.; Keefer, M.C.; Fast, P.; Ho, D.D. 2010: Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine. Plos one 5(1): E8617

Goepfert, P.A.; Elizaga, M.L.; Sato, A.; Qin, L.; Cardinali, M.; Hay, C.M.; Hural, J.; DeRosa, S.C.; DeFawe, O.D.; Tomaras, G.D.; Montefiori, D.C.; Xu, Y.; Lai, L.; Kalams, S.A.; Baden, L.R.; Frey, S.E.; Blattner, W.A.; Wyatt, L.S.; Moss, B.; Robinson, H.L. 2011: Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. Journal of Infectious Diseases 203(5): 610-619

Hunter, D.J.; Pike, M.C.; Jonas, B.L.; Kissin, E.; Krop, J.; McAlindon, T. 2010: Phase 1 safety and tolerability study of BMP-7 in symptomatic knee osteoarthritis. Bmc Musculoskeletal Disorders 11: 232

Cherry, C.L.; Hoy, J.F.; Rowe, J.S.; Krum, H.; Mills, J.; Lewin, S.R. 2008: Phase 1 single dose studies to optimize the pharmacokinetics of DG17, a novel HIV-protease inhibitor pro-drug, using sodium bicarbonate and ritonavir. Current HIV Research 6(3): 272-275

Ellis, R.D.; Wu, Y.; Martin, L.B.; Shaffer, D.; Miura, K.; Aebig, J.; Orcutt, A.; Rausch, K.; Zhu, D.; Mogensen, A.; Fay, M.P.; Narum, D.L.; Long, C.; Miller, L.; Durbin, A.P. 2012: Phase 1 study in malaria naïve adults of BSAM2/Alhydrogel®+CPG 7909, a blood stage vaccine against P. falciparum malaria. Plos one 7(10): E46094

Mita, A.C.; Takimoto, C.H.; Mita, M.; Tolcher, A.; Sankhala, K.; Sarantopoulos, J.; Valdivieso, M.; Wood, L.; Rasmussen, E.; Sun, Y.-N.; Zhong, Z.D.; Bass, M.B.; Le, N.; LoRusso, P. 2010: Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 16(11): 3044-3056

Kantarjian, H.; le Coutre, P.; Cortes, J.; Pinilla-Ibarz, J.; Nagler, A.; Hochhaus, A.; Kimura, S.; Ottmann, O. 2010: Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance. Cancer 116(11): 2665-2672

Dees, E.C.; Infante, J.R.; Cohen, R.B.; O'Neil, B.H.; Jones, S.; von Mehren, M.; Danaee, H.; Lee, Y.; Ecsedy, J.; Manfredi, M.; Galvin, K.; Stringer, B.; Liu, H.; Eton, O.; Fingert, H.; Burris, H. 2011: Phase 1 study of MLN8054, a selective inhibitor of Aurora a kinase in patients with advanced solid tumors. Cancer ChemoTherapy and Pharmacology 67(4): 945-954

Goyal, L.; Supko, J.G.; Berlin, J.; Blaszkowsky, L.S.; Carpenter, A.; Heuman, D.M.; Hilderbrand, S.L.; Stuart, K.E.; Cotler, S.; Senzer, N.N.; Chan, E.; Berg, C.L.; Clark, J.W.; Hezel, A.F.; Ryan, D.P.; Zhu, A.X. 2013: Phase 1 study of N(1),N(11)‑diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinoma. Cancer ChemoTherapy and Pharmacology 72(6): 1305-1314

Overman, M.J.; Varadhachary, G.; Kopetz, S.; Thomas, M.B.; Fukushima, M.; Kuwata, K.; Mita, A.; Wolff, R.A.; Hoff, P.M.; Xiong, H.; Abbruzzese, J.L. 2008: Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. Investigational new Drugs 26(5): 445-454

Dicko, A.; Sagara, I.; Ellis, R.D.; Miura, K.; Guindo, O.; Kamate, B.; Sogoba, M.; Niambelé, M.B.; Sissoko, M.; Baby, M.; Dolo, A.; Mullen, G.E.D.; Fay, M.P.; Pierce, M.; Diallo, D.A.; Saul, A.; Miller, L.H.; Doumbo, O.K. 2008: Phase 1 study of a combination AMA1 blood stage malaria vaccine in Malian children. Plos one 3(2): E1563

Tew, W.P.; Gordon, M.; Murren, J.; Dupont, J.; Pezzulli, S.; Aghajanian, C.; Sabbatini, P.; Mendelson, D.; Schwartz, L.; Gettinger, S.; Psyrri, A.; Cedarbaum, J.M.; Spriggs, D.R. 2010: Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 16(1): 358-366

McGregor, L.M.; Spunt, S.L.; Santana, V.M.; Stewart, C.F.; Ward, D.A.; Watkins, A.; Laningham, F.H.; Ivy, P.; Furman, W.L.; Fouladi, M. 2009: Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumors. Cancer 115(3): 655-664

Adler, S.G.; Schwartz, S.; Williams, M.E.; Arauz-Pacheco, C.; Bolton, W.K.; Lee, T.; Li, D.; Neff, T.B.; Urquilla, P.R.; Sewell, K.L. 2010: Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria. Clinical Journal of the American Society of Nephrology: Cjasn 5(8): 1420-1428

Wang, C.; He, X.; Zhou, B.; Li, J.; Li, B.; Qian, W.; Hou, S.; Wang, H.; Shi, Y.; Guo, Y. 2011: Phase 1 study of anti-epidermal growth factor receptor monoclonal antibody in patients with solid tumors. Mabs 3(1): 67-75

Wetzler, M.; Andrews, C.; Ford, L.A.; Tighe, S.; Barcos, M.; Sait, S.N.J.; Block, A.W.; Nowak, N.J.; Baer, M.R.; Wang, E.S.; Baumann, H. 2011: Phase 1 study of arsenic trioxide, high-dose cytarabine, and idarubicin to down-regulate constitutive signal transducer and activator of transcription 3 activity in patients aged <60 years with acute myeloid leukemia. Cancer 117(21): 4861-4868

Moreno, V.; García-Carbonero, R.; Maurel, J.; Feliu, J. 2014: Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma. Cancer 120(3): 454-456

Langenberg, M.H.G.; Witteveen, P.O.; Lankheet, N.A.G.; Roodhart, J.M.; Rosing, H.; van den Heuvel, I.J.G.M.; Beijnen, J.H.; Voest, E.E. 2010: Phase 1 study of combination treatment with PTK 787/ZK 222584 and cetuximab for patients with advanced solid tumors: safety, pharmacokinetics, pharmacodynamics analysis. Neoplasia 12(2): 206-213

Doi, T.; Murakami, H.; Ohtsu, A.; Fuse, N.; Yoshino, T.; Yamamoto, N.; Boku, N.; Onozawa, Y.; Hsu, C.-P.; Gorski, K.S.; Friberg, G.; Kawaguchi, T.; Sasaki, T. 2011: Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors. Cancer ChemoTherapy and Pharmacology 68(3): 733-741

Kao, J.; Packer, S.; Vu, H.Linh.; Schwartz, M.E.; Sung, M.W.; Stock, R.G.; Lo, Y-Chi.; Huang, D.; Chen, S-Hsia.; Cesaretti, J.A. 2009: Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response. Cancer 115(15): 3571-3580

Komatsu, Y.; Yoshino, T.; Yamazaki, K.; Yuki, S.; Machida, N.; Sasaki, T.; Hyodo, I.; Yachi, Y.; Onuma, H.; Ohtsu, A. 2014: Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRi as second-line therapy in patients with metastatic colorectal cancer. Investigational new Drugs 32(3): 473-480

Scandura, J.M.; Roboz, G.J.; Moh, M.; Morawa, E.; Brenet, F.; Bose, J.R.; Villegas, L.; Gergis, U.S.; Mayer, S.A.; Ippoliti, C.M.; Curcio, T.J.; Ritchie, E.K.; Feldman, E.J. 2011: Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML. Blood 118(6): 1472-1480

Shlansky-Goldberg, R. 2008: Phase 1 study of human plasma-derived plasmin (TAL-05-00018) in hemodialysis graft occlusion. Thrombosis Research 122(Suppl 3): S16-S19

Ohnuma, T.; Lehrer, D.; Ren, C.; Cho, S.Y.; Maniar, M.; Silverman, L.; Sung, M.; Gretz, H.F.; Benisovich, V.; Navada, S.; Akahoho, E.; Wilck, E.; Taft, D.R.; Roboz, J.; Wilhelm, F.; Holland, J.F. 2013: Phase 1 study of intravenous rigosertib (ON 01910.Na), a novel benzyl styryl sulfone structure producing G2/M arrest and apoptosis, in adult patients with advanced cancer. American Journal of Cancer Research 3(3): 323-338

Byrd, J.C.; O'Brien, S.; Flinn, I.W.; Kipps, T.J.; Weiss, M.; Rai, K.; Lin, T.S.; Woodworth, J.; Wynne, D.; Reid, J.; Molina, A.; Leigh, B.; Harris, S. 2007: Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 13(15 Part 1): 4448-4455

Loong, H.H.; Winquist, E.; Waldron, J.; Chen, E.X.; Kim, J.; Palma, D.; Read, N.; Razak, A.R.A.; Diaz-Padilla, I.; Chan, K.; Bayley, A.; Hossain, M.; Wang, L.; Chin, S.; Siu, L.L.; Hope, A. 2014: Phase 1 study of nab-paclitaxel, cisplatin and 5-fluorouracil as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced squamous cell carcinoma of the oropharynx. European Journal of Cancer 50(13): 2263-2270

McGregor, L.M.; Spunt, S.L.; Furman, W.L.; Stewart, C.F.; Schaiquevich, P.; Krailo, M.D.; Speights, R.; Ivy, P.; Adamson, P.C.; Blaney, S.M. 2009: Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: a children's oncology group study. Cancer 115(8): 1765-1775

Inada-Inoue, M.; Ando, Y.; Kawada, K.; Mitsuma, A.; Sawaki, M.; Yokoyama, T.; Sunakawa, Y.; Ishida, H.; Araki, K.; Yamashita, K.; Mizuno, K.; Nagashima, F.; Takekura, A.; Nagamatsu, K.; Sasaki, Y. 2014: Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors. Cancer ChemoTherapy and Pharmacology 73(4): 673-683

Elstrom, R.L.; Ruan, J.; Christos, P.J.; Martin, P.; Lebovic, D.; Osborne, J.; Goldsmith, S.; Greenberg, J.; Furman, R.R.; Avram, A.; Putman, R.; Chapman, E.; Mazumdar, M.; Griffith, K.; Coleman, M.; Leonard, J.P.; Kaminski, M.S. 2015: Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with 131I-tositumomab. Leukemia and Lymphoma 56(2): 342-346

Kumar, S.K.; Jett, J.; Marks, R.; Richardson, R.; Quevedo, F.; Moynihan, T.; Croghan, G.; Markovic, S.N.; Bible, K.C.; Qin, R.; Tan, A.; Molina, J.; Kaufmann, S.H.; Erlichman, C.; Adjei, A.A. 2013: Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies. Investigational new Drugs 31(5): 1201-1206

Seung, S.K.; Curti, B.D.; Crittenden, M.; Walker, E.; Coffey, T.; Siebert, J.C.; Miller, W.; Payne, R.; Glenn, L.; Bageac, A.; Urba, W.J. 2012: Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses. Science Translational Medicine 4(137): 137ra74

Wun, T.; Styles, L.; DeCastro, L.; Telen, M.J.; Kuypers, F.; Cheung, A.; Kramer, W.; Flanner, H.; Rhee, S.; Magnani, J.L.; Thackray, H. 2014: Phase 1 study of the E-selectin inhibitor GMi 1070 in patients with sickle cell anemia. Plos one 9(7): E101301

Nelissen, N.; Van Laere, K.; Thurfjell, L.; Owenius, R.; Vandenbulcke, M.; Koole, M.; Bormans, G.; Brooks, D.J.; Vandenberghe, R. 2009: Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. Journal of Nuclear Medicine: Official Publication Society of Nuclear Medicine 50(8): 1251-1259

Hassan, R.; Sharon, E.; Thomas, A.; Zhang, J.; Ling, A.; Miettinen, M.; Kreitman, R.J.; Steinberg, S.M.; Hollevoet, K.; Pastan, I. 2014: Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125. Cancer 120(21): 3311-3319

Braeckman, R.A.; Stirtan, W.G.; Soni, P.N. 2014: Phase 1 study of the effect of icosapent ethyl on warfarin pharmacokinetic and anticoagulation parameters. Clinical Drug Investigation 34(7): 449-456

Fujisaka, Y.; Yamada, Y.; Yamamoto, N.; Shimizu, T.; Fujiwara, Y.; Yamada, K.; Tamura, T.; Watanabe, H.; Sun, Y.-N.; Bass, M.B.; Seki, M. 2010: Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors. Cancer ChemoTherapy and Pharmacology 66(5): 935-943

Millward, M.; Mainwaring, P.; Mita, A.; Federico, K.; Lloyd, G.K.; Reddinger, N.; Nawrocki, S.; Mita, M.; Spear, M.A. 2012: Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel. Investigational new Drugs 30(3): 1065-1073

Bernstein, D.I.; Malkin, E.; Abughali, N.; Falloon, J.; Yi, T.; Dubovsky, F. 2012: Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children. Pediatric Infectious Disease Journal 31(2): 109-114

Weiss, G.J.; Infante, J.R.; Chiorean, E.G.; Borad, M.J.; Bendell, J.C.; Molina, J.R.; Tibes, R.; Ramanathan, R.K.; Lewandowski, K.; Jones, S.F.; Lacouture, M.E.; Langmuir, V.K.; Lee, H.; Kroll, S.; Burris, H.A. 2011: Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 17(9): 2997-3004

Rischin, D.; Narayan, K.; Oza, A.M.; Mileshkin, L.; Bernshaw, D.; Choi, J.; Hicks, R.; McClure, B.; Fyles, A. 2010: Phase 1 study of tirapazamine in combination with radiation and weekly cisplatin in patients with locally advanced cervical cancer. International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society 20(5): 827-833

Richardson, P.G.; Baz, R.; Wang, M.; Jakubowiak, A.J.; Laubach, J.P.; Harvey, R.D.; Talpaz, M.; Berg, D.; Liu, G.; Yu, J.; Gupta, N.; Di Bacco, A.; Hui, A.-M.; Lonial, S. 2014: Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. Blood 124(7): 1038-1046

Malkin, E.; Long, C.A.; Stowers, A.W.; Zou, L.; Singh, S.; MacDonald, N.J.; Narum, D.L.; Miles, A.P.; Orcutt, A.C.; Muratova, O.; Moretz, S.E.; Zhou, H.; Diouf, A.; Fay, M.; Tierney, E.; Leese, P.; Mahanty, S.; Miller, L.H.; Saul, A.; Martin, L.B. 2007: Phase 1 study of two merozoite surface protein 1 (MSP1(42)) vaccines for Plasmodium falciparum malaria. Plos Clinical Trials 2(4): E12

Su, J.M.; Li, X-Nan.; Thompson, P.; Ou, C-Nan.; Ingle, A.M.; Russell, H.; Lau, C.C.; Adamson, P.C.; Blaney, S.M. 2011: Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children's oncology group report. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 17(3): 589-597

Kumar, S.K.; Bensinger, W.I.; Zimmerman, T.M.; Reeder, C.B.; Berenson, J.R.; Berg, D.; Hui, A.-M.; Gupta, N.; Di Bacco, A.; Yu, J.; Shou, Y.; Niesvizky, R. 2014: Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. Blood 124(7): 1047-1055

Salles, G.; Morschhauser, F.; Lamy, T.; Milpied, N.; Thieblemont, C.; Tilly, H.é; Bieska, G.; Asikanius, E.; Carlile, D.; Birkett, J.; Pisa, P.; Cartron, G. 2012: Phase 1 study results of the type Ii glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood 119(22): 5126-5132

Fox, E.; Razzouk, B.I.; Widemann, B.C.; Xiao, S.; O'Brien, M.; Goodspeed, W.; Reaman, G.H.; Blaney, S.M.; Murgo, A.J.; Balis, F.M.; Adamson, P.C. 2008: Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma. Blood 111(2): 566-573

Widemann, B.C.; Arceci, R.J.; Jayaprakash, N.; Fox, E.; Zannikos, P.; Goodspeed, W.; Goodwin, A.; Wright, J.J.; Blaney, S.M.; Adamson, P.C.; Balis, F.M. 2011: Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: a report from the Children's Oncology Group. Pediatric Blood and Cancer 56(2): 226-233

Hansen, A.R.; Graham, D.M.; Pond, G.R.; Siu, L.L. 2014: Phase 1 trial design: is 3 + 3 the best?. Cancer Control: Journal of the Moffitt Cancer Center 21(3): 200-208

La Gamma, E.F.; van Wassenaer, A.G.; Ares, S.; Golombek, S.G.; Kok, J.H.; Quero, J.; Hong, T.; Rahbar, M.H.; de Escobar, G.M.; Fisher, D.A.; Paneth, N. 2009: Phase 1 trial of 4 thyroid hormone regimens for transient hypothyroxinemia in neonates of <28 weeks' gestation. Pediatrics 124(2): E258-E268

Mullen, G.E.D.; Ellis, R.D.; Miura, K.; Malkin, E.; Nolan, C.; Hay, M.; Fay, M.P.; Saul, A.; Zhu, D.; Rausch, K.; Moretz, S.; Zhou, H.; Long, C.A.; Miller, L.H.; Treanor, J. 2008: Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria. Plos one 3(8): E2940

Waldmann, T.A.; Conlon, K.C.; Stewart, D.M.; Worthy, T.A.; Janik, J.E.; Fleisher, T.A.; Albert, P.S.; Figg, W.D.; Spencer, S.D.; Raffeld, M.; Decker, J.R.; Goldman, C.K.; Bryant, B.R.; Petrus, M.N.; Creekmore, S.P.; Morris, J.C. 2013: Phase 1 trial of IL-15 trans presentation blockade using humanized Mikβ1 mAb in patients with T-cell large granular lymphocytic leukemia. Blood 121(3): 476-484

Kaida, M.; Morita-Hoshi, Y.; Soeda, A.; Wakeda, T.; Yamaki, Y.; Kojima, Y.; Ueno, H.; Kondo, S.; Morizane, C.; Ikeda, M.; Okusaka, T.; Takaue, Y.; Heike, Y. 2011: Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer. Journal of ImmunoTherapy 34(1): 92-99

Joy, M.S.; Gipson, D.S.; Powell, L.; MacHardy, J.; Jennette, J.Charles.; Vento, S.; Pan, C.; Savin, V.; Eddy, A.; Fogo, A.B.; Kopp, J.B.; Cattran, D.; Trachtman, H. 2010: Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group. American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation 55(1): 50-60

Buchner, A.; Pohla, H.; Willimsky, G.; Frankenberger, B.; Frank, R.; Baur-Melnyk, A.; Siebels, M.; Stief, C.G.; Hofstetter, A.; Kopp, J.; Pezzutto, A.; Blankenstein, T.; Oberneder, R.; Schendel, D.J. 2010: Phase 1 trial of allogeneic gene-modified tumor cell vaccine RCC-26/CD80/IL-2 in patients with metastatic renal cell carcinoma. Human Gene Therapy 21(3): 285-297

Mohamadnejad, M.; Alimoghaddam, K.; Mohyeddin-Bonab, M.; Bagheri, M.; Bashtar, M.; Ghanaati, H.; Baharvand, H.; Ghavamzadeh, A.; Malekzadeh, R. 2007: Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis. Archives of Iranian Medicine 10(4): 459-466

Furman, R.R.; Martin, P.; Ruan, J.; Cheung, Y.-K.K.; Vose, J.M.; LaCasce, A.S.; Elstrom, R.; Coleman, M.; Leonard, J.P. 2010: Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma. Cancer 116(23): 5432-5439

Kao, J.; Genden, E.M.; Chen, C.-T.; Rivera, M.; Tong, C.C.L.; Misiukiewicz, K.; Gupta, V.; Gurudutt, V.; Teng, M.; Packer, S.H. 2011: Phase 1 trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer. Cancer 117(14): 3173-3181

Dunbar, E.M.; Coats, B.S.; Shroads, A.L.; Langaee, T.; Lew, A.; Forder, J.R.; Shuster, J.J.; Wagner, D.A.; Stacpoole, P.W. 2014: Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors. Investigational new Drugs 32(3): 452-464

Molina, A.M.; Feldman, D.R.; Voss, M.H.; Ginsberg, M.S.; Baum, M.S.; Brocks, D.R.; Fischer, P.M.; Trinos, M.J.; Patil, S.; Motzer, R.J. 2012: Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 118(7): 1868-1876

Bommakanti, S.V.; Dudek, A.Z.; Khatri, A.; Kirstein, M.N.; Gada, P.D. 2011: Phase 1 trial of gemcitabine with bortezomib in elderly patients with advanced solid tumors. American Journal of Clinical Oncology 34(6): 597-602

Ito, Y.; Wakita, A.; Takada, S.; Mihara, M.; Gotoh, M.; Ohyashiki, K.; Ohtake, S.; Miyawaki, S.; Ohnishi, K.; Naoe, T. 2012: Phase 1 trial of gemtuzumab ozogamicin in combination with enocitabine and daunorubicin for elderly patients with relapsed or refractory acute myeloid leukemia: Japan Adult Leukemia Study Group (JALSG)-GML208 study. International Journal of Hematology 96(4): 485-491

Morris, M.J.; Huang, D.; Kelly, W.K.; Slovin, S.F.; Stephenson, R.D.; Eicher, C.; Delacruz, A.; Curley, T.; Schwartz, L.H.; Scher, H.I. 2009: Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. European Urology 56(2): 237-244

Stephenson, C.M.; Levin, R.D.; Lis, C.G. 2007: Phase 1 trial of high-dose intravenous vitamin C treatment for patients with cancer. Journal of the American Osteopathic Association 107(6): 212-213

Wang, E.S.; Yee, K.; Koh, L.P.; Hogge, D.; Enschede, S.; Carlson, D.M.; Dudley, M.; Glaser, K.; McKeegan, E.; Albert, D.H.; Li, X.; Pradhan, R.; Stock, W. 2012: Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia. Leukemia and Lymphoma 53(8): 1543-1551

Froudarakis, M.E.; Pataka, A.; Pappas, P.; Anevlavis, S.; Argiana, E.; Nikolaidou, M.; Kouliatis, G.; Pozova, S.; Marselos, M.; Bouros, D. 2008: Phase 1 trial of lipoplatin and gemcitabine as a second-line chemotherapy in patients with nonsmall cell lung carcinoma. Cancer 113(10): 2752-2760

Wu, Y.; Ellis, R.D.; Shaffer, D.; Fontes, E.; Malkin, E.M.; Mahanty, S.; Fay, M.P.; Narum, D.; Rausch, K.; Miles, A.P.; Aebig, J.; Orcutt, A.; Muratova, O.; Song, G.; Lambert, L.; Zhu, D.; Miura, K.; Long, C.; Saul, A.; Miller, L.H.; Durbin, A.P. 2008: Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. Plos one 3(7): E2636

Shinoto, M.; Yamada, S.; Yasuda, S.; Imada, H.; Shioyama, Y.; Honda, H.; Kamada, T.; Tsujii, H.; Saisho, H. 2013: Phase 1 trial of preoperative, short-course carbon-ion radiotherapy for patients with resectable pancreatic cancer. Cancer 119(1): 45-51

Quinn, J.A.; Jiang, S.Xiaoyin.; Reardon, D.A.; Desjardins, A.; Vredenburgh, J.J.; Gururangan, S.; Sampson, J.H.; McLendon, R.E.; Herndon, J.E.; Friedman, H.S. 2009: Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma. Cancer 115(13): 2964-2970

Bagatell, R.; Norris, R.; Ingle, A.M.; Ahern, C.; Voss, S.; Fox, E.; Little, A.R.; Weigel, B.J.; Adamson, P.C.; Blaney, S. 2014: Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study. Pediatric Blood and Cancer 61(5): 833-839

Ellis, R.D.; Martin, L.B.; Shaffer, D.; Long, C.A.; Miura, K.; Fay, M.P.; Narum, D.L.; Zhu, D.; Mullen, G.E.D.; Mahanty, S.; Miller, L.H.; Durbin, A.P. 2010: Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naïve adults. Plos one 5(1): E8787

Wright, P.F.; Durbin, A.P.; Whitehead, S.S.; Ikizler, M.R.; Henderson, S.; Blaney, J.E.; Thumar, B.; Ankrah, S.; Rock, M.T.; McKinney, B.A.; Murphy, B.R.; Schmidt, A.C. 2009: Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4{Delta}30-4995 in healthy adult volunteers. American Journal of Tropical Medicine and Hygiene 81(5): 834-841

Molife, L.R.; Yan, L.; Vitfell-Rasmussen, J.; Zernhelt, A.M.; Sullivan, D.M.; Cassier, P.A.; Chen, E.; Biondo, A.; Tetteh, E.; Siu, L.L.; Patnaik, A.; Papadopoulos, K.P.; de Bono, J.S.; Tolcher, A.W.; Minton, S. 2014: Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors. Journal of Hematology and Oncology 7: 1

Puzanov, I.; Sosman, J.; Santoro, A.; Saif, M.W.; Goff, L.; Dy, G.K.; Zucali, P.; Means-Powell, J.A.; Ma, W.W.; Simonelli, M.; Martell, R.; Chai, F.; Lamar, M.; Savage, R.E.; Schwartz, B.; Adjei, A.A. 2015: Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors. Investigational new Drugs 33(1): 159-168

Anonymous 2009: Phase 1 trial starts for HCV protease inhibitor. Aids Patient Care and Stds 23(3): 225

Sharma, S. 2009: Phase 1 trials in oncology in India: the clear case for innovation. Journal of Cancer Research and Therapeutics 5(2): 69-70

Yu, E.; Saif, M.W.; Huber, K. 2014: Phase 1 trials in pancreatic cancer. Jop: Journal of the Pancreas 15(4): 326-328

Soria, J.-C. 2011: Phase 1 trials of molecular targeted therapies: are we evaluating toxicities properly?. European Journal of Cancer 47(10): 1443-1445

Kubota, R.; Al-Fayoumi, S.; Mallikaarjun, S.; Patil, S.; Bavik, C.; Chandler, J.W. 2014: Phase 1, dose-ranging study of emixustat hydrochloride (ACU-4429), a novel visual cycle modulator, in healthy volunteers. Retina 34(3): 603-609

Bendell, J.C.; Patel, M.R.; Infante, J.R.; Kurkjian, C.D.; Jones, S.F.; Pant, S.; Burris, H.A.; Moreno, O.; Esquibel, V.; Levin, W.; Moore, K.N. 2015: Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors. Cancer 121(7): 1056-1063

Bendell, J.C.; Hong, D.S.; Burris, H.A.; Naing, A.; Jones, S.F.; Falchook, G.; Bricmont, P.; Elekes, A.; Rock, E.P.; Kurzrock, R. 2014: Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors. Cancer ChemoTherapy and Pharmacology 74(1): 125-130

Olsen, N.J.; Branch, V.K.; Jonnala, G.; Seskar, M.; Cooper, M. 2010: Phase 1, placebo-controlled, dose escalation trial of chicory root extract in patients with osteoarthritis of the hip or knee. Bmc Musculoskeletal Disorders 11: 156

Yau, T.; Chan, P.; Pang, R.; Ng, K.; Fan, S.T.; Poon, R.T. 2010: Phase 1-2 trial of PTK787/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma: implication for antiangiogenic approach to hepatocellular carcinoma. Cancer 116(21): 5022-5029

Raza, A.; Galili, N.; Callander, N.; Ochoa, L.; Piro, L.; Emanuel, P.; Williams, S.; Burris, H.; Faderl, S.; Estrov, Z.; Curtin, P.; Larson, R.A.; Keck, J.G.; Jones, M.; Meng, L.; Brown, G.L. 2009: Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome. Journal of Hematology and Oncology 2: 20

Sequist, L.V.; Fidias, P.M.; Temel, J.S.; Kolevska, T.; Rabin, M.S.; Boccia, R.V.; Burris, H.A.; Belt, R.J.; Huberman, M.S.; Melnyk, O.; Mills, G.M.; Englund, C.W.; Caldwell, D.C.; Keck, J.G.; Meng, L.; Jones, M.; Brown, G.L.; Edelman, M.J.; Lynch, T.J. 2009: Phase 1-2a multicenter dose-ranging study of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 4(11): 1389-1396

Zimran, A.; Altarescu, G.; Philips, M.; Attias, D.; Jmoudiak, M.; Deeb, M.; Wang, N.; Bhirangi, K.; Cohn, G.M.; Elstein, D. 2010: Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience. Blood 115(23): 4651-4656

Sakamaki, H.; Ishizawa, K.-I.; Taniwaki, M.; Fujisawa, S.; Morishima, Y.; Tobinai, K.; Okada, M.; Ando, K.; Usui, N.; Miyawaki, S.; Utsunomiya, A.; Uoshima, N.; Nagai, T.; Naoe, T.; Motoji, T.; Jinnai, I.; Tanimoto, M.; Miyazaki, Y.; Ohnishi, K.; Iida, S.; Okamoto, S.; Seriu, T.; Ohno, R. 2009: Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. International Journal of Hematology 89(3): 332-341

Komatsu, Y.; Yuki, S.; Fuse, N.; Kato, T.; Miyagishima, T.; Kudo, M.; Kunieda, Y.; Tateyama, M.; Wakahama, O.; Meguro, T.; Sakata, Y.; Asaka, M. 2010: Phase 1/2 clinical study of irinotecan and oral S-1 (IRIS) in patients with advanced gastric cancer. Advances in Therapy 27(7): 483-492

Boorjian, S.A.; Milowsky, M.I.; Kaplan, J.; Albert, M.; Cobham, M.V.; Coll, D.M.; Mongan, N.P.; Shelton, G.; Petrylak, D.; Gudas, L.J.; Nanus, D.M. 2007: Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma. Journal of ImmunoTherapy 30(6): 655-662

Dudek, A.Z.; Larson, T.; McCleod, M.J.; Schneider, D.J.; Dowell, J.E.; Banerjee, T.K.; Pandya, K.J.; Bromund, J.L.; Chen, R.; Monberg, M.J.; Obasaju, C.K. 2008: Phase 1/2 dose escalating study of twice-monthly pemetrexed and gemcitabine in patients with advanced cancer and non-small cell lung cancer. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 3(4): 394-399

Higano, C.S.; Corman, J.M.; Smith, D.C.; Centeno, A.S.; Steidle, C.P.; Gittleman, M.; Simons, J.W.; Sacks, N.; Aimi, J.; Small, E.J. 2008: Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 113(5): 975-984

Weisman, L.E.; Thackray, H.M.; Garcia-Prats, J.A.; Nesin, M.; Schneider, J.H.; Fretz, J.; Kokai-Kun, J.F.; Mond, J.J.; Kramer, W.G.; Fischer, G.W. 2009: Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates. Antimicrobial Agents and ChemoTherapy 53(7): 2879-2886

Bendell, J.C.; Lenz, H-Josef.; Ryan, T.; El-Rayes, B.F.; Marshall, J.L.; Modiano, M.R.; Hart, L.L.; Kingsley, C.D.; George, T.J.; Nakashima, D.; Berlin, J.D. 2014: Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer. Investigational new Drugs 32(4): 682-690

Witteveen, P.O.; van der Mijn, K.J.C.; Los, M.; Kronemeijer, R.H.; Groenewegen, G.; Voest, E.E. 2010: Phase 1/2 study of atrasentan combined with pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer. Neoplasia 12(11): 941-945

Zhu, A.X.; Abrams, T.A.; Miksad, R.; Blaszkowsky, L.S.; Meyerhardt, J.A.; Zheng, H.; Muzikansky, A.; Clark, J.W.; Kwak, E.L.; Schrag, D.; Jors, K.R.; Fuchs, C.S.; Iafrate, A.J.; Borger, D.R.; Ryan, D.P. 2011: Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer 117(22): 5094-5102

Illidge, T.M.; Bayne, M.; Brown, N.S.; Chilton, S.; Cragg, M.S.; Glennie, M.J.; Du, Y.; Lewington, V.; Smart, J.; Thom, J.; Zivanovic, M.; Johnson, P.W.M. 2009: Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood 113(7): 1412-1421

Di Lorenzo, G.; Montesarchio, V.; Autorino, R.; Bellelli, T.; Longo, N.; Imbimbo, C.; Morelli, E.; Giannarini, G.; Mirone, V.; De Placido, S. 2009: Phase 1/2 study of intravenous paclitaxel and oral cyclophosphamide in pretreated metastatic urothelial bladder cancer patients. Cancer 115(3): 517-523

Byrd, J.C.; Kipps, T.J.; Flinn, I.W.; Castro, J.; Lin, T.S.; Wierda, W.; Heerema, N.; Woodworth, J.; Hughes, S.; Tangri, S.; Harris, S.; Wynne, D.; Molina, A.; Leigh, B.; O'Brien, S. 2010: Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 115(3): 489-495

Shimoni, A.; Volchek, Y.; Koren-Michowitz, M.; Varda-Bloom, N.; Somech, R.; Shem-Tov, N.; Yerushalmi, R.; Nagler, A. 2015: Phase 1/2 study of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer 121(6): 863-871

Ganjoo, K.N.; de Vos, S.; Pohlman, B.L.; Flinn, I.W.; Forero-Torres, A.; Enas, N.H.; Cronier, D.M.; Dang, N.H.; Foon, K.A.; Carpenter, S.P.; Slapak, C.A.; Link, B.K.; Smith, M.R.; Mapara, M.Y.; Wooldridge, J.E. 2015: Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphoma. Leukemia and Lymphoma 56(1): 42-48

Garzotto, M.; Higano, C.S.; O'Brien, C.; Rademacher, B.L.S.; Janeba, N.; Fazli, L.; Lange, P.H.; Lieberman, S.; Beer, T.M. 2010: Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer. Cancer 116(7): 1699-1708

Avallone, A.; Piccirillo, M.C.; Delrio, P.; Pecori, B.; Di Gennaro, E.; Aloj, L.; Tatangelo, F.; D'Angelo, V.; Granata, C.; Cavalcanti, E.; Maurea, N.; Maiolino, P.; Bianco, F.; Montano, M.; Silvestro, L.; Terranova Barberio, M.; Roca, M.S.; Di Maio, M.; Marone, P.; Botti, G.; Petrillo, A.; Daniele, G.; Lastoria, S.; Iaffaioli, V.R.; Romano, G.; Caracò, C.; Muto, P.; Gallo, C.; Perrone, F.; Budillon, A. 2014: Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid--short Radiotherapy--rectum 3rd trial). Bmc Cancer 14: 875

Löwenberg, B.; Muus, P.; Ossenkoppele, G.; Rousselot, P.; Cahn, J.-Y.; Ifrah, N.; Martinelli, G.; Amadori, S.; Berman, E.; Sonneveld, P.; Jongen-Lavrencic, M.; Rigaudeau, S.; Stockman, P.; Goudie, A.; Faderl, S.; Jabbour, E.; Kantarjian, H. 2011: Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. Blood 118(23): 6030-6036

Garg, A.K.; Shiu, A.S.; Yang, J.; Wang, X-Shelley.; Allen, P.; Brown, B.W.; Grossman, P.; Frija, E.K.; McAleer, M.Frances.; Azeem, S.; Brown, P.D.; Rhines, L.D.; Chang, E.L. 2012: Phase 1/2 trial of single-session stereotactic body radiotherapy for previously unirradiated spinal metastases. Cancer 118(20): 5069-5077

Rosenthal, J.; Wong, J.; Stein, A.; Qian, D.; Hitt, D.; Naeem, H.; Dagis, A.; Thomas, S.H.; Forman, S. 2011: Phase 1/2 trial of total marrow and lymph node irradiation to augment reduced-intensity transplantation for advanced hematologic malignancies. Blood 117(1): 309-315

Spring, M.D.; Cummings, J.F.; Ockenhouse, C.F.; Dutta, S.; Reidler, R.; Angov, E.; Bergmann-Leitner, E.; Stewart, V.A.; Bittner, S.; Juompan, L.; Kortepeter, M.G.; Nielsen, R.; Krzych, U.; Tierney, E.; Ware, L.A.; Dowler, M.; Hermsen, C.C.; Sauerwein, R.W.; de Vlas, S.J.; Ofori-Anyinam, O.; Lanar, D.E.; Williams, J.L.; Kester, K.E.; Tucker, K.; Shi, M.; Malkin, E.; Long, C.; Diggs, C.L.; Soisson, L.; Dubois, M.-C.; Ballou, W.R.; Cohen, J.; Heppner, D.G. 2009: Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. Plos one 4(4): E5254

Andreopoulou, E.; Chen, T.; Liebes, L.; Curtin, J.; Blank, S.; Wallach, R.; Hochster, H.; Muggia, F. 2011: Phase 1/pharmacology study of intraperitoneal topotecan alone and with cisplatin: potential for consolidation in ovarian cancer. Cancer ChemoTherapy and Pharmacology 68(2): 457-463

Fridrich, P.; Colvin, H.P.; Zizza, A.; Wasan, A.D.; Lukanich, J.; Lirk, P.; Saria, A.; Zernig, G.; Hamp, T.; Gerner, P. 2007: Phase 1A safety assessment of intravenous amitriptyline. Journal of Pain 8(7): 549-555

Mita, M.; Gordon, M.; Rosen, L.; Kapoor, N.; Choy, G.; Redkar, S.; Taverna, P.; Oganesian, A.; Sahai, A.; Azab, M.; Bristow, R.; Tolcher, A.W. 2014: Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors. Cancer ChemoTherapy and Pharmacology 74(1): 195-204

Maertens, J.; Cornely, O.A.; Ullmann, A.J.; Heinz, W.J.; Krishna, G.; Patino, H.; Caceres, M.; Kartsonis, N.; Waskin, H.; Robertson, M.N. 2014: Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease. Antimicrobial Agents and ChemoTherapy 58(7): 3610-3617

Palacpac, N.M.Q.; Ntege, E.; Yeka, A.; Balikagala, B.; Suzuki, N.; Shirai, H.; Yagi, M.; Ito, K.; Fukushima, W.; Hirota, Y.; Nsereko, C.; Okada, T.; Kanoi, B.N.; Tetsutani, K.; Arisue, N.; Itagaki, S.; Tougan, T.; Ishii, K.J.; Ueda, S.; Egwang, T.G.; Horii, T. 2013: Phase 1b randomized trial and follow-up study in Uganda of the blood-stage malaria vaccine candidate BK-SE36. Plos one 8(5): E64073

Soria, J.-C.; Smit, E.; Khayat, D.; Besse, B.; Yang, X.; Hsu, C.-P.; Reese, D.; Wiezorek, J.; Blackhall, F. 2010: Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 28(9): 1527-1533

Blumenschein, G.R.; Reckamp, K.; Stephenson, G.J.; O'Rourke, T.; Gladish, G.; McGreivy, J.; Sun, Y.-N.; Ye, Y.; Parson, M.; Sandler, A. 2010: Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 16(1): 279-290

Duarte, R.F.; López-Jiménez, J.; Cornely, O.A.; Laverdiere, M.; Helfgott, D.; Haider, S.; Chandrasekar, P.; Langston, A.; Perfect, J.; Ma, L.; van Iersel, M.L.P.S.; Connelly, N.; Kartsonis, N.; Waskin, H. 2014: Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia. Antimicrobial Agents and ChemoTherapy 58(10): 5758-5765

Gopal, A.K.; Tarantolo, S.R.; Bellam, N.; Green, D.J.; Griffin, M.; Feldman, T.; Mato, A.R.; Eisenfeld, A.J.; Stromatt, S.C.; Goy, A. 2014: Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients. Investigational new Drugs 32(6): 1213-1225

Muir, A.J.; Shiffman, M.L.; Zaman, A.; Yoffe, B.; de la Torre, A.; Flamm, S.; Gordon, S.C.; Marotta, P.; Vierling, J.M.; Lopez-Talavera, J.C.; Byrnes-Blake, K.; Fontana, D.; Freeman, J.; Gray, T.; Hausman, D.; Hunder, N.N.; Lawitz, E. 2010: Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 52(3): 822-832

Mahadevan, D.; Sutton, G.R.; Arteta-Bulos, R.; Bowden, C.J.; Miller, P.J.E.; Swart, R.E.; Walker, M.S.; Haluska, P.; Munster, P.N.; Marshall, J.; Hamid, O.; Kurzrock, R. 2014: Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies. Cancer ChemoTherapy and Pharmacology 73(3): 467-473

Limaye, S.A.; Haddad, R.I.; Cilli, F.; Sonis, S.T.; Colevas, A.D.; Brennan, M.T.; Hu, K.S.; Murphy, B.A. 2013: Phase 1b, multicenter, single blinded, placebo-controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy. Cancer 119(24): 4268-4276

Fu, S.; Hu, W.; Iyer, R.; Kavanagh, J.J.; Coleman, R.L.; Levenback, C.F.; Sood, A.K.; Wolf, J.K.; Gershenson, D.M.; Markman, M.; Hennessy, B.T.; Kurzrock, R.; Bast, R.C. 2011: Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer 117(8): 1661-1669

Von Mehren, M.; Rankin, C.; Goldblum, J.R.; Demetri, G.D.; Bramwell, V.; Ryan, C.W.; Borden, E. 2012: Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. Cancer 118(3): 770-776

Thompson, J.F.; Agarwala, S.S.; Smithers, B.M.; Ross, M.I.; Scoggins, C.R.; Coventry, B.J.; Neuhaus, S.J.; Minor, D.R.; Singer, J.M.; Wachter, E.A. 2015: Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma. Annals of Surgical Oncology 22(7): 2135-2142

Balakrishnan, K.; Verma, D.; O'Brien, S.; Kilpatrick, J.M.; Chen, Y.; Tyler, B.F.; Bickel, S.; Bantia, S.; Keating, M.J.; Kantarjian, H.; Gandhi, V.; Ravandi, F. 2010: Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia. Blood 116(6): 886-892

Chen, W.H.; Winokur, P.L.; Edwards, K.M.; Jackson, L.A.; Wald, A.; Walter, E.B.; Noah, D.L.; Wolff, M.; Kotloff, K.L.; Chua, J.V.; Hutter, J.; Stephens, I.; Stapleton, J.; Meier, J.; Callahan, S.Todd.; Creech, C.Buddy.; Halasa, N.B.; Johnston, C.; Dolor, R.J.; Schmader, K.E.; Woods, C.W.; Hill, H. 2012: Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009. Vaccine 30(28): 4240-4248

Raffoux, E.; Cras, A.; Recher, C.; Boëlle, P.-Y.; de Labarthe, A.; Turlure, P.; Marolleau, J.-P.; Reman, O.; Gardin, C.; Victor, M.; Maury, S.éb.; Rousselot, P.; Malfuson, J.-V.èr.; Maarek, O.; Daniel, M.-T.ér.ès.; Fenaux, P.; Degos, L.; Chomienne, C.; Chevret, S.; Dombret, H.é 2010: Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. Oncotarget 1(1): 34-42

Flotte, T.R.; Trapnell, B.C.; Humphries, M.; Carey, B.; Calcedo, R.; Rouhani, F.; Campbell-Thompson, M.; Yachnis, A.T.; Sandhaus, R.A.; McElvaney, N.G.; Mueller, C.; Messina, L.M.; Wilson, J.M.; Brantly, M.; Knop, D.R.; Ye, G.-j.; Chulay, J.D. 2011: Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing α1-antitrypsin: interim results. Human Gene Therapy 22(10): 1239-1247

Potter, S.L.P.; Berg, S.; Ingle, A.M.; Krailo, M.; Adamson, P.C.; Blaney, S.M. 2012: Phase 2 clinical trial of intrathecal topotecan in children with refractory leptomeningeal leukemia: a Children's Oncology Group trial (P9962). Pediatric Blood and Cancer 58(3): 362-365

Sun, W.; Cunningham, D.; Wasserman, S.S.; Perry, J.; Putnak, J.R.; Eckels, K.H.; Vaughn, D.W.; Thomas, S.J.; Kanesa-Thasan, N.; Innis, B.L.; Edelman, R. 2009: Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults. Human Vaccines 5(1): 33-40

Anonymous 2008: Phase 2 clinical trials started on PRO 140. Aids Patient Care and Stds 22(2): 159-160

Lee, B.; Rhead, W.; Diaz, G.A.; Scharschmidt, B.F.; Mian, A.; Shchelochkov, O.; Marier, J.F.; Beliveau, M.; Mauney, J.; Dickinson, K.; Martinez, A.; Gargosky, S.; Mokhtarani, M.; Berry, S.A. 2010: Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control. Molecular Genetics and Metabolism 100(3): 221-228

Scuderi, Nò.; Dessy, L.A.; Buccheri, E.M.; Marchetti, F.; Mazzocchi, M.; Chiummariello, S.; Klinger, F.; Onesti, M.G.; Klinger, M.; Alfano, C. 2011: Phase 2 cross-over multicenter trial on the efficacy and safety of topical cyanoacrylates compared with topical silicone gel in the prevention of pathologic scars. Aesthetic Plastic Surgery 35(3): 373-381

Wang, M.; Martin, T.; Bensinger, W.; Alsina, M.; Siegel, D.S.; Kavalerchik, E.; Huang, M.; Orlowski, R.Z.; Niesvizky, R. 2013: Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood 122(18): 3122-3128

Gazzard, B.; Duvivier, C.; Zagler, C.; Castagna, A.; Hill, A.; van Delft, Y.; Marks, S. 2011: Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results. Aids 25(18): 2249-2258

Kim, H.A.; Yeo, Y.; Kim, W.-U.; Kim, S. 2009: Phase 2 enzyme inducer sulphoraphane blocks matrix metalloproteinase production in articular chondrocytes. Rheumatology 48(8): 932-938

Kim, H.-A.; Yeo, Y.; Jung, H.A.; Jung, Y.O.; Park, S.J.; Kim, S.J. 2012: Phase 2 enzyme inducer sulphoraphane blocks prostaglandin and nitric oxide synthesis in human articular chondrocytes and inhibits cartilage matrix degradation. Rheumatology 51(6): 1006-1016

Donahue, M.; Smith, L.; Dykes, P.; Fitzpatrick, J.J. 2010: Phase 2 of the EMPOWER project: enhancing communication for paraprofessionals. Journal of Continuing Education in Nursing 41(5): 197-198

Yau, T.; Chan, P.; Ng, K.K.; Chok, S.Ho.; Cheung, T.To.; Fan, S.Tat.; Poon, R.T. 2009: Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer 115(2): 428-436

Homsi, J.; Bedikian, A.Y.; Kim, K.B.; Papadopoulos, N.E.; Hwu, W.-J.; Mahoney, S.L.; Hwu, P. 2009: Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients. Melanoma Research 19(4): 238-242

Homsi, J.; Bedikian, A.Y.; Papadopoulos, N.E.; Kim, K.B.; Hwu, W.-J.; Mahoney, S.L.; Hwu, P. 2010: Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma. Melanoma Research 20(6): 507-510

Abernethy, A.P.; Herndon, J.E.; Coan, A.; Staley, T.; Wheeler, J.L.; Rowe, K.; Smith, S.K.; Shaw, H.; Lyerly, H.K. 2010: Phase 2 pilot study of Pathfinders: a psychosocial intervention for cancer patients. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer 18(7): 893-898

San-Miguel, J.ús.; Bladé, J.; Shpilberg, O.; Grosicki, S.; Maloisel, F.éd.ér.; Min, C.-K.; Polo Zarzuela, M.; Robak, T.; Prasad, S.V.S.S.; Tee Goh, Y.; Laubach, J.; Spencer, A.; Mateos, M.ía.-V.; Palumbo, A.; Puchalski, T.; Reddy, M.; Uhlar, C.; Qin, X.; van de Velde, H.; Xie, H.; Orlowski, R.Z. 2014: Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. Blood 123(26): 4136-4142

Cortes, J.; Kantarjian, H.; Ball, E.D.; Dipersio, J.; Kolitz, J.E.; Fernandez, H.F.; Goodman, M.; Borthakur, G.; Baer, M.R.; Wetzler, M. 2012: Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia. Cancer 118(2): 418-427

Widemann, B.C.; Dombi, E.; Gillespie, A.; Wolters, P.L.; Belasco, J.; Goldman, S.; Korf, B.R.; Solomon, J.; Martin, S.; Salzer, W.; Fox, E.; Patronas, N.; Kieran, M.W.; Perentesis, J.P.; Reddy, A.; Wright, J.J.; Kim, A.; Steinberg, S.M.; Balis, F.M. 2014: Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. Neuro-Oncology 16(5): 707-718

Wong, R.K.W.; James, J.L.; Sagar, S.; Wyatt, G.; Nguyen-Tân, P.F.; Singh, A.K.; Lukaszczyk, B.; Cardinale, F.; Yeh, A.M.; Berk, L. 2012: Phase 2 results from Radiation Therapy Oncology Group Study 0537: a phase 2/3 study comparing acupuncture-like transcutaneous electrical nerve stimulation versus pilocarpine in treating early radiation-induced xerostomia. Cancer 118(17): 4244-4252

Fleisher, A.S.; Raman, R.; Siemers, E.R.; Becerra, L.; Clark, C.M.; Dean, R.A.; Farlow, M.R.; Galvin, J.E.; Peskind, E.R.; Quinn, J.F.; Sherzai, A.; Sowell, B.B.; Aisen, P.S.; Thal, L.J. 2008: Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Archives of Neurology 65(8): 1031-1038

Cevette, M.J.; Barrs, D.M.; Patel, A.; Conroy, K.P.; Sydlowski, S.; Noble, B.N.; Nelson, G.A.; Stepanek, J. 2011: Phase 2 study examining magnesium-dependent tinnitus. International Tinnitus Journal 16(2): 168-173

Ebbinghaus, S.; Hussain, M.; Tannir, N.; Gordon, M.; Desai, A.A.; Knight, R.A.; Humerickhouse, R.A.; Qian, J.; Gordon, G.B.; Figlin, R. 2007: Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 13(22 Part 1): 6689-6695

Halbsguth, T.V.; Nogová, L.; Mueller, H.; Sieniawski, M.; Eichenauer, D.A.; Schober, T.; Nisters-Backes, H.; Borchmann, P.; Diehl, V.; Engert, A.; Josting, A. 2010: Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood 116(12): 2026-2032

Santos, F.P.S.; Kantarjian, H.M.; Jain, N.; Manshouri, T.; Thomas, D.A.; Garcia-Manero, G.; Kennedy, D.; Estrov, Z.; Cortes, J.; Verstovsek, S. 2010: Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood 115(6): 1131-1136

Schiff, D.; Kesari, S.; de Groot, J.; Mikkelsen, T.; Drappatz, J.; Coyle, T.; Fichtel, L.; Silver, B.; Walters, I.; Reardon, D. 2015: Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma. Investigational new Drugs 33(1): 247-253

Lee, S.M.; Moon, J.; Redman, B.G.; Chidiac, T.; Flaherty, L.E.; Zha, Y.; Othus, M.; Ribas, A.; Sondak, V.K.; Gajewski, T.F.; Margolin, K.A. 2015: Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121(3): 432-440

Kaira, K.; Sunaga, N.; Yanagitani, N.; Imai, H.; Utsugi, M.; Iwasaki, Y.; Shimizu, K.; Iijima, H.; Tsurumaki, H.; Tomizawa, Y.; Hisada, T.; Ishizuka, T.; Saito, R.; Mori, M. 2010: Phase 2 study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 68(2): 253-257

Goldstein, S.; Bates, E.R.; Bhatt, D.L.; Cao, C.; Holmes, D.; Kupfer, S.; Martinez, F.; Spaeder, J.; Weitz, J.I.; Ye, Z.; Zannad, F.; Massie, B.; Bassand, J.-P.; Becker, R.; DeMets, D.; Kleiman, N.; Aroesty, J.; Berger, C.; Binkert, C.; Bowen, F.; Carrozza, J.; Charytan, D.; Chauhan, M.; Chun, A.; Cohen, D.; Cutlip, D.; Dashe, J.; Epstein, L.; Garcia, L.; Gelfand, E.; Giri, S.; Gossman, D.; Gravereaux, E.; Hamdan, A.; Ho, K.; Kannam, J.; Khabbaz, K.; Kimmelstiel, C.; Laham, R.; Leary, M.; Manning, W.; Markis, J.; Nohria, A.; Oettgen, P.; Pinto, D.; Sanjay, S.A.; Savitz, S.; Schermerhorn, M.; Selke, F.; Shah, P.B.; Thaler, D.; Waxman, S.; Albrini, A.; Araneda Vidal, G.A.; Arneja, J.S.; Arutyunov, G.; Aycock, G.R.; Azarin, O.; Azize, G.M.és. 2014: Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome. Thrombosis and Haemostasis 111(6): 1141-1152

Chang, J.E.; Li, H.; Smith, M.R.; Gascoyne, R.D.; Paietta, E.M.; Yang, D.T.; Advani, R.H.; Horning, S.J.; Kahl, B.S. 2014: Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405). Blood 123(11): 1665-1673

Pirayesh, E.; Amoui, M.; Mirzaee, H.R.; Tabei, F.; Rakhsha, A.; Kalantari, B.A.; Shafiei, B.; Assadi, M.; Asli, I.N. 2013: Phase 2 study of a high dose of 186Re-HEDP for bone pain palliation in patients with widespread skeletal metastases. Journal of Nuclear Medicine Technology 41(3): 192-196

Faucher, N.; Ehrler, S.; Vin, F.; Dugré, T.; Dugré, T.; Ehrler, S.; Faucher, N.; Guiguen, Y.; Le Pillouet-Prost, A.; Rudondy, P.; Vasseur, P.; Vin, F.éd.; Hyland, D.; Lathan, J.N.; Ottino, J. 2008: Phase 2 study of a new Hydrofiber dressing for superficial chronic or acute wounds. Journal of Wound Care 17(4): 180-182; 184, 187

Hendricksen, K.; Cornel, E.B.; de Reijke, T.M.; Arentsen, H.C.; Chawla, S.; Witjes, J.A. 2012: Phase 2 study of adjuvant intravesical instillations of apaziquone for high risk nonmuscle invasive bladder cancer. Journal of Urology 187(4): 1195-1199

Philip, P.A.; Mahoney, M.R.; Holen, K.D.; Northfelt, D.W.; Pitot, H.C.; Picus, J.; Flynn, P.J.; Erlichman, C. 2012: Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer. Cancer 118(9): 2424-2430

Taylor, J.W.; Dietrich, J.; Gerstner, E.R.; Norden, A.D.; Rinne, M.L.; Cahill, D.P.; Stemmer-Rachamimov, A.; Wen, P.Y.; Betensky, R.A.; Giorgio, D.H.; Snodgrass, K.; Randall, A.E.; Batchelor, T.T.; Chi, A.S. 2015: Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma. Journal of Neuro-Oncology 121(3): 557-563

Kavanagh, J.J.; Levenback, C.F.; Ramirez, P.T.; Wolf, J.L.; Moore, C.L.; Jones, M.R.; Meng, L.; Brown, G.L.; Bast, R.C. 2010: Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer. Journal of Hematology and Oncology 3: 9

Luo, H-Yan.; Wang, Z-Qiang.; Wang, F-Hua.; Qiu, M-Zhen.; Teng, K-Yuan.; Ruan, D-Yun.; He, Y-Jian.; Li, Y-Hong.; Xu, R-Hua. 2011: Phase 2 study of capecitabine and irinotecan combination chemotherapy (modified XELIRI regimen) in patients with advanced gastric cancer. American Journal of Clinical Oncology 34(6): 555-560

William, W.N.; Kies, M.S.; Fossella, F.V.; Liu, D.D.; Gladish, G.; Tse, W.H.; Lee, J.J.; Hong, W.K.; Lippman, S.M.; Kim, E.S. 2010: Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer. Cancer 116(10): 2401-2408

Reardon, D.A.; Desjardins, A.; Peters, K.B.; Vredenburgh, J.J.; Gururangan, S.; Sampson, J.H.; McLendon, R.E.; Herndon, J.E.; Coan, A.; Threatt, S.; Friedman, A.H.; Friedman, H.S. 2011: Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer 117(23): 5351-5358

Sonneveld, P.; Asselbergs, E.; Zweegman, S.; van der Holt, B.; Kersten, M.J.; Vellenga, E.; van Marwijk-Kooy, M.; Broyl, A.; de Weerdt, O.; Lonergan, S.; Palumbo, A.; Lokhorst, H. 2015: Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma. Blood 125(3): 449-456

Elion, R.; Cohen, C.; Gathe, J.; Shalit, P.; Hawkins, T.; Liu, H.C.; Mathias, A.A.; Chuck, S.L.; Kearney, B.P.; Warren, D.R. 2011: Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection. Aids 25(15): 1881-1886

Chen, S.-W.; Lin, L.-C.; Kuo, Y.-C.; Liang, J.-A.; Kuo, C.-C.; Chiou, J.-F. 2014: Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma. International Journal of Radiation Oncology Biology Physics 88(5): 1041-1047

Dilling, T.J.; Extermann, M.; Kim, J.; Thompson, L.M.; Yue, B.; Stevens, C.W.; Antonia, S.; Gray, J.; Williams, C.; Haura, E.; Pinder-Schenck, M.; Tanvetyanon, T.; Kim, S.; Chiappori, A. 2014: Phase 2 study of concurrent cetuximab plus definitive thoracic radiation therapy followed by consolidation docetaxel plus cetuximab in poor prognosis or elderly patients with locally advanced non-small cell lung cancer. International Journal of Radiation Oncology Biology Physics 90(4): 828-833

Brooks, H.D.; Glisson, B.S.; Bekele, B.N.; Johnson, F.M.; Ginsberg, L.E.; El-Naggar, A.; Culotta, K.S.; Takebe, N.; Wright, J.; Tran, H.T.; Papadimitrakopoulou, V.A. 2011: Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma. Cancer 117(10): 2112-2119

Scheid, C.; Reece, D.; Beksac, M.; Spencer, A.; Callander, N.; Sonneveld, P.; Kalimi, G.; Cai, C.; Shi, M.; Scott, J.W.; Stewart, A.K. 2015: Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation. European Journal of Haematology 95(4): 316-324

McIntyre, K.; O'Shaughnessy, J.; Schwartzberg, L.; Glück, S.; Berrak, E.; Song, J.X.; Cox, D.; Vahdat, L.T. 2014: Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer. Breast Cancer Research and Treatment 146(2): 321-328

Oh, D.-Y.; Kim, T.-W.; Park, Y.S.; Shin, S.J.; Shin, S.H.; Song, E.-K.; Lee, H.J.; Lee, K.-W.; Bang, Y.-J. 2012: Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas. Cancer 118(24): 6162-6170

Moulder, S.; Valkov, N.; Neuger, A.; Choi, J.; Lee, J.Hyun.; Minton, S.; Munster, P.; Gump, J.; Lacevic, M.; Lush, R.; Sullivan, D. 2008: Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response. Cancer 113(10): 2646-2654

Amato, R.J.; Hernandez-McClain, J.; Henary, H. 2009: Phase 2 study of granulocyte-macrophage colony-stimulating factor plus thalidomide in patients with hormone-naïve adenocarcinoma of the prostate. Urologic Oncology 27(1): 8-13

Chang, J.Y.; Komaki, R.; Lu, C.; Wen, H.Y.; Allen, P.K.; Tsao, A.; Gillin, M.; Mohan, R.; Cox, J.D. 2011: Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage IIi nonsmall cell lung cancer. Cancer 117(20): 4707-4713

Barr, P.M.; Miller, T.P.; Friedberg, J.W.; Peterson, D.R.; Baran, A.M.; Herr, M.; Spier, C.M.; Cui, H.; Roe, D.J.; Persky, D.O.; Casulo, C.; Littleton, J.; Schwartz, M.; Puvvada, S.; Landowski, T.H.; Rimsza, L.M.; Dorr, R.T.; Fisher, R.I.; Bernstein, S.H.; Briehl, M.M. 2014: Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma. Blood 124(8): 1259-1265

Spina, M.; Chimienti, E.; Martellotta, F.; Vaccher, E.; Berretta, M.; Zanet, E.; Lleshi, A.; Canzonieri, V.; Bulian, P.; Tirelli, U. 2010: Phase 2 study of intrathecal, long-acting liposomal cytarabine in the prophylaxis of lymphomatous meningitis in human immunodeficiency virus-related non-Hodgkin lymphoma. Cancer 116(6): 1495-1501

Ramalingam, S.S.; Foster, J.; Gooding, W.; Evans, T.; Sulecki, M.; Belani, C.P. 2010: Phase 2 study of irinotecan and paclitaxel in patients with recurrent or refractory small cell lung cancer. Cancer 116(5): 1344-1349

Raza, A.; Reeves, J.A.; Feldman, E.J.; Dewald, G.W.; Bennett, J.M.; Deeg, H.J.; Dreisbach, L.; Schiffer, C.A.; Stone, R.M.; Greenberg, P.L.; Curtin, P.T.; Klimek, V.M.; Shammo, J.M.; Thomas, D.; Knight, R.D.; Schmidt, M.; Wride, K.; Zeldis, J.B.; List, A.F. 2008: Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 111(1): 86-93

Greco, F.A.; Bonomi, P.; Crawford, J.; Kelly, K.; Oh, Y.; Halpern, W.; Lo, L.; Gallant, G.; Klein, J. 2008: Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 61(1): 82-90

Ross, R.W.; Galsky, M.D.; Febbo, P.; Barry, M.; Richie, J.P.; Xie, W.; Fennessy, F.M.; Bhatt, R.S.; Hayes, J.; Choueiri, T.K.; Tempany, C.M.; Kantoff, P.W.; Taplin, M.E.; Oh, W.K. 2012: Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial. Cancer 118(19): 4777-4784

Montero, A.J.; Diaz-Montero, C.M.; Deutsch, Y.E.; Hurley, J.; Koniaris, L.G.; Rumboldt, T.; Yasir, S.; Jorda, M.; Garret-Mayer, E.; Avisar, E.; Slingerland, J.; Silva, O.; Welsh, C.; Schuhwerk, K.; Seo, P.; Pegram, M.D.; Glück, S. 2012: Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer. Breast Cancer Research and Treatment 132(1): 215-223

Sawaki, A.; Nishida, T.; Doi, T.; Yamada, Y.; Komatsu, Y.; Kanda, T.; Kakeji, Y.; Onozawa, Y.; Yamasaki, M.; Ohtsu, A. 2011: Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor. Cancer 117(20): 4633-4641

Rudin, C.M.; Brahmer, J.R.; Juergens, R.A.; Hann, C.L.; Ettinger, D.S.; Sebree, R.; Smith, R.; Aftab, B.T.; Huang, P.; Liu, J.O. 2013: Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 8(5): 619-623

Choy, H.; Schwartzberg, L.S.; Dakhil, S.R.; Garon, E.B.; Gerber, D.E.; Choksi, J.K.; Govindan, R.; Peng, G.; Koustenis, A.; Treat, J.; Obasaju, C. 2013: Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B non-small-cell lung cancer. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 8(10): 1308-1316

Vanderwalde, N.A.; Jones, E.L.; Kimple, R.J.; Moore, D.T.; Klauber-Demore, N.; Sartor, C.I.; Ollila, D.W. 2013: Phase 2 study of pre-excision single-dose intraoperative radiation therapy for early-stage breast cancers: six-year update with application of the ASTRO accelerated partial breast irradiation consensus statement criteria. Cancer 119(9): 1736-1743

O'Sullivan, B.; Griffin, A.M.; Dickie, C.I.; Sharpe, M.B.; Chung, P.W.M.; Catton, C.N.; Ferguson, P.C.; Wunder, J.S.; Deheshi, B.M.; White, L.M.; Kandel, R.A.; Jaffray, D.A.; Bell, R.S. 2013: Phase 2 study of preoperative image-guided intensity-modulated radiation therapy to reduce wound and combined modality morbidities in lower extremity soft tissue sarcoma. Cancer 119(10): 1878-1884

Landry, J.C.; Feng, Y.; Cohen, S.J.; Staley, C.A.; Whittington, R.; Sigurdson, E.Ruth.; Nimeiri, H.; Verma, U.; Prabhu, R.S.; Benson, A.Bowen. 2013: Phase 2 study of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: ECOG 3204. Cancer 119(8): 1521-1527

Kantarjian, H.M.; Giles, F.J.; Greenberg, P.L.; Paquette, R.L.; Wang, E.S.; Gabrilove, J.L.; Garcia-Manero, G.; Hu, K.; Franklin, J.L.; Berger, D.P. 2010: Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood 116(17): 3163-3170

Bartels, U.; Wolff, J.; Gore, L.; Dunkel, I.; Gilheeney, S.; Allen, J.; Goldman, S.; Yalon, M.; Packer, R.J.; Korones, D.N.; Smith, A.; Cohen, K.; Kuttesch, J.; Strother, D.; Baruchel, S.; Gammon, J.; Kowalski, M.; Bouffet, E. 2014: Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma. Neuro-Oncology 16(11): 1554-1559

Vavassis, P.; Gelinas, M.; Chabot Tr, J.; Nguyen-Tân, P.F. 2008: Phase 2 study of silver leaf dressing for treatment of radiation-induced dermatitis in patients receiving radiotherapy to the head and neck. Journal of Otolaryngology - Head and Neck Surgery 37(1): 124-129

Fumoleau, P.; Cortés-Funes, H.; Taleb, A.B.; Chan, S.; Campone, M.; Pouget, J.-C.; Tubiana-Hulin, M.èl.; Slabber, C.F.; Caroff-Paraïso, I.; Alberts, A.S.; Ben Ayed, F. 2009: Phase 2 study of single-agent IV vinflunine as third-line treatment of metastatic breast cancer after failure of anthracycline-/taxane-based chemotherapy. American Journal of Clinical Oncology 32(4): 375-380

Cudkowicz, M.E.; Andres, P.L.; Macdonald, S.A.; Bedlack, R.S.; Choudry, R.; Brown, R.H.; Zhang, H.; Schoenfeld, D.A.; Shefner, J.; Matson, S.; Matson, W.R.; Ferrante, R.J.; Kruczek, K.; Sherman, A.; Yu, H.; Opoliner, A.; Maragakis, N.; Clawson, L.; Kimball, R.; Smith, K.; Hetherington, W.; Loya, P.; Golightly, Y.; Mosier, D.; Ali, N.; Allred, M.; Kasarskis, E.; Taylor, D.; English, R.; Vriesendorp, F.; Schad, L.; Zivkovic, S.; Van Cott, A.; Brice, V.; Sams, L.; Story, M.; Taft, J. 2009: Phase 2 study of sodium phenylbutyrate in ALS. Amyotrophic Lateral Sclerosis: Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases 10(2): 99-106

Papa, S.; Popat, S.; Shah, R.; Prevost, A.T.; Lal, R.; McLennan, B.; Cane, P.; Lang-Lazdunski, L.; Viney, Z.; Dunn, J.T.; Barrington, S.; Landau, D.; Spicer, J. 2013: Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 8(6): 783-787

Cortes, J.; Lipton, J.H.; Rea, D.; Digumarti, R.; Chuah, C.; Nanda, N.; Benichou, A.-C.; Craig, A.R.; Michallet, M.; Nicolini, F.E.; Kantarjian, H.; Ailawadhi, S.; Akard, L.; Baer, M.; Baccarani, M.; Emmons, R.; Etienne, G.; Guerci, A.ès.; Guilhot, F.ço.; Hellmann, A.; Huguet-Rigal, F.ço.; Khoury, H. J.; Laneuville, P.; Coutre, P.L.; Legros, L.; Leitner, A.; Maloisel, F.; Marin, D.; Masszi, T.; Parikh, P.; Rivera, C.; Rousselot, P.; Facon, T.; Van Etten, R.; Warzocha, K.; Wetzler, M.; Wiernik, P. 2012: Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKi failure in patients with chronic-phase CML with T315i mutation. Blood 120(13): 2573-2580

Cortes, J.; Digumarti, R.; Parikh, P.M.; Wetzler, M.; Lipton, J.H.; Hochhaus, A.; Craig, A.R.; Benichou, A.-C.; Nicolini, F.E.; Kantarjian, H.M. 2013: Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors. American Journal of Hematology 88(5): 350-354

Kchour, G.; Tarhini, M.; Kooshyar, M.-M.; El Hajj, H.; Wattel, E.; Mahmoudi, M.; Hatoum, H.; Rahimi, H.; Maleki, M.; Rafatpanah, H.; Rezaee, S.A.R.; Yazdi, M.T.; Shirdel, A.; de Thé, H.; Hermine, O.; Farid, R.; Bazarbachi, A. 2009: Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). Blood 113(26): 6528-6532

Sekeres, M.A.; Tiu, R.V.; Komrokji, R.; Lancet, J.; Advani, A.S.; Afable, M.; Englehaupt, R.; Juersivich, J.; Cuthbertson, D.; Paleveda, J.; Tabarroki, A.; Visconte, V.; Makishima, H.; Jerez, A.; Paquette, R.; List, A.F.; Maciejewski, J.P. 2012: Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Blood 120(25): 4945-4951

Gulick, R.M.; Su, Z.; Flexner, C.; Hughes, M.D.; Skolnik, P.R.; Wilkin, T.J.; Gross, R.; Krambrink, A.; Coakley, E.; Greaves, W.L.; Zolopa, A.; Reichman, R.; Godfrey, C.; Hirsch, M.; Kuritzkes, D.R. 2007: Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. Journal of Infectious Diseases 196(2): 304-312

Bensinger, W.I.; Jagannath, S.; Vescio, R.; Camacho, E.; Wolf, J.; Irwin, D.; Capo, G.; McKinley, M.; Potts, P.; Vesole, D.H.; Mazumder, A.; Crowley, J.; Becker, P.; Hilger, J.; Durie, B.G.M. 2010: Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma. British Journal of Haematology 148(4): 562-568

Gerecitano, J.; Portlock, C.; Moskowitz, C.; Hamlin, P.; Straus, D.; Zelenetz, A.D.; Zhang, Z.; Dumitrescu, O.; Sarasohn, D.; Lin, D.; Pappanicholaou, J.; Cortelli, B.M.; Neylon, E.; Hamelers, R.; Wright, J.; O'Connor, O.A. 2009: Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma. British Journal of Haematology 146(6): 652-655

Galanis, E.; Wu, W.; Cloughesy, T.; Lamborn, K.; Mann, B.; Wen, P.Y.; Reardon, D.A.; Wick, W.; Macdonald, D.; Armstrong, T.S.; Weller, M.; Vogelbaum, M.; Colman, H.; Sargent, D.J.; van den Bent, M.J.; Gilbert, M.; Chang, S. 2012: Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. Lancet. Oncology 13(5): e196-e204

Lancet, J.E.; Cortes, J.E.; Hogge, D.E.; Tallman, M.S.; Kovacsovics, T.J.; Damon, L.E.; Komrokji, R.; Solomon, S.R.; Kolitz, J.E.; Cooper, M.; Yeager, A.M.; Louie, A.C.; Feldman, E.J. 2014: Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood 123(21): 3239-3246

Tan, E.-H.; Goss, G.D.; Salgia, R.; Besse, B.; Gandara, D.R.; Hanna, N.H.; Yang, J.C.-H.; Thertulien, R.; Wertheim, M.; Mazieres, J.; Hensing, T.; Lee, C.; Gupta, N.; Pradhan, R.; Qian, J.; Qin, Q.; Scappaticci, F.A.; Ricker, J.L.; Carlson, D.M.; Soo, R.A. 2011: Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 6(8): 1418-1425

Gajria, D.; Feigin, K.; Tan, L.K.; Patil, S.; Geneus, S.; Theodoulou, M.; Norton, L.; Hudis, C.A.; Traina, T.A. 2011: Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer. Cancer 117(18): 4125-4131

Kim, J.Y.; Jung, S.-Y.; Lee, S.; Kang, H.-S.; Lee, E.S.; Park, I.H.; Lee, K.S.; Ro, J.; Lee, N.K.; Shin, K.H. 2013: Phase 2 trial of accelerated, hypofractionated whole-breast irradiation of 39 Gy in 13 fractions followed by a tumor bed boost sequentially delivering 9 Gy in 3 fractions in early-stage breast cancer. International Journal of Radiation Oncology Biology Physics 87(5): 1037-1042

George, S.; Feng, Y.; Manola, J.; Nucci, M.R.; Butrynski, J.E.; Morgan, J.A.; Ramaiya, N.; Quek, R.; Penson, R.T.; Wagner, A.J.; Harmon, D.; Demetri, G.D.; Krasner, C. 2014: Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors. Cancer 120(5): 738-743

Sun, W.; Sohal, D.; Haller, D.G.; Mykulowycz, K.; Rosen, M.; Soulen, M.C.; Caparro, M.; Teitelbaum, U.R.; Giantonio, B.; O'Dwyer, P.J.; Shaked, A.; Reddy, R.; Olthoff, K. 2011: Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma. Cancer 117(14): 3187-3192

Perez, D.G.; Suman, V.J.; Fitch, T.R.; Amatruda, T.; Morton, R.F.; Jilani, S.Z.; Constantinou, C.L.; Egner, J.R.; Kottschade, L.A.; Markovic, S.N. 2009: Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A. Cancer 115(1): 119-127

Weigel, B.; Malempati, S.; Reid, J.M.; Voss, S.D.; Cho, S.Y.; Chen, H.X.; Krailo, M.; Villaluna, D.; Adamson, P.C.; Blaney, S.M. 2014: Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group. Pediatric Blood and Cancer 61(3): 452-456

Hijiya, N.; Thomson, B.; Isakoff, M.S.; Silverman, L.B.; Steinherz, P.G.; Borowitz, M.J.; Kadota, R.; Cooper, T.; Shen, V.; Dahl, G.; Thottassery, J.V.; Jeha, S.; Maloney, K.; Paul, J.-A.; Barry, E.; Carroll, W.L.; Gaynon, P.S. 2011: Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood 118(23): 6043-6049

Clark, J.I.; Moon, J.; Hutchins, L.F.; Sosman, J.A.; Kast, W.M.; Da Silva, D.M.; Liu, P.Y.; Thompson, J.A.; Flaherty, L.E.; Sondak, V.K. 2010: Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. Cancer 116(2): 424-431

Mahadevan, D.; Unger, J.M.; Spier, C.M.; Persky, D.O.; Young, F.; LeBlanc, M.; Fisher, R.I.; Miller, T.P. 2013: Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. Cancer 119(2): 371-379

Kao, J.; Genden, E.M.; Gupta, V.; Policarpio, E.L.; Burri, R.J.; Rivera, M.; Gurudutt, V.; Som, P.M.; Teng, M.; Packer, S.H. 2011: Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer. Cancer 117(2): 318-326

Shanafelt, T.D.; Call, T.G.; Zent, C.S.; Leis, J.F.; LaPlant, B.; Bowen, D.A.; Roos, M.; Laumann, K.; Ghosh, A.K.; Lesnick, C.; Lee, M.-J.; Yang, C.S.; Jelinek, D.F.; Erlichman, C.; Kay, N.E. 2013: Phase 2 trial of daily, oral Polyphenon e in patients with asymptomatic, Rai stage 0 to Ii chronic lymphocytic leukemia. Cancer 119(2): 363-370

Seliger, G.; Mueller, L.P.; Kegel, T.; Kantelhardt, E.J.; Grothey, A.; Groe, R.; Strauss, H.-G.; Koelbl, H.; Thomssen, C.; Schmoll, H.-J. 2009: Phase 2 trial of docetaxel, gemcitabine, and oxaliplatin combination chemotherapy in platinum- and paclitaxel-pretreated epithelial ovarian cancer. International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society 19(8): 1446-1453

Tidswell, M.; Tillis, W.; Larosa, S.P.; Lynn, M.; Wittek, A.E.; Kao, R.; Wheeler, J.; Gogate, J.; Opal, S.M.; Kennedy, J.I.; Deza, J.C.; Belzberg, H.; Stewart, J.O.; Parrish, J.S.; Sasse, S.A.; Roum, J.; Waxman, K.S.; Heit, J.; Moore, E.; Amin, D.; Anderson, C.L.C.; Brown, M.A.; Phillips, D.E.; Lorch, D.G.; Rumbak, M.J.; Schein, R.M.H.; Quartin, A.A.; Nicolais, V.; Ramsey, J.G.; Berman, S.J.; Tice, A.D.; Dematte D'Amico, J.E.; Grove, E.; Dugan, G.; Tillis, W.P.; Whitten, P.E.; Rahman, R.; Zun, L.; Witty, L.A.; Naum, C.C.; Hicklin, G.A.; Moines, D.; Peterson, G.E.; Moncure, M.; Rehm, J.R.; Hoffman, W.; Tidswell, M.; Farra, W.; Kruse, J.A.; Ravikrishnan, K.P.; Quickel, R.R.; Richart, C.M.; Shander, A.; Lisco, S.J.; Shore, N.; Nolan, J.P. 2010: Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis. Critical Care Medicine 38(1): 72-83

Nogueira-Rodrigues, A.; Moralez, G.; Grazziotin, R.; Carmo, C.C.; Small, I.A.; Alves, F.V.G.; Mamede, M.; Erlich, F.; Viegas, C.; Triginelli, S.A.; Ferreira, C.G. 2014: Phase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer. Cancer 120(8): 1187-1193

Reardon, D.A.; Desjardins, A.; Vredenburgh, J.J.; Gururangan, S.; Friedman, A.H.; Herndon, J.E.; Marcello, J.; Norfleet, J.A.; McLendon, R.E.; Sampson, J.H.; Friedman, H.S. 2010: Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. Journal of Neuro-Oncology 96(2): 219-230

Belani, C.P.; Nemunaitis, J.J.; Chachoua, A.; Eisenberg, P.D.; Raez, L.E.; Cuevas, J.D.; Mather, C.B.; Benner, R.J.; Meech, S.J. 2013: Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer. Cancer Biology and Therapy 14(7): 557-563

Singh, J.; Novik, Y.; Stein, S.; Volm, M.; Meyers, M.; Smith, J.; Omene, C.; Speyer, J.; Schneider, R.; Jhaveri, K.; Formenti, S.; Kyriakou, V.; Joseph, B.; Goldberg, J.D.; Li, X.; Adams, S.; Tiersten, A. 2014: Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer. Breast Cancer Research: Bcr 16(2): R32

Chen, Y.-B.; Batchelor, T.; Li, S.; Hochberg, E.; Brezina, M.; Jones, S.; Del Rio, C.; Curtis, M.; Ballen, K.K.; Barnes, J.; Chi, A.S.; Dietrich, J.; Driscoll, J.; Gertsner, E.R.; Hochberg, F.; LaCasce, A.S.; McAfee, S.L.; Spitzer, T.R.; Nayak, L.; Armand, P. 2015: Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma. Cancer 121(2): 226-233

Iuchi, T.; Hatano, K.; Kodama, T.; Sakaida, T.; Yokoi, S.; Kawasaki, K.; Hasegawa, Y.; Hara, R. 2014: Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma. International Journal of Radiation Oncology Biology Physics 88(4): 793-800

Ilson, D.H.; Minsky, B.D.; Ku, G.Y.; Rusch, V.; Rizk, N.; Shah, M.; Kelsen, D.P.; Capanu, M.; Tang, L.; Campbell, J.; Bains, M. 2012: Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer. Cancer 118(11): 2820-2827

Esnaola, N.F.; Chaudhary, U.B.; O'Brien, P.; Garrett-Mayer, E.; Camp, E.R.; Thomas, M.B.; Cole, D.J.; Montero, A.J.; Hoffman, B.J.; Romagnuolo, J.; Orwat, K.P.; Marshall, D.T. 2014: Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer. International Journal of Radiation Oncology Biology Physics 88(4): 837-844

Giglio, P.; Dhamne, M.; Hess, K.R.; Gilbert, M.R.; Groves, M.D.; Levin, V.A.; Kang, S.L.; Ictech, S.E.; Liu, V.; Colman, H.; Conrad, C.A.; Loghin, M.; de Groot, J.; Yung, W.K.Alfred.; Puduvalli, V.K. 2012: Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma. Cancer 118(14): 3599-3606

Banno, H.; Katsuno, M.; Suzuki, K.; Takeuchi, Y.; Kawashima, M.; Suga, N.; Takamori, M.; Ito, M.; Nakamura, T.; Matsuo, K.; Yamada, S.; Oki, Y.; Adachi, H.; Minamiyama, M.; Waza, M.; Atsuta, N.; Watanabe, H.; Fujimoto, Y.; Nakashima, T.; Tanaka, F.; Doyu, M.; Sobue, G. 2009: Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy. Annals of Neurology 65(2): 140-150

Stevenson, J.P.; Langer, C.J.; Somer, R.A.; Evans, T.L.; Rajagopalan, K.; Krieger, K.; Jacobs-Small, M.; Dyanick, N.; Milcarek, B.; Coakley, S.; Walker, S.; Eaby-Sandy, B.; Hageboutros, A. 2012: Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung cancer. Cancer 118(22): 5580-5587

Ramondetta, L.M.; Johnson, A.J.; Sun, C.C.; Atkinson, N.; Smith, J.A.; Jung, M.S.; Broaddus, R.; Iyer, R.B.; Burke, T. 2009: Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma. Cancer 115(9): 1867-1874

Karam, J.A.; Devine, C.E.; Urbauer, D.L.; Lozano, M.; Maity, T.; Ahrar, K.; Tamboli, P.; Tannir, N.M.; Wood, C.G. 2014: Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma. European Urology 66(5): 874-880

Di Legge, A.; Trivellizzi, I.N.; Moruzzi, M.C.; Pesce, A.; Scambia, G.; Lorusso, D. 2011: Phase 2 trial of nonpegylated doxorubicin (Myocet) as second-line treatment in advanced or recurrent endometrial cancer. International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society 21(8): 1446-1451

Ina, S.; Tani, M.; Kawai, M.; Hirono, S.; Miyazawa, M.; Nishioka, R.; Fujita, Y.; Yamaue, H. 2008: Phase 2 trial of oral S-1 combined with low-dose cisplatin for unresectable advanced pancreatic cancer. Anticancer Research 28(4c): 2373-2377

Gilbert, J.; Murphy, B.; Dietrich, M.S.; Henry, E.; Jordan, R.; Counsell, A.; Wirth, P.; Yarbrough, W.G.; Slebos, R.J.; Chung, C.H. 2012: Phase 2 trial of oxaliplatin and pemetrexed as an induction regimen in locally advanced head and neck cancer. Cancer 118(4): 1007-1013

Xiong, H.Q.; Varadhachary, G.R.; Blais, J.C.; Hess, K.R.; Abbruzzese, J.L.; Wolff, R.A. 2008: Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer 113(8): 2046-2052

Northfelt, D.W.; Allred, J.B.; Liu, H.; Hobday, T.J.; Rodacker, M.W.; Lyss, A.P.; Fitch, T.R.; Perez, E.A. 2014: Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer. American Journal of Clinical Oncology 37(2): 167-171

Song, M.; DiPaola, R.S.; Cracchiolo, B.M.; Gibbon, D.G.; Hellmann, M.; Nieves-Neira, W.; Vaidya, A.; Wagreich, A.R.; Shih, W.J.; Rodriguez-Rodriguez, L. 2014: Phase 2 trial of paclitaxel, 13-cis retinoic acid, and interferon alfa-2b in the treatment of advanced stage or recurrent cervical cancer. International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society 24(9): 1636-1641

Chee, C.E.; Jett, J.R.; Bernath, A.M.; Foster, N.R.; Nelson, G.D.; Molina, J.; Nikcevich, D.A.; Steen, P.D.; Flynn, P.J.; Rowland, K.M. 2010: Phase 2 trial of pemetrexed disodium and carboplatin in previously untreated extensive-stage small cell lung cancer, N0423. Cancer 116(10): 2382-2389

Knox, J.J.; Wong, R.; Visbal, A.L.; Horgan, A.M.; Guindi, M.; Hornby, J.; Xu, W.; Ringash, J.; Keshavjee, S.; Chen, E.; Haider, M.; Darling, G. 2010: Phase 2 trial of preoperative irinotecan plus cisplatin and conformal radiotherapy, followed by surgery for esophageal cancer. Cancer 116(17): 4023-4032

Liu, L.; Jia, W.; Liu, R.; Shen, J. 2018: Clinical study of pregnancy-associated fulminant type 1 diabetes. Endocrine 60(2): 301-307

Meany, H.J.; Seibel, N.L.; Sun, J.; Finklestein, J.Z.; Sato, J.; Kelleher, J.; Sondel, P.; Reaman, G. 2008: Phase 2 trial of recombinant tumor necrosis factor-alpha in combination with dactinomycin in children with recurrent Wilms tumor. Journal of ImmunoTherapy 31(7): 679-683

Baiocchi, R.A.; Alinari, L.; Lustberg, M.E.; Lin, T.S.; Porcu, P.; Li, X.; Johnston, J.S.; Byrd, J.C.; Blum, K.A. 2011: Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma. Cancer 117(11): 2442-2451

Wang, M.; Fayad, L.; Cabanillas, F.; Hagemeister, F.; McLaughlin, P.; Rodriguez, M.A.; Kwak, L.W.; Zhou, Y.; Kantarjian, H.; Romaguera, J. 2008: Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma. Cancer 113(10): 2734-2741

Royal, R.E.; Levy, C.; Turner, K.; Mathur, A.; Hughes, M.; Kammula, U.S.; Sherry, R.M.; Topalian, S.L.; Yang, J.C.; Lowy, I.; Rosenberg, S.A. 2010: Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. Journal of ImmunoTherapy 33(8): 828-833

Dreicer, R.; Li, H.; Stein, M.; DiPaola, R.; Eleff, M.; Roth, B.J.; Wilding, G. 2009: Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer 115(18): 4090-4095

Iwamoto, F.M.; Kreisl, T.N.; Kim, L.; Duic, J.P.; Butman, J.A.; Albert, P.S.; Fine, H.A. 2010: Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas. Cancer 116(7): 1776-1782

Addeo, R.; De Rosa, C.; Faiola, V.; Leo, L.; Cennamo, G.; Montella, L.; Guarrasi, R.; Vincenzi, B.; Caraglia, M.; Del Prete, S. 2008: Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases. Cancer 113(9): 2524-2531

Niesvizky, R.; Ely, S.; Mark, T.; Aggarwal, S.; Gabrilove, J.L.; Wright, J.J.; Chen-Kiang, S.; Sparano, J.A. 2011: Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer 117(2): 336-342

Berger, M.; Massimo, B.; Grignani, G.; Giovanni, G.; Ferrari, S.; Stefano, F.; Biasin, E.; Eleonora, B.; Brach del Prever, A.; Adalberto, B.Del.Prever.; Aliberti, S.; Sandra, A.; Saglio, F.; Francesco, S.; Aglietta, M.; Massimo, A.; Fagioli, F.; Franca, F. 2009: Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high-risk osteosarcoma patients. Cancer 115(13): 2980-2987

Chadha, M.K.; Tian, L.; Mashtare, T.; Payne, V.; Silliman, C.; Levine, E.; Wong, M.; Johnson, C.; Trump, D.L. 2010: Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (calcitriol) in combination with dexamethasone for castration-resistant prostate cancer. Cancer 116(9): 2132-2139

Jiang, M.; Zhang, H.; Jiang, Y.; Yang, Q.; Xie, L.; Liu, W.; Zhang, W.; Ji, X.; Li, P.; Chen, N.; Zhao, S.; Wang, F.; Zou, L. 2012: Phase 2 trial of "sandwich" L-asparaginase, vincristine, and prednisone chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T-cell lymphoma. Cancer 118(13): 3294-3301

Arpornwirat, W.; Albert, I.; Hansen, V.L.; Levin, J.; Bandekar, R.R.; Grunberg, S.M. 2009: Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy. Cancer 115(24): 5807-5816

Habib, A.S.; Minkowitz, H.; Osborn, T.; Ogunnaike, B.; Candiotti, K.; Viscusi, E.; Gu, J.; Creed, M.R.; Gan, T.J.; Adams, D.; Belani, K.; Candiotti, K.; Habib, A.; Gratz, I.; O'Connor, M.; Adsumelli, R.; Viscusi, E.; Ogunnaike, B.; Sinha, A.; Mayfield, J.B.; Minkowitz, H.; Osborn, T.C.; Yost, S.; Jones, R.K.; Miller, H. 2008: Phase 2, double-blind, placebo-controlled, dose-response trial of intravenous adenosine for perioperative analgesia. Anesthesiology 109(6): 1085-1091

Forero-Torres, A.; Infante, J.R.; Waterhouse, D.; Wong, L.; Vickers, S.; Arrowsmith, E.; He, A.R.; Hart, L.; Trent, D.; Wade, J.; Jin, X.; Wang, Q.; Austin, T.; Rosen, M.; Beckman, R.; von Roemeling, R.; Greenberg, J.; Saleh, M. 2013: Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer. Cancer Medicine 2(6): 925-932

Wilks, S.; Puhalla, S.; O'Shaughnessy, J.; Schwartzberg, L.; Berrak, E.; Song, J.; Cox, D.; Vahdat, L. 2014: Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer. Clinical Breast Cancer 14(6): 405-412

Ruzsa, A.; Sen, M.; Evans, M.; Lee, L.W.; Hideghety, K.; Rottey, S.; Klimak, P.; Holeckova, P.; Fayette, J.; Csoszi, T.; Erfan, J.; Forssmann, U.; Goddemeier, T.; Bexon, A.; Nutting, C. 2014: Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Investigational new Drugs 32(6): 1278-1284

Solomkin, J.S.; Ramesh, M.K.; Cesnauskas, G.; Novikovs, N.; Stefanova, P.; Sutcliffe, J.A.; Walpole, S.M.; Horn, P.T. 2014: Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections. Antimicrobial Agents and ChemoTherapy 58(4): 1847-1854

Prokocimer, P.; Bien, P.; Surber, J.; Mehra, P.; DeAnda, C.; Bulitta, J.B.; Corey, G.R. 2011: Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. Antimicrobial Agents and ChemoTherapy 55(2): 583-592

Doebele, R.C.; Spigel, D.; Tehfe, M.; Thomas, S.; Reck, M.; Verma, S.; Eakle, J.; Bustin, F.; Goldschmidt, J.; Cao, D.; Alexandris, E.; Yurasov, S.; Camidge, D.R.; Bonomi, P. 2015: Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer. Cancer 121(6): 883-892

DuVall, G.A.; Tarabar, D.; Seidel, R.H.; Elstad, N.L.; Fowers, K.D. 2009: Phase 2: a dose-escalation study of OncoGel (ReGel/paclitaxel), a controlled-release formulation of paclitaxel, as adjunctive local therapy to external-beam radiation in patients with inoperable esophageal cancer. Anti-Cancer Drugs 20(2): 89-95

Moyle, G.; Boffito, M.; Stoehr, A.; Rieger, A.; Shen, Z.; Manhard, K.; Sheedy, B.; Hingorani, V.; Raney, A.; Nguyen, M.; Nguyen, T.; Ong, V.; Yeh, L.-T.; Quart, B. 2010: Phase 2a randomized controlled trial of short-term activity, safety, and pharmacokinetics of a novel nonnucleoside reverse transcriptase inhibitor, RDEA806, in HIV-1-positive, antiretroviral-naive subjects. Antimicrobial Agents and ChemoTherapy 54(8): 3170-3178

Hemmerling, A.; Harrison, W.; Schroeder, A.; Park, J.; Korn, A.; Shiboski, S.; Foster-Rosales, A.; Cohen, C.R. 2010: Phase 2a study assessing colonization efficiency, safety, and acceptability of Lactobacillus crispatus CTV-05 in women with bacterial vaginosis. Sexually Transmitted Diseases 37(12): 745-750

Finkel, R.S.; Flanigan, K.M.; Wong, B.; Bönnemann, C.; Sampson, J.; Sweeney, H.L.; Reha, A.; Northcutt, V.J.; Elfring, G.; Barth, J.; Peltz, S.W. 2013: Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy. Plos one 8(12): E81302

Jacobson, J.M.; Lalezari, J.P.; Thompson, M.A.; Fichtenbaum, C.J.; Saag, M.S.; Zingman, B.S.; D'Ambrosio, P.; Stambler, N.; Rotshteyn, Y.; Marozsan, A.J.; Maddon, P.J.; Morris, S.A.; Olson, W.C. 2010: Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults. Antimicrobial Agents and ChemoTherapy 54(10): 4137-4142

Kester, K.E.; Cummings, J.F.; Ockenhouse, C.F.; Nielsen, R.; Hall, B.Ted.; Gordon, D.M.; Schwenk, R.J.; Krzych, U.; Holland, C.A.; Richmond, G.; Dowler, M.G.; Williams, J.; Wirtz, R.A.; Tornieporth, N.; Vigneron, L.; Delchambre, M.; Demoitie, M-Ange.; Ballou, W.Ripley.; Cohen, J.; Heppner, D.Gray.; Gasser, R.A.; Oster, C.N.; Duffy, P.E.; Wortmann, G.; English, C.K.; Diggs, C.L.; Soisson, L.; Fitzpatrick, S. 2008: Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research. Vaccine 26(18): 2191-2202

Gelbard, M.; Lipshultz, L.I.; Tursi, J.; Smith, T.; Kaufman, G.; Levine, L.A. 2012: Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease. Journal of Urology 187(6): 2268-2274

Kowdley, K.V.; Lawitz, E.; Poordad, F.; Cohen, D.E.; Nelson, D.R.; Zeuzem, S.; Everson, G.T.; Kwo, P.; Foster, G.R.; Sulkowski, M.S.; Xie, W.; Pilot-Matias, T.; Liossis, G.; Larsen, L.; Khatri, A.; Podsadecki, T.; Bernstein, B. 2014: Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. New England Journal of Medicine 370(3): 222-232

Anonymous 1973: Phase 3 and beyond. British Medical Journal 4(5889): 374

Bolaños-Meade, J.; Logan, B.R.; Alousi, A.M.; Antin, J.H.; Barowski, K.; Carter, S.L.; Goldstein, S.C.; Hexner, E.O.; Horowitz, M.M.; Lee, S.J.; Levine, J.E.; MacMillan, M.L.; Martin, P.J.; Mendizabal, A.M.; Nakamura, R.; Pasquini, M.C.; Weisdorf, D.J.; Westervelt, P.; Ho, V.T. 2014: Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. Blood 124(22): 3221-3227; Quiz 3335

Gutierrez, J.E.; Rosenberg, M.; Duhaney, M.; Simon, J.A.; Brueggenwerth, G.; Agris, J.M.; Knopp, E.A. 2015: Phase 3 efficacy and safety trial of gadobutrol, a 1.0 molar macrocyclic MR imaging contrast agent, in patients referred for contrast-enhanced MR imaging of the central nervous system. Journal of Magnetic Resonance Imaging: Jmri 41(3): 788-796

Ginsberg, D.; Gousse, A.; Keppenne, V.; Sievert, K.-D.; Thompson, C.; Lam, W.; Brin, M.F.; Jenkins, B.; Haag-Molkenteller, C. 2012: Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. Journal of Urology 187(6): 2131-2139

Vergote, I.; Finkler, N.; del Campo, J.; Lohr, A.; Hunter, J.; Matei, D.; Kavanagh, J.; Vermorken, J.B.; Meng, L.; Jones, M.; Brown, G.; Kaye, S. 2009: Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer. European Journal of Cancer 45(13): 2324-2332

Nguyen, Q.H.; McMenemy, M.G.; Realini, T.; Whitson, J.T.; Goode, S.M. 2013: Phase 3 randomized 3-month trial with an ongoing 3-month safety extension of fixed-combination brinzolamide 1%/brimonidine 0.2%. Journal of Ocular Pharmacology and Therapeutics: the Official Journal of the Association for Ocular Pharmacology and Therapeutics 29(3): 290-297

Pinkerton, J.V.; Kagan, R.; Portman, D.; Sathyanarayana, R.; Sweeney, M. 2014: Phase 3 randomized controlled study of gastroretentive gabapentin for the treatment of moderate-to-severe hot flashes in menopause. Menopause 21(6): 567-573

Bilton, D.; Daviskas, E.; Anderson, S.D.; Kolbe, J.; King, G.; Stirling, R.G.; Thompson, B.R.; Milne, D.; Charlton, B. 2013: Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis. Chest 144(1): 215-225

Lefebvre, J.L.; Rolland, F.; Tesselaar, M.; Bardet, E.; Leemans, C.R.; Geoffrois, L.; Hupperets, P.; Barzan, L.; de Raucourt, D.; Chevalier, D.; Licitra, L.; Lunghi, F.; Stupp, R.; Lacombe, D.; Bogaerts, J.; Horiot, J.C.; Bernier, J.; Vermorken, J.B.; de Montreuil, B.; Bensadoun, R.J.; Buter, J.; Coche-Dequeant, B.; Degardin, M.; Dehesdin, D.; Duvillard, C.; Kutem, A.; Langendiijk, J.A.; Rame, J.P.; Truc, G.; van den Weynaert, D. 2009: Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. Journal of the National Cancer Institute 101(3): 142-152

Giles, F.; Vey, N.; DeAngelo, D.; Seiter, K.; Stock, W.; Stuart, R.; Boskovic, D.; Pigneux, A.; Tallman, M.; Brandwein, J.; Kell, J.; Robak, T.; Staib, P.; Thomas, X.; Cahill, A.; Albitar, M.; O'Brien, S. 2009: Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse. Blood 114(19): 4027-4033

Rivera, E.; Mejia, J.A.; Arun, B.K.; Adinin, R.B.; Walters, R.S.; Brewster, A.; Broglio, K.R.; Yin, G.; Esmaeli, B.; Hortobagyi, G.N.; Valero, V. 2008: Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer 112(7): 1455-1461

Lauf, L.; Ozsvár, Z.óf.; Mitha, I.; Regöly-Mérei, J.; Embil, J.M.; Cooper, A.; Sabol, M.B.; Castaing, N.; Dartois, N.; Yan, J.; Dukart, G.; Maroko, R. 2014: Phase 3 study comparing tigecycline and ertapenem in patients with diabetic foot infections with and without osteomyelitis. Diagnostic Microbiology and Infectious Disease 78(4): 469-480

Kantarjian, H.; Cortes, J.; Kim, D.-W.; Dorlhiac-Llacer, P.; Pasquini, R.; DiPersio, J.; Müller, M.C.; Radich, J.P.; Khoury, H.J.; Khoroshko, N.; Bradley-Garelik, M.B.; Zhu, C.; Tallman, M.S. 2009: Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood 113(25): 6322-6329

Bedikian, A.Y.; DeConti, R.C.; Conry, R.; Agarwala, S.; Papadopoulos, N.; Kim, K.B.; Ernstoff, M. 2011: Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma. Annals of Oncology: Official Journal of the European Society for Medical Oncology 22(4): 787-793

Powell, J.S.; Pasi, K.John.; Ragni, M.V.; Ozelo, M.C.; Valentino, L.A.; Mahlangu, J.N.; Josephson, N.C.; Perry, D.; Manco-Johnson, M.J.; Apte, S.; Baker, R.I.; Chan, G.C.; Novitzky, N.; Wong, R.S.; Krassova, S.; Allen, G.; Jiang, H.; Innes, A.; Li, S.; Cristiano, L.M.; Goyal, J.; Sommer, J.M.; Dumont, J.A.; Nugent, K.; Vigliani, G.; Brennan, A.; Luk, A.; Pierce, G.F. 2013: Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. New England Journal of Medicine 369(24): 2313-2323

Mahlangu, J.; Powell, J.S.; Ragni, M.V.; Chowdary, P.; Josephson, N.C.; Pabinger, I.; Hanabusa, H.; Gupta, N.; Kulkarni, R.; Fogarty, P.; Perry, D.; Shapiro, A.; Pasi, K.J.; Apte, S.; Nestorov, I.; Jiang, H.; Li, S.; Neelakantan, S.; Cristiano, L.M.; Goyal, J.; Sommer, J.M.; Dumont, J.A.; Dodd, N.; Nugent, K.; Vigliani, G.; Luk, A.; Brennan, A.; Pierce, G.F.; McRae, S.J.; Pabinger, I.; Hermans, C.; Ozelo, M.C.; Blanchette, V.; Poon, M.-C.; Negrier, C.; Oldenburg, J.; Klamroth, R.; Wong, R.S.; Chan, G.C.-F.; Srivastava, A.; Apte, S.J.; Ross, C.R.; John, J.M.; Gupta, N.; Luboshitz, J.; Santagostino, E.; Morfini, M.; Castaman, G.; Fukutake, K.; Hanabusa, H.; Taki, M.; Sakai, M.; Matsushita, T.; Nogami, K.; Harper, P.; Ockelford, P.; Smith, M.; 2014: Phase 3 study of recombinant factor VIIi Fc fusion protein in severe hemophilia a. Blood 123(3): 317-325

Anonymous 2010: Phase 3 study results released for telaprevir and HCV. AIDS patient care and STDs 24(10): 685-686

Hopkins, R.J.; Howard, C.; Hunter-Stitt, E.; Kaptur, P.E.; Pleune, B.; Muse, D.; Sheldon, E.; Davis, M.; Strout, C.; Vert-Wong, K. 2014: Phase 3 trial evaluating the immunogenicity and safety of a three-dose BioThrax® regimen for post-exposure prophylaxis in healthy adults. Vaccine 32(19): 2217-2224

Gadzinowski, J.; Albrecht, P.; Hasiec, B.; Konior, R.; Dziduch, J.; Witor, A.; Mellelieu, T.; Tansey, S.P.; Jones, T.; Sarkozy, D.; Emini, E.A.; Gruber, W.C.; Scott, D.A. 2011: Phase 3 trial evaluating the immunogenicity, safety, and tolerability of manufacturing scale 13-valent pneumococcal conjugate vaccine. Vaccine 29(16): 2947-2955

Macann, A.; Fua, T.; Milross, C.G.; Porceddu, S.V.; Penniment, M.; Wratten, C.; Krawitz, H.; Poulsen, M.; Tang, C.I.; Morton, R.P.; Hay, K.David.; Thomson, V.; Bell, M.L.; King, M.T.; Fraser-Browne, C.L.; Hockey, H-Ulrich.P. 2014: Phase 3 trial of domiciliary humidification to mitigate acute mucosal toxicity during radiation therapy for head-and-neck cancer: first report of Trans Tasman Radiation Oncology Group (TROG) 07.03 RadioHUM study. International Journal of Radiation Oncology Biology Physics 88(3): 572-579

Motzer, R.J.; Escudier, B.; Oudard, S.; Hutson, T.E.; Porta, C.; Bracarda, S.; Grünwald, V.; Thompson, J.A.; Figlin, R.A.; Hollaender, N.; Kay, A.; Ravaud, A.; Davis, I.; Gurney, H.; Pittman, K.; Goldstein, D.; Mainwaring, P.; Knox, J.; Ades, S.; Cheng, T.; Hotte, S.; Ko, Y.-J.; MacKenzie, M.; North, S.; Escudier, B.; Oudard, S.; Ravaud, A.; Caty, A.; Rolland, F.; Chevreau, C.; Duclos, B.; Negrier, S.; Grunwald, V.; Gschwend, J.; Albers, P.; Bergmann, L.; Beck, J.; Porta, C.; Bracarda, S.; Conte, P.; Bajetta, E.; Passalacqua, R.; Sternberg, C.; Boccardo, F.; Carteni, G.; Akaza, H.; Uemura, H.; Shinohara, N.; Tsuchiya, N.; Fujimoto, H.; Niwakawa, M.; Kanayama, H.; Eto, M.; Sumiyoshi, Y.; Tsukamoto, T.; Usami, M.; Terai, A.; Hamamoto, Y.; Ma 2010: Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer 116(18): 4256-4265

Kim, T.Hyun.; Park, S.Ryun.; Ryu, K.Won.; Kim, Y-Woo.; Bae, J-Moon.; Lee, J.Ho.; Choi, I.Ju.; Kim, Y-Joo.; Kim, D.Yong. 2012: Phase 3 trial of postoperative chemotherapy alone versus chemoradiation therapy in stage III-IV gastric cancer treated with R0 gastrectomy and D2 lymph node dissection. International Journal of Radiation Oncology Biology Physics 84(5): E585-E592

Targett, G. 2015: Phase 3 trial with the RTS,S/AS01 malaria vaccine shows protection against clinical and severe malaria in infants and children in Africa. Evidence-Based Medicine 20(1): 9

Salloway, S.; Sperling, R.; Brashear, H.Robert. 2014: Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease. New England Journal of Medicine 370(15): 1460

Doody, R.S.; Thomas, R.G.; Farlow, M.; Iwatsubo, T.; Vellas, B.; Joffe, S.; Kieburtz, K.; Raman, R.; Sun, X.; Aisen, P.S.; Siemers, E.; Liu-Seifert, H.; Mohs, R. 2014: Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. New England Journal of Medicine 370(4): 311-321

Hampton, T. 2008: Phase 3 trials suggest ways to improve current hematologic cancer therapies. JAMA 299(5): 510-512

Nelson, J.B.; Love, W.; Chin, J.L.; Saad, F.; Schulman, C.C.; Sleep, D.J.; Qian, J.; Steinberg, J.; Carducci, M. 2008: Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 113(9): 2478-2487

Doria, C.; Fischer, C.P.; Wood, C.G.; Li, P.M.; Marra, S.; Hart, J. 2008: Phase 3, randomized, double-blind study of plasma-derived human thrombin versus bovine thrombin in achieving hemostasis in patients undergoing surgery. Current Medical Research and Opinion 24(3): 785-794

Nelson, J.B.; Fizazi, K.; Miller, K.; Higano, C.; Moul, J.W.; Akaza, H.; Morris, T.; McIntosh, S.; Pemberton, K.; Gleave, M. 2012: Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. Cancer 118(22): 5709-5718

Riedmann, E.M. 2013: Phase 3: RTS,S almost halves malaria cases in young children. Human Vaccines and Immunotherapeutics 9(12): 2501

Sauer, W.H.; Lowery, C.M.; Callans, D.J.; Lewkowiez, L. 2007: Phase 4 conduction block of a right midseptal accessory pathway. Heart Rhythm 4(5): 686-687

Ibarrola, M.ín.; Chiale, P.A.; Pérez-Riera, A.és.R.; Baranchuk, A. 2014: Phase 4 left septal fascicular block. Heart Rhythm 11(9): 1655-1657

Sinha, P.K.; Jha, T.K.; Thakur, C.P.; Nath, D.; Mukherjee, S.; Aditya, A.K.; Sundar, S. 2011: Phase 4 pharmacovigilance trial of paromomycin injection for the treatment of visceral leishmaniasis in India. Journal of Tropical Medicine 2011: 645203

Ansaldi, F.; Valle, L.; de Florentiis, D.; Parodi, V.; Murdaca, G.; Bruzzone, B.; Durando, P.; Setti, M.; Icardi, G. 2012: Phase 4 randomized trial of intradermal low-antigen-content inactivated influenza vaccine versus standard-dose intramuscular vaccine in HIV-1-infected adults. Human Vaccines and Immunotherapeutics 8(8): 1048-1052

Brower, A. 2007: Phase 4 research grows despite lack of FDA oversight. Biotechnology Healthcare 4(5): 16-22

Crowther, M. 2013: Phase 4 research: what happens when the rubber meets the road?. HEMATOLOGY. American Society of Hematology. Education Program 2013: 15-18

Eichenfield, L.F.; Nighland, M.; Rossi, A.B.; Cook-Bolden, F.; Grimes, P.; Fried, R.; Levy, S.; Barba, A.; Battle, E.; Baumann, L.; Brodell, R.; Bucko, A.; Burkhart, C.; Callender, V.; Cook-Bolden, F.; Dawes, K.; Del Rosso, J.; Dosik, J.; Downie, J.; Eichenfield, L.; English, P.; Forsha, D.; Fowler, J.; Fried, R.; Funicella, T.; Gold, L.; Gold, M.; Grimes, P.; Gross, A.; Kaplan, D.; Kircik, L.; Leyden, J.; Loven, K.; Lucky, A.; Paller, A.; Rafal, E.; Rodriquez, D.; Sadick, N.; Schlessinger, J.; Schiavone, F.; Shavin, J.; Spencer, J.; Spiers, E.; Taylor, S.; Werschler, W.; Wilson, D. 2008: Phase 4 study to assess tretinoin pump for the treatment of facial acne. Journal of Drugs in Dermatology: Jdd 7(12): 1129-1136

Rodriguez, P.A.; Calhoun, V.D.; Adalı, Tülay. 2012: Phase Ambiguity Correction and Visualization Techniques for Complex-Valued ICA of Group fMRI Data. Pattern Recognition 45(6): 2050-2063

Kumar, S.; Dutt, A.; Hemraj, S.; Bhat, S.; Manipadybhima, B. 2012: Phase Angle Measurement in Healthy Human Subjects through Bio-Impedance Analysis. Iranian Journal of Basic Medical Sciences 15(6): 1180-1184

Fu, J.; Rice, J.W.; Suuberg, E.M. 2010: Phase Behavior and Vapor Pressures of the Pyrene + 9,10-Dibromoanthracene System. Fluid Phase Equilibria 298(2): 219-224

Liu, J.; Conboy, J.C. 2009: Phase Behavior of Planar Supported Lipid Membranes Composed of Cholesterol and 1,2-Distearoyl-sn-Glycerol-3-Phosphocholine Examined by Sum-Frequency Vibrational Spectroscopy. Vibrational Spectroscopy 50(1): 106-115

Ahn, H.; Naidu, S.; Ryu, D.Y.; Cho, J. 2009: Phase Behavior of a Weakly Interacting Polystyrene and Poly(n-hexyl methacrylate) System: Evidence for the Coexistence of UCST and LCST. Macromolecular Rapid Communications 30(6): 469-474

Sclar, C.B.; Carrison, L.C. 1963: Phase Composition of Commercial "Ammonium Carbonate". Science 140(3572): 1205-1207

Nocetti, L.; Mantovani, A.; Vallone, S.; Costi, T.; Carpeggiani, P.; Pinna, G. 2011: Phase Contrast MR as Non-Invasive Tool in the Diagnosis of Benign Intracranial Hypertension. Neuroradiology Journal 24(2): 271-272

Xie, Q.; Xiao, L.; Cheng, L.; Liu, J.; Li, H.; Deng, F. 2013: Phase Correction-Adaptive Line Enhancement for Noise Reduction of Low-Field NMR. Applied Magnetic Resonance 44: 1381-1391

Pyne, S.; Gutman, R.; Kim, C.S.; Futcher, B. 2009: Phase Coupled Meta-analysis: sensitive detection of oscillations in cell cycle gene expression, as applied to fission yeast. Bmc Genomics 10: 440

Wang, Q.; Zhao, X. 2014: Phase Diagrams of Instabilities in Compressed Film-Substrate Systems. Journal of Applied Mechanics 81(5): 0510041-5100410

Sassaroli, A.; Zheng, F.; Pierro, M.; Bergethon, P.R.; Fantini, S. 2011: Phase Difference between Low-Frequency Oscillations of Cerebral Deoxy- and Oxy-Hemoglobin Concentrations during a Mental Task. Journal of Innovative Optical Health Sciences 4(2): 151-158

Lutomirski, R.F.; Buser, R.G. 1974: Phase Difference and Angle-of-Arrival Fluctuations in Tracking a Moving Point Source. Applied Optics 13(12): 2869-2873

Chen, Y.; Wen, C.; Zhou, X.; Zeng, J. 2014: Phase Equilibria of Ternary and Quaternary Systems Containing Diethyl Carbonate with Water. Journal of Solution Chemistry 43(8): 1374-1387

Ioniţă, S.; Feroiu, V.; Geană, D. 2013: Phase Equilibria of the Carbon Dioxide + 1-Decanol System at High Pressures. Journal of Chemical and Engineering Data 58(11): 3069-3077

Vallés, J.é J.; Garcia-Martinez, P.; García, J.; Ferreira, C. 2007: Phase Fourier vector model for scale invariant three-dimensional image detection. Optics Express 15(12): 7818-7825

Siiman, L.A.; Lumeau, J.; Glebov, L.B. 2009: Phase Fresnel lens recorded in photo-thermo-refractive glass by selective exposure to infrared ultrashort laser pulses. Optics Letters 34(1): 40-42

Focan, C.; Kreutz, F.; Graas, M-P.; Longrée, L.; Focan-Henrard, D.; Demolin, G.; Moeneclaey, N. 2013: Phase I - II study to assess the feasibility and activity of the triple combination of 5-fluorouracil/folinic acid, carboplatin and irinotecan (CPT-11) administered by chronomodulated infusion for the treatment of advanced colorectal cancer. Final report of the BE-1603 study. Pathologie-Biologie 61(2): E27-E31

Sato, A.; Doi, T.; Boku, N.; Kato, K.; Komatsu, Y.; Yamaguchi, K.; Muro, K.; Hamamoto, Y.; Koizumi, W.; Mizunuma, N.; Takiuchi, H. 2011: Phase i / Ii study of XELOX plus bevacizumab in Japanese patients with metastatic colorectal cancer(JO19380). Gan to Kagaku Ryoho. Cancer and ChemoTherapy 38(4): 561-569

Kresge, K.J. 2006: Phase i AIDS vaccine trial in infants begins in Uganda. Iavi Report: Newsletter on International Aids Vaccine Research 10(5): 16

Ohno, S.; Sumiyoshi, Y.; Hashine, K.; Shirato, A.; Kyo, S.; Inoue, M. 2011: Phase I Clinical Study of the Dietary Supplement, Agaricus blazei Murill, in Cancer Patients in Remission. Evidence-BasedComplementaryandAlternativeMedicine:Ecam 2011: 192381

Kawada, H.; Sawanobori, M.; Tsuma-Kaneko, M.; Wasada, I.; Miyamoto, M.; Murayama, H.; Toyosaki, M.; Onizuka, M.; Tsuboi, K.; Tazume, K.; Shirasugi, Y.; Ohmachi, K.; Ogawa, Y.; Kobayashi, H.; Ando, K. 2014: Phase i Clinical Trial of Intravenous L-ascorbic Acid Following Salvage Chemotherapy for Relapsed B-cell non-Hodgkin's Lymphoma. Tokai Journal of Experimental and Clinical Medicine 39(3): 111-115

Gaddipati, H.; Fu, P.; Dowlati, A. 2011: Phase i Clinical Trials in Patients ≥80. Journal of Geriatric Oncology 2(2): 142-146

Naing, A.; Reuben, J.M.; Camacho, L.H.; Gao, H.; Lee, B.-N.; Cohen, E.N.; Verschraegen, C.; Stephen, S.; Aaron, J.; Hong, D.; Wheler, J.; Kurzrock, R. 2011: Phase i Dose Escalation Study of Sodium Stibogluconate (SSG), a Protein Tyrosine Phosphatase Inhibitor, Combined with Interferon Alpha for Patients with Solid Tumors. Journal of Cancer 2: 81-89

Chou, H-Hsueh.; Huang, H-Jean.; Lin, H.; Yang, L-Yan.; Hsueh, S.; Liu, F-Yuan.; Liou, Y-Lyin.; Liou, J-Der.; Chen, M-Yu.; Chao, A.; Lin, G.; Chang, T-Chang.; Lai, C-Huey. 2017: Phase I Dose-Escalation Study of Weekly Paclitaxel and Cisplatin Followed by Radical Hysterectomy in Stages IB2 and IIA2 Cervical Cancer. American Journal of Clinical Oncology 40(3): 241-249

Kajiura, S.; Hosokawa, A.; Yoshita, H.; Ueda, Y.; Ueda, A.; Mihara, H.; Ando, T.; Fujinami, H.; Nishikawa, J.; Ogawa, K.; Minemura, M.; Sugiyama, T. 2016: Phase i Study of Docetaxel Plus Nedaplatin in Patients with Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment. American Journal of Clinical Oncology 39(1): 13-17

Ganesan, C.; Obulareddy, S.J.; Fischer, J.H.; Antonysamy, M.A.; Jha, G.; Bliss, R.L.; Dudek, A.Z. 2016: Phase i Study of Pazopanib and Ixabepilone in Patients with Solid Tumors. American Journal of Clinical Oncology 39(3): 280-287

Perkins, J.B.; Goldstein, S.C.; Dawson, J.L.; Kim, J.; Field, T.L.; Partyka, J.S.; Fields, K.K.; Maddox, B.L.; Simonelli, C.E.; Neuger, A.M.; Lush, R.M.; Sullivan, D.M. 2011: Phase i Study of Topotecan, Ifosfamide, and Etoposide (TIME) with autologous stem cell transplant in refractory cancer: pharmacokinetic and pharmacodynamic correlates. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 17(24): 7743-7753

Ring, A.; Wheatley, D.; Hatcher, H.; Laing, R.; Plummer, R.; Uttenreuther-Fischer, M.; Temple, G.; Pelling, K.; Schnell, D. 2015: Phase i Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 21(12): 2737-2744

Esaki, T.; Seto, T.; Ariyama, H.; Arita, S.; Fujimoto, C.; Tsukasa, K.; Kometani, T.; Nosaki, K.; Hirai, F.; Yagawa, K. 2011: Phase i Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 in Japanese Patients with Solid Tumors. Archives of Drug Information 4(2): 23-31

Rheingold, S.R.; Hogarty, M.D.; Blaney, S.M.; Zwiebel, J.A.; Sauk-Schubert, C.; Chandula, R.; Krailo, M.D.; Adamson, P.C. 2007: Phase i Trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology Group Study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 25(12): 1512-1518

Kaumaya, P.T.P.; Foy, K.C.; Garrett, J.; Rawale, S.V.; Vicari, D.; Thurmond, J.M.; Lamb, T.; Mani, A.; Kane, Y.; Balint, C.R.; Chalupa, D.; Otterson, G.A.; Shapiro, C.L.; Fowler, J.M.; Grever, M.R.; Bekaii-Saab, T.S.; Carson, W.E. 2009: Phase i active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 27(31): 5270-5277

Clark, J.I.; Eisner, R.M.; Hofmeister, C.; Norton, J.; Thomas, S.; Choudhury, A.; Petruzzelli, G.; Lathers, D.; Young, M.R.I.; Lau, A.; Emami, B. 2009: Phase i adjuvant radiation with docetaxel in high-risk head and neck cancer. American Journal of Clinical Oncology 32(4): 396-400

Jia, N.; Liou, I.; Halldorson, J.; Carithers, R.; Perkins, J.; Reyes, J.; Yeh, M.; Stohr, E.; Rao, S.; Lin, E.H. 2013: Phase i adjuvant trial of sorafenib in patients with hepatocellular carcinoma after orthotopic liver transplantation. Anticancer Research 33(6): 2797-2800

Olson, J.J.; McKenzie, E.; Skurski-Martin, M.; Zhang, Z.; Brat, D.; Phuphanich, S. 2008: Phase i analysis of BCNU-impregnated biodegradable polymer wafers followed by systemic interferon alfa-2b in adults with recurrent glioblastoma multiforme. Journal of Neuro-Oncology 90(3): 293-299

Abdayem, P.; Ghosn, M.; Valero, V.; Walters, R.; Arun, B.; Murray, J.L.; Theriault, R.; Frye, D.; Ibrahim, N.K. 2014: Phase I and II Study of Gemcitabine and Vinorelbine in Heavily Pretreated Patients with Metastatic Breast Cancer and Review of the Literature. Journal of Cancer 5(5): 351-359

Trisciani, A.; Perra, G.; Caruso, T.; Focardi, S.; Corsi, I. 2012: Phase i and Ii biotransformation enzymes and polycyclic aromatic hydrocarbons in the Mediterranean mussel (Mytilus galloprovincialis, Lamarck, 1819) collected in front of an oil refinery. Marine Environmental Research 79: 29-36

Desrosiers, N.A.; Himes, S.K.; Scheidweiler, K.B.; Concheiro-Guisan, M.; Gorelick, D.A.; Huestis, M.A. 2014: Phase i and Ii cannabinoid disposition in blood and plasma of occasional and frequent smokers following controlled smoked cannabis. Clinical Chemistry 60(4): 631-643

Khushalani, N.I. 2012: Phase i and Ii clinical trials for gastric cancer. Surgical Oncology Clinics of North America 21(1): 113-128

Bull, L.M.; White, D.L.; Bray, M.; Nurgalieva, Z.; El-Serag, H.B. 2009: Phase i and Ii enzyme polymorphisms as risk factors for Barrett's esophagus and esophageal adenocarcinoma: a systematic review and meta-analysis. Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus 22(7): 571-587

Fahrmayr, C.; König, J.; Auge, D.; Mieth, M.; Münch, K.; Segrestaa, J.; Pfeifer, T.; Treiber, A.; Fromm, M. 2013: Phase i and Ii metabolism and MRP2-mediated export of bosentan in a MDCKII-OATP1B1-CYP3A4-UGT1A1-MRP2 quadruple-transfected cell line. British Journal of Pharmacology 169(1): 21-33

Philipp, A.A.; Wissenbach, D.K.; Weber, A.A.; Zapp, J.; Maurer, H.H. 2010: Phase i and Ii metabolites of speciogynine, a diastereomer of the main Kratom alkaloid mitragynine, identified in rat and human urine by liquid chromatography coupled to low- and high-resolution linear ion trap mass spectrometry. Journal of Mass Spectrometry: Jms 45(11): 1344-1357

Uchida, T.; Ogawa, Y.; Kobayashi, Y.; Ishikawa, T.; Ohashi, H.; Hata, T.; Usui, N.; Taniwaki, M.; Ohnishi, K.; Akiyama, H.; Ozawa, K.; Ohyashiki, K.; Okamoto, S.; Tomita, A.; Nakao, S.; Tobinai, K.; Ogura, M.; Ando, K.; Hotta, T. 2011: Phase i and Ii study of azacitidine in Japanese patients with myelodysplastic syndromes. Cancer Science 102(9): 1680-1686

Smith, P.F.; Ogundele, A.; Forrest, A.; Wilton, J.; Salzwedel, K.; Doto, J.; Allaway, G.P.; Martin, D.E. 2007: Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrobial Agents and ChemoTherapy 51(10): 3574-3581

Takatani, H.; Nakamura, Y.; Nagashima, S.; Soda, H.; Kinoshita, A.; Fukuda, M.; Fukuda, M.; Soejima, Y.; Kasai, T.; Nakatomi, K.; Iida, T.; Oka, M.; Tsukamoto, K.; Kohno, S. 2012: Phase I and II trials of vinorelbine with carboplatin for patients 75 years of age or older with previously untreated non-small-cell lung cancer. Clinical lung cancer 13(5): 347-351

Stickney, D.R.; Ahlem, C.N.; Morgan, E.; Reading, C.L.; Onizuka, N.; Frincke, J.M. 2011: Phase i and Phase Ii clinical trials of androst-5-ene-3β,7β,17β-triol. American Journal of Translational Research 3(3): 275-283

Srinivas, N.R.; Mullangi, R. 2013: Phase i and beyond - the importance of switching to patient's plasma: considerations and perspectives on bioanalytical procedures. Bioanalysis 5(18): 2215-2218

Wong, C.-I.; Koh, T.-S.; Soo, R.; Hartono, S.; Thng, C.-H.; McKeegan, E.; Yong, W.-P.; Chen, C.-S.; Lee, S.-C.; Wong, J.; Lim, R.; Sukri, N.; Lim, S.-E.; Ong, A.-B.; Steinberg, J.; Gupta, N.; Pradhan, R.; Humerickhouse, R.; Goh, B.-C. 2009: Phase i and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 27(28): 4718-4726

Navid, F.; Baker, S.D.; McCarville, M.B.; Stewart, C.F.; Billups, C.A.; Wu, J.; Davidoff, A.M.; Spunt, S.L.; Furman, W.L.; McGregor, L.M.; Hu, S.; Panetta, J.C.; Turner, D.; Fofana, D.; Reddick, W.E.; Leung, W.; Santana, V.M. 2013: Phase i and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 19(1): 236-246

Nabors, L.B.; Mikkelsen, T.; Rosenfeld, S.S.; Hochberg, F.; Akella, N.S.; Fisher, J.D.; Cloud, G.A.; Zhang, Y.; Carson, K.; Wittemer, S.M.; Colevas, A.D.; Grossman, S.A. 2007: Phase i and correlative biology study of cilengitide in patients with recurrent malignant glioma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 25(13): 1651-1657

Faderl, S.; Balakrishnan, K.; Thomas, D.A.; Ravandi, F.; Borthakur, G.; Burger, J.; Ferrajoli, A.; Cortes, J.; O'Brien, S.; Kadia, T.; Feliu, J.; Plunkett, W.; Gandhi, V.; Kantarjian, H.M. 2014: Phase i and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia. Clinical Lymphoma Myeloma and Leukemia 14(3): 231-238

Ramanathan, R.K.; Egorin, M.J.; Eiseman, J.L.; Ramalingam, S.; Friedland, D.; Agarwala, S.S.; Ivy, S.P.; Potter, D.M.; Chatta, G.; Zuhowski, E.G.; Stoller, R.G.; Naret, C.; Guo, J.; Belani, C.P. 2007: Phase i and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 13(6): 1769-1774

Yong, W.P.; Goh, B.C.; Soo, R.A.; Toh, H.C.; Ethirajulu, K.; Wood, J.; Novotny-Diermayr, V.; Lee, S.C.; Yeo, W.L.; Chan, D.; Lim, D.; Seah, E.; Lim, R.; Zhu, J. 2011: Phase i and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies. Annals of Oncology: Official Journal of the European Society for Medical Oncology 22(11): 2516-2522

Yoo, C.; Ryu, M.-H.; Na, Y.-S.; Ryoo, B.-Y.; Lee, C.-W.; Maeng, J.; Kim, S.-Y.; Koo, D.H.; Park, I.; Kang, Y.-K. 2014: Phase i and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer. Investigational new Drugs 32(2): 271-278

Appleton, K.; Mackay, H.J.; Judson, I.; Plumb, J.A.; McCormick, C.; Strathdee, G.; Lee, C.; Barrett, S.; Reade, S.; Jadayel, D.; Tang, A.; Bellenger, K.; Mackay, L.; Setanoians, A.; Schätzlein, A.; Twelves, C.; Kaye, S.B.; Brown, R. 2007: Phase i and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 25(29): 4603-4609

Libutti, S.K.; Paciotti, G.F.; Byrnes, A.A.; Alexander, H.R.; Gannon, W.E.; Walker, M.; Seidel, G.D.; Yuldasheva, N.; Tamarkin, L. 2010: Phase i and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 16(24): 6139-6149

Broniscer, A.; Baker, S.J.; Stewart, C.F.; Merchant, T.E.; Laningham, F.H.; Schaiquevich, P.; Kocak, M.; Morris, E.B.; Endersby, R.; Ellison, D.W.; Gajjar, A. 2009: Phase i and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 15(2): 701-707

Hammond-Thelin, L.A.; Thomas, M.B.; Iwasaki, M.; Abbruzzese, J.L.; Lassere, Y.; Meyers, C.A.; Hoff, P.; de Bono, J.; Norris, J.; Matsushita, H.; Mita, A.; Rowinsky, E.K. 2012: Phase i and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, Ii and III,in patients with advanced solid malignancies. Investigational new Drugs 30(1): 316-326

Edelman, M.J.; Bauer, K.S.; Wu, S.; Smith, R.; Bisacia, S.; Dancey, J. 2007: Phase i and pharmacokinetic study of 7-hydroxystaurosporine and carboplatin in advanced solid tumors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 13(9): 2667-2674

Yamada, K.; Yamamoto, N.; Yamada, Y.; Mukohara, T.; Minami, H.; Tamura, T. 2010: Phase i and pharmacokinetic study of ABI-007, albumin-bound paclitaxel, administered every 3 weeks in Japanese patients with solid tumors. Japanese Journal of Clinical Oncology 40(5): 404-411

Mita, A.C.; Olszanski, A.J.; Walovitch, R.C.; Perez, R.P.; MacKay, K.; Tuck, D.P.; Simmons, C.; Hammond, S.; Mita, M.M.; Beeram, M.; Stone, A.J.; Rowinsky, E.K.; Lewis, L.D. 2007: Phase I and pharmacokinetic study of AI-850, a novel microparticle hydrophobic drug delivery system for paclitaxel. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 13(11): 3293-3301

Tolcher, A.W.; Sweeney, C.J.; Papadopoulos, K.; Patnaik, A.; Chiorean, E.G.; Mita, A.C.; Sankhala, K.; Furfine, E.; Gokemeijer, J.; Iacono, L.; Eaton, C.; Silver, B.A.; Mita, M. 2011: Phase i and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 17(2): 363-371

Yamamoto, N.; Yamada, Y.; Fujiwara, Y.; Yamada, K.; Fujisaka, Y.; Shimizu, T.; Tamura, T. 2009: Phase i and pharmacokinetic study of HER2-targeted rhu MAb 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumors. Japanese Journal of Clinical Oncology 39(4): 260-266

Infante, J.R.; Keedy, V.L.; Jones, S.F.; Zamboni, W.C.; Chan, E.; Bendell, J.C.; Lee, W.; Wu, H.; Ikeda, S.; Kodaira, H.; Rothenberg, M.L.; Burris, H.A. 2012: Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors. Cancer ChemoTherapy and Pharmacology 70(5): 699-705

Tournoux-Facon, C.; Robinet, G.; Pinel, M.-C.; Ferre, P.; Tourani, J.-M. 2012: Phase i and pharmacokinetic study of IV vinflunine in combination with carboplatin in chemonaive patients with advanced non-small cell lung cancer. American Journal of Clinical Oncology 35(4): 378-385

Tournoux-Facon, C.; Senellart, H.él.èn.; Lemarie, E.; Tourani, J.M.; Favrel, S.ép.; Pouget, J.C.; Pinel, M.C.; Bennouna, J. 2011: Phase i and pharmacokinetic study of IV vinflunine in combination with gemcitabine for treatment of advanced non-small cell lung cancer in Chemonaive patients. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 6(7): 1247-1253

Ueda, Y.; Shimoyama, T.; Murakami, H.; Yamamoto, N.; Yamada, Y.; Arioka, H.; Tamura, T. 2011: Phase i and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors. Cancer ChemoTherapy and Pharmacology 67(5): 1101-1109

Mita, A.C.; Denis, L.J.; Rowinsky, E.K.; Debono, J.S.; Goetz, A.D.; Ochoa, L.; Forouzesh, B.; Beeram, M.; Patnaik, A.; Molpus, K.; Semiond, Dée.; Besenval, Mèle.; Tolcher, A.W. 2009: Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 15(2): 723-730

Tolcher, A.W.; Mita, A.; Lewis, L.D.; Garrett, C.R.; Till, E.; Daud, A.I.; Patnaik, A.; Papadopoulos, K.; Takimoto, C.; Bartels, P.; Keating, A.; Antonia, S. 2008: Phase i and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 26(32): 5198-5203

Petty, W.J.; Miller, A.A.; McCoy, T.P.; Gallagher, P.E.; Tallant, E.A.; Torti, F.M. 2009: Phase i and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 15(23): 7398-7404

Ogura, M.; Uchida, T.; Taniwaki, M.; Ando, K.; Watanabe, T.; Kasai, M.; Matsumoto, Y.; Shimizu, D.; Ogawa, Y.; Ohmachi, K.; Yokoyama, H.; Tobinai, K. 2010: Phase i and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Science 101(9): 2054-2058

Padda, S.K.; Chhatwani, L.; Zhou, L.; Jacobs, C.D.; Lopez-Anaya, A.; Wakelee, H.A. 2013: Phase I and pharmacokinetic study of bexarotene in combination with gefitinib in the third-line treatment of non-small-cell lung cancer: brief report. Anti-Cancer Drugs 24(7): 731-735

Attar, E.C.; De Angelo, D.J.; Supko, J.G.; D'Amato, F.; Zahrieh, D.; Sirulnik, A.; Wadleigh, M.; Ballen, K.K.; McAfee, S.; Miller, K.B.; Levine, J.; Galinsky, I.; Trehu, E.G.; Schenkein, D.; Neuberg, D.; Stone, R.M.; Amrein, P.C. 2008: Phase i and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 14(5): 1446-1454

Trippett, T.M.; Herzog, C.; Whitlock, J.A.; Wolff, J.; Kuttesch, J.; Bagatell, R.; Hunger, S.P.; Boklan, J.; Smith, A.A.; Arceci, R.J.; Katzenstein, H.M.; Harbison, C.; Zhou, X.; Lu, H.; Langer, C.; Weber, M.; Gore, L. 2009: Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators' consortium. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 27(30): 5102-5108

Lin, C.-C.; Beeram, M.; Rowinsky, E.K.; Takimoto, C.H.; Ng, C.M.; Geyer, C.E.; Denis, L.J.; De Bono, J.S.; Hao, D.; Tolcher, A.W.; Rha, S.-Y.; Jolivet, J.; Patnaik, A. 2009: Phase i and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies. Cancer ChemoTherapy and Pharmacology 65(1): 167-175

Asai, G.; Yamamoto, N.; Kurata, T.; Tamura, K.; Uejima, H.; Nakagawa, K.; Fukuoka, M. 2006: Phase I and pharmacokinetic study of combination chemotherapy using irinotecan and paclitaxel in patients with lung cancer. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 1(3): 226-230

Takahashi, T.; Boku, N.; Murakami, H.; Naito, T.; Tsuya, A.; Nakamura, Y.; Ono, A.; Machida, N.; Yamazaki, K.; Watanabe, J.; Ruiz-Garcia, A.; Imai, K.; Ohki, E.; Yamamoto, N. 2012: Phase i and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors. Investigational new Drugs 30(6): 2352-2363

Laurie, S.A.; Gauthier, I.; Arnold, A.; Shepherd, F.A.; Ellis, P.M.; Chen, E.; Goss, G.; Powers, J.; Walsh, W.; Tu, D.; Robertson, J.; Puchalski, T.A.; Seymour, L. 2008: Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 26(11): 1871-1878

Kraut, E.H.; Rhoades, C.; Zhang, Y.; Cheng, H.; Aimiumu, J.; Chen, P.; Lang, J.; Young, D.C.; Agrawal, A.; Dancey, J.; Chan, K.K.; Grever, M.R. 2011: Phase i and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous cell carcinoma of the head and neck (SSCHN). Cancer ChemoTherapy and Pharmacology 67(3): 579-586

Miller, A.A.; Murry, D.J.; Owzar, K.; Hollis, D.R.; Lewis, L.D.; Kindler, H.L.; Marshall, J.L.; Villalona-Calero, M.A.; Edelman, M.J.; Hohl, R.J.; Lichtman, S.M.; Ratain, M.J. 2007: Phase i and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 25(21): 3055-3060

Delbaldo, C.; Raymond, E.; Vera, K.; Hammershaimb, L.; Kaucic, K.; Lozahic, S.ép.; Marty, M.; Faivre, S. 2008: Phase i and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors. Investigational new Drugs 26(1): 35-43

Nieto, Y.; Aldaz, A.; Rifón, J.é; Pérez-Calvo, J.; Zafra, A.; Zufia, L.; Viúdez, A.; Viteri, S.; Aramendía, J.é M.; Aristu, J.; Centeno, C.; Moreno, M.; Sayar, O.; Hernández, M. 2007: Phase i and pharmacokinetic study of gemcitabine administered at fixed-dose rate, combined with docetaxel/melphalan/carboplatin, with autologous hematopoietic progenitor-cell support, in patients with advanced refractory tumors. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation 13(11): 1324-1337

Zhu, A.X.; Ready, N.; Clark, J.W.; Safran, H.; Amato, A.; Salem, N.; Pace, S.; He, X.; Zvereva, N.; Lynch, T.J.; Ryan, D.P.; Supko, J.G. 2009: Phase i and pharmacokinetic study of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 15(1): 374-381

Ali, Y.; Lin, Y.; Gharibo, M.M.; Gounder, M.K.; Stein, M.N.; Lagattuta, T.F.; Egorin, M.J.; Rubin, E.H.; Poplin, E.A. 2007: Phase i and pharmacokinetic study of imatinib mesylate (Gleevec) and gemcitabine in patients with refractory solid tumors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 13(19): 5876-5882

Ramanathan, R.K.; Egorin, M.J.; Takimoto, C.H.M.; Remick, S.C.; Doroshow, J.H.; LoRusso, P.A.; Mulkerin, D.L.; Grem, J.L.; Hamilton, A.; Murgo, A.J.; Potter, D.M.; Belani, C.P.; Hayes, M.J.; Peng, B.; Ivy, S.Percy. 2008: Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 26(4): 563-569

Gibbons, J.; Egorin, M.J.; Ramanathan, R.K.; Fu, P.; Mulkerin, D.L.; Shibata, S.; Takimoto, C.H.M.; Mani, S.; LoRusso, P.A.; Grem, J.L.; Pavlick, A.; Lenz, H-Josef.; Flick, S.M.; Reynolds, S.; Lagattuta, T.F.; Parise, R.A.; Wang, Y.; Murgo, A.J.; Ivy, S.Percy.; Remick, S.C. 2008: Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 26(4): 570-576

Grossman, S.A.; Carson, K.A.; Phuphanich, S.; Batchelor, T.; Peereboom, D.; Nabors, L.B.; Lesser, G.; Hausheer, F.; Supko, J.G. 2008: Phase i and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas. Neuro-Oncology 10(4): 608-616

LoRusso, P.M.; Jones, S.F.; Koch, K.M.; Arya, N.; Fleming, R.A.; Loftiss, J.; Pandite, L.; Gadgeel, S.; Weber, B.L.; Burris, H.A. 2008: Phase i and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 26(18): 3051-3056

Chu, Q.S.C.; Schwartz, G.; de Bono, J.; Smith, D.A.; Koch, K.M.; Versola, M.J.; Pandite, L.; Arya, N.; Curtright, J.; Fleming, R.A.; Ho, P.T.C.; Rowinsky, E.K. 2007: Phase i and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 25(24): 3753-3758

Wakelee, H.A.; Patnaik, A.; Sikic, B.I.; Mita, M.; Fox, N.L.; Miceli, R.; Ullrich, S.J.; Fisher, G.A.; Tolcher, A.W. 2010: Phase i and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. Annals of Oncology: Official Journal of the European Society for Medical Oncology 21(2): 376-381

Castaneda, C.; Meadows, K.L.; Truax, R.; Morse, M.A.; Kaufmann, S.H.; Petros, W.P.; Zhu, Y.; Statkevich, P.; Cutler, D.L.; Hurwitz, H.I. 2011: Phase i and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors. Cancer ChemoTherapy and Pharmacology 67(2): 455-463

Xu, Y.; Kolesar, J.M.; Schaaf, L.J.; Drengler, R.; Duan, W.; Otterson, G.; Shapiro, C.; Kuhn, J.; Villalona-Calero, M.A. 2009: Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies. Cancer ChemoTherapy and Pharmacology 63(6): 1073-1082

Zamboni, W.C.; Ramalingam, S.; Friedland, D.M.; Edwards, R.P.; Stoller, R.G.; Strychor, S.; Maruca, L.; Zamboni, B.A.; Belani, C.P.; Ramanathan, R.K. 2009: Phase i and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 15(4): 1466-1472

Dickgreber, N.J.; Fink, T.H.; Latz, J.E.; Hossain, A.M.; Musib, L.C.; Thomas, M. 2009: Phase i and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 15(1): 382-389

Takimoto, C.H.; Hammond-Thelin, L.A.; Latz, J.E.; Forero, L.; Beeram, M.; Forouzesh, B.; de Bono, J.; Tolcher, A.W.; Patnaik, A.; Monroe, P.; Wood, L.; Schneck, K.B.; Clark, R.; Rowinsky, E.K. 2007: Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 13(9): 2675-2683

Lv, F.; Cao, J.; Zhang, J.; Qian, J.; Peng, W.; Sun, S.; Li, W.; Zhang, W.; Guo, W.; Li, J. 2014: Phase i and pharmacokinetic study of polymeric micelle‑formulated paclitaxel in adult Chinese patients with advanced solid tumors. Cancer ChemoTherapy and Pharmacology 73(6): 1173-1179

Chu, Q.; Mita, A.; Forouzesh, B.; Tolcher, A.W.; Schwartz, G.; Nieto, A.; Soto-Matos, A.; Alfaro, V.; Lebedinsky, C.; Rowinsky, E.K. 2010: Phase i and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 16(9): 2656-2665

Miller, A.A.; Murry, D.J.; Owzar, K.; Hollis, D.R.; Kennedy, E.B.; Abou-Alfa, G.; Desai, A.; Hwang, J.; Villalona-Calero, M.A.; Dees, E.C.; Lewis, L.D.; Fakih, M.G.; Edelman, M.J.; Millard, F.; Frank, R.C.; Hohl, R.J.; Ratain, M.J. 2009: Phase i and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 27(11): 1800-1805

Dubois, S.G.; Shusterman, S.; Ingle, A.M.; Ahern, C.H.; Reid, J.M.; Wu, B.; Baruchel, S.; Glade-Bender, J.; Ivy, P.; Grier, H.E.; Adamson, P.C.; Blaney, S.M. 2011: Phase i and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 17(15): 5113-5122

Chayahara, N.; Tamura, T.; Yamamori, M.; Kadowaki, Y.; Okuno, T.; Miki, I.; Tsuda, M.; Nishisaki, H.; Maeda, T.; Inoue, Y.; Okumura, K.; Azuma, T.; Kasuga, M.; Sakaeda, T.; Hirai, M. 2009: Phase I and pharmacokinetic study of tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer. American Journal of Clinical Oncology 32(1): 56-60

Unger, C.; Häring, B.; Medinger, M.; Drevs, J.; Steinbild, S.; Kratz, F.; Mross, K. 2007: Phase i and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 13(16): 4858-4866

Kieran, M.W.; Packer, R.J.; Onar, A.; Blaney, S.M.; Phillips, P.; Pollack, I.F.; Geyer, J.R.; Gururangan, S.; Banerjee, A.; Goldman, S.; Turner, C.D.; Belasco, J.B.; Broniscer, A.; Zhu, Y.; Frank, E.; Kirschmeier, P.; Statkevich, P.; Yver, A.; Boyett, J.M.; Kun, L.E. 2007: Phase i and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 25(21): 3137-3143

Forouzesh, B.; Hidalgo, M.; Chu, Q.; Mita, A.; Mita, M.; Schwartz, G.; Jimeno, J.é; Gómez, J.; Alfaro, V.; Lebedinsky, C.; Zintl, P.; Rowinsky, E.K. 2009: Phase i and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 15(10): 3591-3599

Ueda, T.; Kakunaga, S.; Ando, M.; Yonemori, K.; Sugiura, H.; Yamada, K.; Kawai, A. 2014: Phase i and pharmacokinetic study of trabectedin, a DNA minor groove binder, administered as a 24-h continuous infusion in Japanese patients with soft tissue sarcoma. Investigational new Drugs 32(4): 691-699

Yamamoto, H.; Ando, M.; Aogi, K.; Iwata, H.; Tamura, K.; Yonemori, K.; Shimizu, C.; Hara, F.; Takabatake, D.; Hattori, M.; Asakawa, T.; Fujiwara, Y. 2015: Phase i and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer. Japanese Journal of Clinical Oncology 45(1): 12-18

Fujiwara, Y.; Yamamoto, N.; Yamada, Y.; Yamada, K.; Otsuki, T.; Kanazu, S.; Iwasa, T.; Hardwick, J.S.; Tamura, T. 2009: Phase i and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors. Cancer Science 100(9): 1728-1734

Ramalingam, S.S.; Parise, R.A.; Ramanathan, R.K.; Ramananthan, R.K.; Lagattuta, T.F.; Musguire, L.A.; Stoller, R.G.; Potter, D.M.; Argiris, A.E.; Zwiebel, J.A.; Egorin, M.J.; Belani, C.P. 2007: Phase i and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 13(12): 3605-3610

Packer, R.J.; Rood, B.R.; Turner, D.C.; Stewart, C.F.; Fisher, M.; Smith, C.; Young-Pouissant, T.; Goldman, S.; Lulla, R.; Banerjee, A.; Pollack, I.; Kun, L.; Onar-Thomas, A.; Wu, S.; Boyett, J.M.; Fouladi, M. 2015: Phase i and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study. Journal of Neuro-Oncology 121(1): 217-224

Masuda, N.; Negoro, S.; Hausheer, F.; Nakagawa, K.; Matsui, K.; Kudoh, S.; Takeda, K.; Yamamoto, N.; Yoshimura, N.; Ohashi, Y.; Fukuoka, M. 2011: Phase i and pharmacologic study of BNP7787, a novel chemoprotector in patients with advanced non-small cell lung cancer. Cancer ChemoTherapy and Pharmacology 67(3): 533-542

Tong, W.-G.; Chen, R.; Plunkett, W.; Siegel, D.; Sinha, R.; Harvey, R.D.; Badros, A.Z.; Popplewell, L.; Coutre, S.; Fox, J.A.; Mahadocon, K.; Chen, T.; Kegley, P.; Hoch, U.; Wierda, W.G. 2010: Phase i and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 28(18): 3015-3022

Kitagawa, C.; Saka, H.; Kajikawa, S.; Mori, K.; Oki, M.; Suzuki, R. 2012: Phase I and pharmacologic study of weekly amrubicin in patients with refractory or relapsed lung cancer: Central Japan Lung Study Group (CJLSG) 0601 trial. Cancer ChemoTherapy and Pharmacology 69(5): 1379-1385

Masuda, N.; Matsui, K.; Negoro, S.; Takeda, K.; Kudoh, S.; Nakagawa, K.; Mukaiyama, A.; Arase, H.; Yoshida, P.; Ijima, T.; Takada, M.; Fukuoka, M. 2010: Phase i and pharmacologic study of weekly bolus topotecan for advanced non-small-cell lung cancer. Clinical Lung Cancer 11(4): 271-279

Karp, J.E.; Thomas, B.M.; Greer, J.M.; Sorge, C.; Gore, S.D.; Pratz, K.W.; Smith, B.D.; Flatten, K.S.; Peterson, K.; Schneider, P.; Mackey, K.; Freshwater, T.; Levis, M.J.; McDevitt, M.A.; Carraway, H.E.; Gladstone, D.E.; Showel, M.M.; Loechner, S.; Parry, D.A.; Horowitz, J.A.; Isaacs, R.; Kaufmann, S.H. 2012: Phase i and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 18(24): 6723-6731

Kaufmann, S.H.; Karp, J.E.; Litzow, M.R.; Mesa, R.A.; Hogan, W.; Steensma, D.P.; Flatten, K.S.; Loegering, D.A.; Schneider, P.A.; Peterson, K.L.; Maurer, M.J.; Smith, B.D.; Greer, J.; Chen, Y.; Reid, J.M.; Ivy, S.P.; Ames, M.M.; Adjei, A.A.; Erlichman, C.; Karnitz, L.M. 2011: Phase i and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia. Haematologica 96(11): 1619-1626

Hermida, C.; Guerra, P.; Martínez-Costa, O.H.; Sánchez, V.; Sánchez, J.é J.; Solera, J.ús.; Fernández-Mayoralas, A.; Codoceo, R.; Frías, J.ús.; Aragón, J.J. 2013: Phase i and phase IB clinical trials for the noninvasive evaluation of intestinal lactase with 4-galactosylxylose (gaxilose). Journal of Clinical Gastroenterology 47(6): 501-508

Al-Ghananeem, A.M.; Crooks, P.A. 2007: Phase i and phase Ii ocular metabolic activities and the role of metabolism in ophthalmic prodrug and codrug design and delivery. Molecules 12(3): 373-388

Bussy, U.; Chung-Davidson, Y.-W.; Li, K.; Li, W. 2014: Phase i and phase Ii reductive metabolism simulation of nitro aromatic xenobiotics with electrochemistry coupled with high resolution mass spectrometry. Analytical and Bioanalytical Chemistry 406(28): 7253-7260

Chakravarty, A.; Shinde, V.; Tabernero, J.; Cervantes, A.; Cohen, R.B.; Dees, E.C.; Burris, H.; Infante, J.R.; Macarulla, T.; Elez, E.; Andreu, J.; Rodriguez-Braun, E.; Rosello, S.; von Mehren, M.; Meropol, N.J.; Langer, C.J.; ONeil, B.; Bowman, D.; Zhang, M.; Danaee, H.; Faron-Yowe, L.; Gray, G.; Liu, H.; Pappas, J.; Silverman, L.; Simpson, C.; Stringer, B.; Tirrell, S.; Veiby, O.P.; Venkatakrishnan, K.; Galvin, K.; Manfredi, M.; Ecsedy, J.A. 2011: Phase i assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora a kinase. Cancer Research 71(3): 675-685

Herbertson, R.A.; Tebbutt, N.C.; Lee, F.-T.; MacFarlane, D.J.; Chappell, B.; Micallef, N.; Lee, S.-T.; Saunder, T.; Hopkins, W.; Smyth, F.E.; Wyld, D.K.; Bellen, J.; Sonnichsen, D.S.; Brechbiel, M.W.; Murone, C.; Scott, A.M. 2009: Phase i biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 15(21): 6709-6715

Cvilink, V.; Szotáková, B.; Krízová, V.; Lamka, J.; Skálová, L. 2009: Phase i biotransformation of albendazole in lancet fluke (Dicrocoelium dendriticum). Research in Veterinary Science 86(1): 49-55

Anonymous 2014: Phase I cancer immunotherapy trial at Roger Williams shows promising results. Rhode Island Medical Journal 97(5): 67

Le Tourneau, C.; Faivre, S.; Raymond, E.; Diéras, V.ér. 2007: Phase i cancer trials methodology. Bulletin du Cancer 94(11): 943-951

Henry, T.D.; Satran, D.; Wilson, R.F. 2008: Phase i cardiovascular cell therapy clinical trials: Are we running with scissors?. American Heart Journal 156(5): 808-809

Van Laarhoven, H.W.M.; Fiedler, W.; Desar, I.M.E.; van Asten, J.J.A.; Marréaud, S.; Lacombe, D.; Govaerts, A.-S.; Bogaerts, J.; Lasch, P.; Timmer-Bonte, J.N.H.; Lambiase, A.; Bordignon, C.; Punt, C.J.A.; Heerschap, A.; van Herpen, C.M.L. 2010: Phase i clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041). Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 16(4): 1315-1323

Zinner, R.G.; Nemunaitis, J.; Eiseman, I.; Shin, H.J.C.; Olson, S.C.; Christensen, J.; Huang, X.; Lenehan, P.F.; Donato, N.J.; Shin, D.M. 2007: Phase i clinical and pharmacodynamic evaluation of oral CI-1033 in patients with refractory cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 13(10): 3006-3014

Patterson, D.M.; Zweifel, M.; Middleton, M.R.; Price, P.M.; Folkes, L.K.; Stratford, M.R.L.; Ross, P.; Halford, S.; Peters, J.; Balkissoon, J.; Chaplin, D.J.; Padhani, A.R.; Rustin, G.J.S. 2012: Phase i clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 18(5): 1415-1425

Shimizu, T.; Yamamoto, N.; Yamada, Y.; Fujisaka, Y.; Yamada, K.; Fujiwara, Y.; Takayama, K.; Tokudome, T.; Klimovsky, J.; Tamura, T. 2008: Phase i clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors. Cancer ChemoTherapy and Pharmacology 61(5): 751-758

Okamoto, I.; Doi, T.; Ohtsu, A.; Miyazaki, M.; Tsuya, A.; Kurei, K.; Kobayashi, K.; Nakagawa, K. 2010: Phase i clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumors. Japanese Journal of Clinical Oncology 40(1): 17-23

Zhang, P.; Sun, M.; Qiu, R.; Tang, L.; Dou, G.; Xu, B. 2011: Phase i clinical and pharmacokinetic study of UTD1, a genetically engineered epothilone analog in patients with advanced solid tumors. Cancer ChemoTherapy and Pharmacology 68(4): 971-978

Blum, W.; Phelps, M.A.; Klisovic, R.B.; Rozewski, D.M.; Ni, W.; Albanese, K.A.; Rovin, B.; Kefauver, C.; Devine, S.M.; Lucas, D.M.; Johnson, A.; Schaaf, L.J.; Byrd, J.C.; Marcucci, G.; Grever, M.R. 2010: Phase i clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias. Haematologica 95(7): 1098-1105

Tsubata, Y.; Okimoto, T.; Miura, K.; Karino, F.; Iwamoto, S.; Tada, M.; Honda, T.; Hamaguchi, S.; Ohe, M.; Sutani, A.; Kuraki, T.; Hamada, A.; Isobe, T. 2013: Phase i clinical and pharmacokinetic study of bi-weekly carboplatin/paclitaxel chemotherapy in elderly patients with advanced non-small cell lung cancer. Anticancer Research 33(1): 261-266

Pardo, B.; Paz-Ares, L.; Tabernero, J.; Ciruelos, E.; García, M.; Salazar, R.ón.; López, A.; Blanco, M.ía.; Nieto, A.; Jimeno, J.é; Izquierdo, M.A.; Trigo, J.é M. 2008: Phase i clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 14(4): 1116-1123

Bahleda, R.; Sessa, C.; Del Conte, G.; Gianni, L.; Capri, G.; Varga, A.; Oprea, C.; Daglish, B.; Hospitel, M.; Soria, J.-C. 2014: Phase i clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors. Investigational new Drugs 32(6): 1188-1196

Kantarjian, H.; Garcia-Manero, G.; O'Brien, S.; Faderl, S.; Ravandi, F.; Westwood, R.; Green, S.R.; Chiao, J.H.; Boone, P.A.; Cortes, J.; Plunkett, W. 2010: Phase i clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 28(2): 285-291

Krishnamurthi, S.S.; Brell, J.M.; Hoppel, C.L.; Egorin, M.J.; Weaver, K.C.; Li, X.; Ingalls, S.T.; Zuhowski, E.G.; Schluchter, M.D.; Dowlati, A.; Cooney, M.M.; Gibbons, J.; Overmoyer, B.A.; Ivy, S.Percy.; Remick, S.C. 2009: Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine. Cancer ChemoTherapy and Pharmacology 63(3): 441-450

Izquierdo, M.A.; Bowman, A.; García, M.; Jodrell, D.; Martinez, M.; Pardo, B.; Gómez, J.; López-Martin, J.é A.; Jimeno, J.é; Germá, J.é R.; Smyth, J.F. 2008: Phase i clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 14(10): 3105-3112

Okamoto, I.; Miyazaki, M.; Morinaga, R.; Kaneda, H.; Ueda, S.; Hasegawa, Y.; Satoh, T.; Kawada, A.; Fukuoka, M.; Fukino, K.; Tanigawa, T.; Nakagawa, K. 2010: Phase i clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Investigational new Drugs 28(6): 844-853

Shimizu, T.; Okamoto, I.; Tamura, K.; Satoh, T.; Miyazaki, M.; Akashi, Y.; Ozaki, T.; Fukuoka, M.; Nakagawa, K. 2010: Phase i clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent D-19575 (glufosfamide) in patients with solid tumors. Cancer ChemoTherapy and Pharmacology 65(2): 243-250

Vidal, L.; Magem, M.; Barlow, C.; Pardo, B.; Florez, A.; Montes, A.; Garcia, M.; Judson, I.; Lebedinsky, C.; Kaye, S.B.; Salazar, R.ón. 2012: Phase i clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors. Investigational new Drugs 30(2): 616-628

Sessa, C.; Del Conte, G.; Christinat, A.; Cresta, S.; Perotti, A.; Gallerani, E.; Lardelli, P.; Kahatt, C.; Alfaro, V.; Iglesias, J.L.; Fernández-Teruel, C.; Gianni, L. 2013: Phase i clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors. Investigational new Drugs 31(5): 1236-1243

Sessa, C.; Cresta, S.; Noberasco, C.; Capri, G.; Gallerani, E.; De Braud, F.; Zucchetti, M.; D'Incalci, M.; Locatelli, A.; Marsoni, S.; Corradino, I.; Minoia, C.; Zintl, P.; Gianni, L. 2009: Phase i clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours. European Journal of Cancer 45(12): 2116-2122

Sessa, C.; Perotti, A.; Noberasco, C.; De Braud, F.; Gallerani, E.; Cresta, S.; Zucchetti, M.; Viganò, L.; Locatelli, A.; Jimeno, J.; Feilchenfeldt, J.W.; D'Incalci, M.; Capri, G.; Ielmini, N.; Gianni, L. 2009: Phase i clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer. European Journal of Cancer 45(7): 1153-1161

Park, S.Ryun.; Hong, Y.Sang.; Lim, H-Seok.; Seong, M-Woo.; Kong, S-Young.; Kim, S.Young.; Park, Y-Iee.; Jung, K.Hae. 2013: Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer. Cancer ChemoTherapy and Pharmacology 72(5): 953-964

Strumberg, D.; Schultheis, B.; Traugott, U.; Vank, C.; Santel, A.; Keil, O.; Giese, K.; Kaufmann, J.ör.; Drevs, J. 2012: Phase i clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors. International Journal of Clinical Pharmacology and Therapeutics 50(1): 76-78

McArthur, J.H.; Durbin, A.P.; Marron, J.A.; Wanionek, K.A.; Thumar, B.; Pierro, D.J.; Schmidt, A.C.; Blaney, J.E.; Murphy, B.R.; Whitehead, S.S. 2008: Phase i clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity. American Journal of Tropical Medicine and Hygiene 79(5): 678-684

Chandra, K.P.; Shiwalkar, A.; Kotecha, J.; Thakkar, P.; Srivastava, A.; Chauthaiwale, V.; Sharma, S.K.; Cross, M.R.; Dutt, C. 2009: Phase i clinical studies of the advanced glycation end-product (AGE)-breaker TRC4186: safety, tolerability and pharmacokinetics in healthy subjects. Clinical Drug Investigation 29(9): 559-575

Drevs, J.; Siegert, P.; Medinger, M.; Mross, K.; Strecker, R.; Zirrgiebel, U.; Harder, J.; Blum, H.; Robertson, J.; Jürgensmeier, J.M.; Puchalski, T.A.; Young, H.; Saunders, O.; Unger, C. 2007: Phase i clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 25(21): 3045-3054

Asano, Y.; Inoue, Y.; Ikeda, Y.; Kikuchi, K.; Hara, T.; Taguchi, C.; Tokushige, T.; Maruo, H.; Takeda, T.; Nakamura, T.; Fujita, T.; Kumagai, Y.; Hayakawa, K. 2011: Phase i clinical study of NMK36: a new PET tracer with the synthetic amino acid analogue anti-[18F]FACBC. Annals of Nuclear Medicine 25(6): 414-418

Rudin, C.M.; Poirier, J.T.; Senzer, N.N.; Stephenson, J.; Loesch, D.; Burroughs, K.D.; Reddy, P.S.; Hann, C.L.; Hallenbeck, P.L. 2011: Phase i clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 17(4): 888-895

Yutani, S.; Komatsu, N.; Shichijo, S.; Yoshida, K.; Takedatsu, H.; Itou, M.; Kuromatu, R.; Ide, T.; Tanaka, M.; Sata, M.; Yamada, A.; Itoh, K. 2009: Phase i clinical study of a peptide vaccination for hepatitis C virus-infected patients with different human leukocyte antigen-class I-A alleles. Cancer Science 100(10): 1935-1942

Yamada, A.; Noguchi, M.; Komatsu, N.; Suekane, S.; Yutani, S.; Moriya, F.; Mine, T.; Momozono, K.; Kawano, K.; Itoh, K. 2011: Phase i clinical study of a personalized peptide vaccination available for six different human leukocyte antigen (HLA-A2, -A3, -A11, -A24, -A31 and -A33)-positive patients with advanced cancer. Experimental and Therapeutic Medicine 2(1): 109-117

Yutani, S.; Yamada, A.; Yoshida, K.; Takao, Y.; Tamura, M.; Komatsu, N.; Ide, T.; Tanaka, M.; Sata, M.; Itoh, K. 2007: Phase i clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy. Vaccine 25(42): 7429-7435

Honma, I.; Kitamura, H.; Torigoe, T.; Takahashi, A.; Tanaka, T.; Sato, E.; Hirohashi, Y.; Masumori, N.; Tsukamoto, T.; Sato, N. 2009: Phase i clinical study of anti-apoptosis protein survivin-derived peptide vaccination for patients with advanced or recurrent urothelial cancer. Cancer Immunology Immunotherapy: Cii 58(11): 1801-1807

Ansell, S.M.; Witzig, T.E.; Inwards, D.J.; Porrata, L.F.; Ythier, A.; Ferrande, L.; Nestorov, I.; Devries, T.; Dillon, S.R.; Hausman, D.; Novak, A.J. 2008: Phase i clinical study of atacicept in patients with relapsed and refractory B-cell non-Hodgkin's lymphoma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 14(4): 1105-1110

Frankel, A.; Liu, J-Sing.; Rizzieri, D.; Hogge, D. 2008: Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia. Leukemia and Lymphoma 49(3): 543-553

Li, H.; Xu, K.; Wang, Y.; Zhang, H.; Li, T.; Meng, L.; Gong, X.; Zhang, H.; Ou, N.; Ruan, J. 2012: Phase i clinical study of edaravone in healthy Chinese volunteers: safety and pharmacokinetics of single or multiple intravenous infusions. Drugs in R&d 12(2): 65-70

Iinuma, H.; Fukushima, R.; Inaba, T.; Tamura, J.; Inoue, T.; Ogawa, E.; Horikawa, M.; Ikeda, Y.; Matsutani, N.; Takeda, K.; Yoshida, K.; Tsunoda, T.; Ikeda, T.; Nakamura, Y.; Okinaga, K. 2014: Phase i clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients. Journal of Translational Medicine 12: 84

Okamoto, I.; Yoshioka, H.; Takeda, K.; Satouchi, M.; Yamamoto, N.; Seto, T.; Kasahara, K.; Miyazaki, M.; Kitamura, R.; Ohyama, A.; Hokoda, N.; Nakayama, H.; Yoshihara, E.; Nakagawa, K. 2012: Phase i clinical study of the angiogenesis inhibitor TSU-68 combined with carboplatin and paclitaxel in chemotherapy-naive patients with advanced non-small cell lung cancer. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 7(2): 427-433

Sessa, C.; Perotti, A.; Lladò, A.; Cresta, S.; Capri, G.; Voi, M.; Marsoni, S.; Corradino, I.; Gianni, L. 2007: Phase i clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule. Annals of Oncology: Official Journal of the European Society for Medical Oncology 18(9): 1548-1553

Overman, M.J.; Kopetz, S.; Varadhachary, G.; Fukushima, M.; Kuwata, K.; Mita, A.; Wolff, R.A.; Hoff, P.; Xiong, H.; Abbruzzese, J.L. 2008: Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Investigation 26(8): 794-799

Bittner, B.; McIntyre, C.; Tian, H.; Tang, K.; Shah, N.; Phuapradit, W.; Ahmed, H.; Chokshi, H.; Infeld, M.; Fotaki, N.; Ma, H.; Portron, A.; Jordan, P.; Schmidt, J. 2012: Phase i clinical study to select a novel oral formulation for ibandronate containing the excipient sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC). Die Pharmazie 67(3): 233-241

Barnard, R.A.; Wittenburg, L.A.; Amaravadi, R.K.; Gustafson, D.L.; Thorburn, A.; Thamm, D.H. 2014: Phase i clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma. Autophagy 10(8): 1415-1425

Abbo, A.H.; Jones, D.R.; Masters, A.R.; Stewart, J.C.; Fourez, L.; Knapp, D.W. 2010: Phase i clinical trial and pharmacokinetics of intravesical mitomycin C in dogs with localized transitional cell carcinoma of the urinary bladder. Journal of Veterinary Internal Medicine 24(5): 1124-1130

Patel, S.; DiBiase, S.; Meisenberg, B.; Flannery, T.; Patel, A.; Dhople, A.; Cheston, S.; Amin, P. 2012: Phase i clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma. International Journal of Radiation Oncology Biology Physics 82(2): 739-742

Pautier, P.; Locher, C.; Robert, C.; Deroussent, A.; Flament, C.; Le Cesne, A.; Rey, A.; Bahleda, R.; Ribrag, V.; Soria, J.-C.; Vassal, G.; Eggermont, A.; Zitvogel, L.; Chaput, N.; Paci, A. 2013: Phase i clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate. Oncoimmunology 2(2): E23079

Chaput, N.; Flament, C.; Locher, C.; Desbois, M.él.; Rey, A.; Rusakiewicz, S.; Poirier-Colame, V.; Pautier, P.; Le Cesne, A.; Soria, J.-C.; Paci, A.; Rosenzwajg, M.; Klatzmann, D.; Eggermont, A.; Robert, C.; Zitvogel, L. 2013: Phase i clinical trial combining imatinib mesylate and IL-2: HLA-DR+ NK cell levels correlate with disease outcome. Oncoimmunology 2(2): E23080

Gonzalez, N.R.; Connolly, M.; Dusick, J.R.; Bhakta, H.; Vespa, P. 2014: Phase i clinical trial for the feasibility and safety of remote ischemic conditioning for aneurysmal subarachnoid hemorrhage. Neurosurgery 75(5): 590-598; Discussion 598

Zent, C.S.; Smith, B.J.; Ballas, Z.K.; Wooldridge, J.E.; Link, B.K.; Call, T.G.; Shanafelt, T.D.; Bowen, D.A.; Kay, N.E.; Witzig, T.E.; Weiner, G.J. 2012: Phase i clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia. Leukemia and Lymphoma 53(2): 211-217

Tsimberidou, A.-M.; Akerley, W.; Schabel, M.C.; Hong, D.S.; Uehara, C.; Chhabra, A.; Warren, T.; Mather, G.G.; Evans, B.A.; Woodland, D.P.; Swabb, E.A.; Kurzrock, R. 2010: Phase i clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer. Molecular Cancer Therapeutics 9(12): 3410-3419

Szu, S.C.; Lin, K.F.-Y.; Hunt, S.; Chu, C.; Thinh, N.D. 2014: Phase i clinical trial of O-acetylated pectin conjugate, a plant polysaccharide based typhoid vaccine. Vaccine 32(22): 2618-2622

Okuno, K.; Sugiura, F.; Hida, J.-I.; Tokoro, T.; Ishimaru, E.; Sukegawa, Y.; Ueda, K. 2011: Phase i clinical trial of a novel peptide vaccine in combination with UFT/LV for metastatic colorectal cancer. Experimental and Therapeutic Medicine 2(1): 73-79

Matsushita, N.; Aruga, A.; Inoue, Y.; Kotera, Y.; Takeda, K.; Yamamoto, M. 2013: Phase i clinical trial of a peptide vaccine combined with tegafur-uracil plus leucovorin for treatment of advanced or recurrent colorectal cancer. Oncology Reports 29(3): 951-959

Attard, G.; Reid, A.H.M.; Yap, T.A.; Raynaud, F.; Dowsett, M.; Settatree, S.; Barrett, M.; Parker, C.; Martins, V.; Folkerd, E.; Clark, J.; Cooper, C.S.; Kaye, S.B.; Dearnaley, D.; Lee, G.; de Bono, J.S. 2008: Phase i clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 26(28): 4563-4571

Hwang, J.H.; Yoo, H.J.; Lim, M.C.; Seo, S.-S.; Park, S.-Y.; Kang, S. 2012: Phase i clinical trial of alternating belotecan and oral etoposide in patients with platinum-resistant or heavily treated ovarian cancer. Anti-Cancer Drugs 23(3): 321-325

Lubaroff, D.M.; Konety, B.R.; Link, B.; Gerstbrein, J.; Madsen, T.; Shannon, M.; Howard, J.; Paisley, J.; Boeglin, D.; Ratliff, T.L.; Williams, R.D. 2009: Phase i clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 15(23): 7375-7380

Tsimberidou, A.M.; Adamopoulos, A.M.; Ye, Y.; Piha-Paul, S.; Janku, F.; Fu, S.; Hong, D.; Falchook, G.S.; Naing, A.; Wheler, J.; Fortier, A.; Kurzrock, R.; Hess, K.R. 2014: Phase i clinical trial of bendamustine and bevacizumab for patients with advanced cancer. Journal of the National Comprehensive Cancer Network: Jnccn 12(2): 194-203

Stessuk, T.; Ruiz, M.A.; Greco, O.T.; Bilaqui, A.; Ribeiro-Paes, M.J.é d.O.; Ribeiro-Paes, J.ão.T. 2013: Phase i clinical trial of cell therapy in patients with advanced chronic obstructive pulmonary disease: follow-up of up to 3 years. Revista Brasileira de Hematologia e Hemoterapia 35(5): 352-357

MacDonald, T.J.; Stewart, C.F.; Kocak, M.; Goldman, S.; Ellenbogen, R.G.; Phillips, P.; Lafond, D.; Poussaint, T.Y.; Kieran, M.W.; Boyett, J.M.; Kun, L.E. 2008: Phase i clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 26(6): 919-924

Wu, K.; Jiang, G.; Liao, Y.; Wang, L.; Qian, H.; Yang, H.; Zhang, Z.; Hu, C.; Zhao, S. 2000: Phase i clinical trial of dose escalation on three dimensional conformal radiation therapy for non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 3(5): 322-325

Ishikawa, T.; Kokura, S.; Enoki, T.; Sakamoto, N.; Okayama, T.; Ideno, M.; Mineno, J.; Uno, K.; Yoshida, N.; Kamada, K.; Katada, K.; Uchiyama, K.; Handa, O.; Takagi, T.; Konishi, H.; Yagi, N.; Naito, Y.; Itoh, Y.; Yoshikawa, T. 2014: Phase i clinical trial of fibronectin CH296-stimulated T cell therapy in patients with advanced cancer. Plos one 9(1): E83786

Tsimberidou, A.M.; Moulder, S.; Fu, S.; Wen, S.; Naing, A.; Bedikian, A.Y.; Daring, S.; Uehara, C.; Ng, C.; Wallace, M.; Camacho, L.; Kurzrock, R. 2010: Phase i clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement. Cancer ChemoTherapy and Pharmacology 66(6): 1087-1093

Tsimberidou, A.M.; Letourneau, K.; Fu, S.; Hong, D.; Naing, A.; Wheler, J.; Uehara, C.; McRae, S.E.; Wen, S.; Kurzrock, R. 2011: Phase i clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvement. Cancer ChemoTherapy and Pharmacology 68(1): 247-253

Lam, C.G.; Furman, W.L.; Wang, C.; Spunt, S.L.; Wu, J.; Ivy, P.; Santana, V.M.; McGregor, L.M. 2015: Phase i clinical trial of ifosfamide, oxaliplatin, and etoposide (IOE) in pediatric patients with refractory solid tumors. Journal of Pediatric Hematology/Oncology 37(1): E13-E18

Ganesan, P.; Piha-Paul, S.; Naing, A.; Falchook, G.; Wheler, J.; Janku, F.; Zinner, R.; Laday, S.; Kies, M.; Tsimberidou, A.M. 2013: Phase i clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer. Investigational new Drugs 31(6): 1505-1513

Antón, A.; Ruiz, A.; Seguí, M.A.; Calvo, L.; Muñoz, M.; Lao, J.; Sancho, F.; Fernández, L. 2009: Phase i clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neo-adjuvant treatment in stages Ii and IIIA, HER2-overexpressing breast cancer patients. GEICAM 2003-03 study. Annals of Oncology: Official Journal of the European Society for Medical Oncology 20(3): 454-459

Opyrchal, M.; Aderca, I.; Galanis, E. 2009: Phase i clinical trial of locoregional administration of the oncolytic adenovirus ONYX-015 in combination with mitomycin-C, doxorubicin, and cisplatin chemotherapy in patients with advanced sarcomas. Methods in Molecular Biology 542: 705-717

Karbach, J.; Neumann, A.; Brand, K.; Wahle, C.; Siegel, E.; Maeurer, M.; Ritter, E.; Tsuji, T.; Gnjatic, S.; Old, L.J.; Ritter, G.; Jäger, E. 2012: Phase i clinical trial of mixed bacterial vaccine (Coley's toxins) in patients with NY-ESO-1 expressing cancers: immunological effects and clinical activity. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 18(19): 5449-5459

Aruga, A.; Takeshita, N.; Kotera, Y.; Okuyama, R.; Matsushita, N.; Ohta, T.; Takeda, K.; Yamamoto, M. 2014: Phase i clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer. Journal of Translational Medicine 12: 61

Spunt, S.L.; Freeman, B.B.; Billups, C.A.; McPherson, V.; Khan, R.B.; Pratt, C.B.; Stewart, C.F. 2007: Phase i clinical trial of oxaliplatin in children and adolescents with refractory solid tumors. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 25(16): 2274-2280

Iqbal, S.; Tsao-Wei, D.D.; Quinn, D.I.; Gitlitz, B.J.; Groshen, S.; Aparicio, A.; Lenz, H.J.; El-Khoueiry, A.; Pinski, J.; Garcia, A.A. 2011: Phase i clinical trial of pegylated liposomal Doxorubicin and docetaxel in patients with advanced solid tumors. American Journal of Clinical Oncology 34(1): 27-31

Yang, J.; Shi, Y.; Li, C.; Gui, L.; Zhao, X.; Liu, P.; Han, X.; Song, Y.; Li, N.; Du, P.; Zhang, S. 2014: Phase i clinical trial of pegylated liposomal mitoxantrone plm60-s: pharmacokinetics, toxicity and preliminary efficacy. Cancer ChemoTherapy and Pharmacology 74(3): 637-646

Higashihara, Y.; Kato, J.; Nagahara, A.; Izumi, K.; Konishi, M.; Kodani, T.; Serizawa, N.; Osada, T.; Watanabe, S. 2014: Phase i clinical trial of peptide vaccination with URLC10 and VEGFR1 epitope peptides in patients with advanced gastric cancer. International Journal of Oncology 44(3): 662-668

Miyazaki, A.; Kobayashi, J.; Torigoe, T.; Hirohashi, Y.; Yamamoto, T.; Yamaguchi, A.; Asanuma, H.; Takahashi, A.; Michifuri, Y.; Nakamori, K.; Nagai, I.; Sato, N.; Hiratsuka, H. 2011: Phase i clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer. Cancer Science 102(2): 324-329

Lu, C.; Stewart, D.J.; Lee, J.Jack.; Ji, L.; Ramesh, R.; Jayachandran, G.; Nunez, M.I.; Wistuba, I.I.; Erasmus, J.J.; Hicks, M.E.; Grimm, E.A.; Reuben, J.M.; Baladandayuthapani, V.; Templeton, N.S.; McMannis, J.D.; Roth, J.A. 2012: Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans. Plos one 7(4): E34833

Piatek, C.I.; Raja, G.L.; Ji, L.; Gitlitz, B.J.; Dorff, T.B.; Quinn, D.I.; Hu, J.; El-Khoueiry, A.B.; Pham, H.Q.; Roman, L.; Garcia, A.A. 2014: Phase i clinical trial of temsirolimus and vinorelbine in advanced solid tumors. Cancer ChemoTherapy and Pharmacology 74(6): 1227-1234

González, G.P.; García, I.G.ía.; González, J.ín.G.ál.; Sánchez, L.P.ér.; Mirabal, M.V.; Marín, C.C.ón.; Ruiz, F.L.G.ía.; Iglesias, E.G.; de Queralta, R.L.óp.; Toirac, R.ón.R.; Avila, M.A.; Díaz, A.ín.L.óp.; Saura, P.A.L.óp.; Gavilondo, J.V.; González, J.P.O. 2011: Phase i clinical trial of the (131)I-labeled anticarcinoembryonic antigen CIGB-M3 multivalent antibody fragment. Cancer BioTherapy and Radiopharmaceuticals 26(3): 353-363

Ryan, C.J.; Smith, M.R.; Fong, L.; Rosenberg, J.E.; Kantoff, P.; Raynaud, F.; Martins, V.; Lee, G.; Kheoh, T.; Kim, J.; Molina, A.; Small, E.J. 2010: Phase i clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 28(9): 1481-1488

Bebb, G.; Smith, C.; Rorke, S.; Boland, W.; Nicacio, L.; Sukhoo, R.; Brade, A. 2011: Phase i clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, IIi or IV non-small cell lung cancer unsuitable for radical therapy. Cancer ChemoTherapy and Pharmacology 67(4): 837-845

Hassan, R.; Cohen, S.J.; Phillips, M.; Pastan, I.; Sharon, E.; Kelly, R.J.; Schweizer, C.; Weil, S.; Laheru, D. 2010: Phase i clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 16(24): 6132-6138

Acevedo-Gadea, C.; Santin, A.D.; Higgins, S.A.; Urva, S.; Ratner, E.; Silasi, D.-A.; Azodi, M.; Rutherford, T.; Schwartz, P.E.; Abu-Khalaf, M.M. 2014: Phase i clinical trial of the mammalian target of rapamycin inhibitor everolimus in combination with oral topotecan for recurrent and advanced endometrial cancer. International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society 24(3): 528-533

Li, S.; Huang, H.; Liao, H.; Zhan, J.; Guo, Y.; Zou, B.-Y.; Jiang, W.-Q.; Guan, Z.-Z.; Yang, X.-Q. 2013: Phase i clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results. International Journal of Clinical Pharmacology and Therapeutics 51(2): 96-105

Baba, T.; Sato-Matsushita, M.; Kanamoto, A.; Itoh, A.; Oyaizu, N.; Inoue, Y.; Kawakami, Y.; Tahara, H. 2010: Phase i clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402. Journal of Translational Medicine 8: 84

Yang, Z.-J.; Zhang, Y.-R.; Chen, B.; Zhang, S.-L.; Jia, E.-Z.; Wang, L.-S.; Zhu, T.-B.; Li, C.-J.; Wang, H.; Huang, J.; Cao, K.-J.; Ma, W.-Z.; Wu, B.; Wang, L.-S.; Wu, C.-T. 2009: Phase i clinical trial on intracoronary administration of Ad-hHGF treating severe coronary artery disease. Molecular Biology Reports 36(6): 1323-1329

Li, C.-Z.; Sun, J.-Y.; Wang, Y.; Qin, Y.-P.; Miao, J. 2014: Phase i clinical trial on the safety of injectable cefetamet sodium with a single dose in healthy volunteers. Sichuan da Xue Xue Bao. Yi Xue Ban 45(4): 637-641

Tsimberidou, A.M.; Letourneau, K.; Wen, S.; Wheler, J.; Hong, D.; Naing, A.; Iskander, N.G.; Uehara, C.; Kurzrock, R. 2011: Phase i clinical trial outcomes in 93 patients with brain metastases: the MD anderson cancer center experience. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 17(12): 4110-4118

Pourgholami, M.H.; Szwajcer, M.; Chin, M.; Liauw, W.; Seef, J.; Galettis, P.; Morris, D.L.; Links, M. 2010: Phase i clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer. Cancer ChemoTherapy and Pharmacology 65(3): 597-605

Miyazawa, M.; Ohsawa, R.; Tsunoda, T.; Hirono, S.; Kawai, M.; Tani, M.; Nakamura, Y.; Yamaue, H. 2010: Phase i clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Science 101(2): 433-439

Tsimberidou, A.Maria.; Vaklavas, C.; Wen, S.; Hong, D.; Wheler, J.; Ng, C.; Naing, A.; Tse, S.; Busaidy, N.; Markman, M.; Sherman, S.I.; Kurzrock, R. 2009: Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience. Journal of Clinical Endocrinology and Metabolism 94(11): 4423-4432

Moroney, J.; Wheler, J.; Hong, D.; Naing, A.; Falchook, G.; Bodurka, D.; Coleman, R.; Lu, K.; Xiao, L.; Kurzrock, R. 2010: Phase I clinical trials in 85 patients with gynecologic cancer: the M. D. Anderson Cancer Center experience. Gynecologic Oncology 117(3): 467-472

Gupta, P.; Gupta, V.; Gupta, Y.K. 2012: Phase I clinical trials of anticancer drugs in healthy volunteers: need for critical consideration. Indian Journal of Pharmacology 44(4): 540-542

Bates, S.E. 2010: Phase i clinical trials: overcoming barriers. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 16(6): 1709

Quintela-Fandino, M.; Le Tourneau, C.; Duran, I.; Chen, E.X.; Wang, L.; Tsao, M.; Bandarchi-Chamkhaleh, B.; Pham, N.-A.; Do, T.; MacLean, M.; Nayyar, R.; Tusche, M.W.; Metser, U.; Wright, J.J.; Mak, T.W.; Siu, L.L. 2010: Phase i combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort. Molecular Cancer Therapeutics 9(3): 751-760

Blay, J.-Y.; von Mehren, M.; Samuels, B.L.; Fanucchi, M.P.; Ray-Coquard, I.; Buckley, B.; Gilles, L.; Lebedinsky, C.; Elsayed, Y.A.; Le Cesne, A. 2008: Phase i combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 14(20): 6656-6662

Sekeres, M.A.; List, A.F.; Cuthbertson, D.; Paquette, R.; Ganetzky, R.; Ganetsky, R.; Latham, D.; Paulic, K.; Afable, M.; Saba, H.I.; Loughran, T.P.; Maciejewski, J.P. 2010: Phase i combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 28(13): 2253-2258

Schuler, P.J.; Harasymczuk, M.; Visus, C.; Deleo, A.; Trivedi, S.; Lei, Y.; Argiris, A.; Gooding, W.; Butterfield, L.H.; Whiteside, T.L.; Ferris, R.L. 2014: Phase i dendritic cell p53 peptide vaccine for head and neck cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 20(9): 2433-2444

Wages, N.A.; O'Quigley, J.; Conaway, M.R. 2014: Phase i design for completely or partially ordered treatment schedules. Statistics in Medicine 33(4): 569-579

Stewart, C.F.; Tagen, M.; Schwartzberg, L.S.; Blakely, L.J.; Tauer, K.W.; Smiley, L.M. 2014: Phase i dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumors. Cancer ChemoTherapy and Pharmacology 73(3): 561-568

Mross, K.; Frost, A.; Steinbild, S.; Hedbom, S.; Rentschler, J.; Kaiser, R.; Rouyrre, N.; Trommeshauser, D.; Hoesl, C.E.; Munzert, G. 2008: Phase i dose escalation and pharmacokinetic study of Bi 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 26(34): 5511-5517

Storniolo, A.M.; Pegram, M.D.; Overmoyer, B.; Silverman, P.; Peacock, N.W.; Jones, S.F.; Loftiss, J.; Arya, N.; Koch, K.M.; Paul, E.; Pandite, L.; Fleming, R.A.; Lebowitz, P.F.; Ho, P.T.C.; Burris, H.A. 2008: Phase i dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 26(20): 3317-3323

Mukohara, T.; Nagai, S.; Koshiji, M.; Yoshizawa, K.; Minami, H. 2010: Phase i dose escalation and pharmacokinetic study of oral enzastaurin (LY317615) in advanced solid tumors. Cancer Science 101(10): 2193-2199

Brennan, R.C.; Furman, W.; Mao, S.; Wu, J.; Turner, D.C.; Stewart, C.F.; Santana, V.; McGregor, L.M. 2014: Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors. Cancer ChemoTherapy and Pharmacology 74(6): 1191-1198

Pegram, M.D.; Borges, V.F.; Ibrahim, N.; Fuloria, J.; Shapiro, C.; Perez, S.; Wang, K.; Schaedli Stark, F.; Courtenay Luck, N. 2009: Phase i dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer. Breast Cancer Research: Bcr 11(5): R73

Polhemus, M.E.; Magill, A.J.; Cummings, J.F.; Kester, K.E.; Ockenhouse, C.F.; Lanar, D.E.; Dutta, S.; Barbosa, A.; Soisson, L.; Diggs, C.L.; Robinson, S.A.; Haynes, J.D.; Stewart, V.Ann.; Ware, L.A.; Brando, C.; Krzych, U.; Bowden, R.A.; Cohen, J.D.; Dubois, M-Claude.; Ofori-Anyinam, O.; De-Kock, E.; Ballou, W.Ripley.; Heppner, D.Gray. 2007: Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research. Vaccine 25(21): 4203-4212

Axiak, S.M.; Selting, K.A.; Decedue, C.J.; Henry, C.J.; Tate, D.; Howell, J.; Bilof, K.J.; Kim, D.Y. 2011: Phase i dose escalation safety study of nanoparticulate paclitaxel (CTi 52010) in normal dogs. International Journal of Nanomedicine 6: 2205-2212

Traynor, A.M.; Hewitt, M.; Liu, G.; Flaherty, K.T.; Clark, J.; Freedman, S.J.; Scott, B.B.; Leighton, A.M.; Watson, P.A.; Zhao, B.; O'Dwyer, P.J.; Wilding, G. 2011: Phase i dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors. Cancer ChemoTherapy and Pharmacology 67(2): 305-314

Jiang, Y.; Mackley, H.B.; Kimchi, E.T.; Zhu, J.; Gusani, N.; Kaifi, J.; Staveley-O'Carroll, K.F.; Belani, C.P. 2014: Phase i dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancer. Cancer ChemoTherapy and Pharmacology 74(1): 205-210

Kim, Y.H.; Seo, H.Y.; Jeen, Y.T.; Kim, H.-K.; Shim, B.Y.; Yang, J. 2009: Phase i dose escalation study of docetaxel with a fixed dose of S-1 in combination chemotherapy for advanced gastric cancer. Cancer ChemoTherapy and Pharmacology 63(2): 253-260

Dugan, E.; Truax, R.; Meadows, K.L.; Blobe, G.C.; Morse, M.A.; Fernando, N.H.; Gockerman, J.P.; Petros, W.P.; Hurwitz, H.I. 2009: Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors. Anticancer Research 29(12): 5149-5153

Eskens, F.A.L.M.; Steeghs, N.; Verweij, J.; Bloem, J.L.; Christensen, O.; van Doorn, L.; Ouwerkerk, J.; de Jonge, M.J.A.; Nortier, J.W.R.; Kraetzschmar, J.; Rajagopalan, P.; Gelderblom, H. 2009: Phase i dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 27(25): 4169-4176

Mansfield, A.S.; Fields, A.P.; Jatoi, A.; Qi, Y.; Adjei, A.A.; Erlichman, C.; Molina, J.R. 2013: Phase i dose escalation study of the PKCι inhibitor aurothiomalate for advanced non-small-cell lung cancer, ovarian cancer, and pancreatic cancer. Anti-Cancer Drugs 24(10): 1079-1083

Haluska, P.; Shaw, H.M.; Batzel, G.N.; Yin, D.; Molina, J.R.; Molife, L.R.; Yap, T.A.; Roberts, M.L.; Sharma, A.; Gualberto, A.; Adjei, A.A.; de Bono, J.S. 2007: Phase i dose escalation study of the anti insulin-like growth factor-i receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 13(19): 5834-5840

Beldner, M.A.; Sherman, C.A.; Green, M.R.; Garrett-Mayer, E.; Chaudhary, U.; Meyer, M.L.; Kraft, A.S.; Montero, A.J. 2007: Phase i dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer. Bmc Cancer 7: 231

Awada, A.; Piccart, M.J.; Jones, S.F.; Peck, R.A.; Gil, T.; Lebwohl, D.; Wu, C.-Y.; Burris, H.A. 2009: Phase i dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy. Cancer ChemoTherapy and Pharmacology 63(3): 417-425

Bayet-Robert, M.; Kwiatkowski, F.; Leheurteur, M.; Gachon, F.ço.; Planchat, E.ïs.; Abrial, C.; Mouret-Reynier, M.-A.; Durando, X.; Barthomeuf, C.; Chollet, P. 2010: Phase i dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer Biology and Therapy 9(1): 8-14